WO2016120850A1 - Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof - Google Patents

Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof Download PDF

Info

Publication number
WO2016120850A1
WO2016120850A1 PCT/IB2016/050477 IB2016050477W WO2016120850A1 WO 2016120850 A1 WO2016120850 A1 WO 2016120850A1 IB 2016050477 W IB2016050477 W IB 2016050477W WO 2016120850 A1 WO2016120850 A1 WO 2016120850A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
juvenile
och
compounds
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2016/050477
Other languages
French (fr)
Other versions
WO2016120850A9 (en
Inventor
Mark Edward SCHNUTE
Andrew Christopher Flick
Peter Jones
Neelu Kaila
Scot Richard MENTE
John David TRZUPEK
Michael L. Vazquez
Li Xing
Liying Zhang
Goran Mattias Wennerstal
Edouard Zamaratski
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to EP16705819.7A priority Critical patent/EP3250561A1/en
Priority to US15/547,228 priority patent/US10385036B2/en
Priority to JP2017539457A priority patent/JP2018510131A/en
Priority to CA2975157A priority patent/CA2975157C/en
Publication of WO2016120850A1 publication Critical patent/WO2016120850A1/en
Publication of WO2016120850A9 publication Critical patent/WO2016120850A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • Retinoid-related orphan receptors are reported to have an important role in numerous biological processes. Scientific investigations relating to each of retinoid-related orphan receptors RORa, ROR , and RORY have been described in the literature. Continuing research in this field is spurred by the promise of developing new therapeutic agents to treat medical disorders associated with retinoid-related orphan receptor activity.
  • RORy has been reported to be expressed in high concentration in various tissues, such as thymus, kidney, liver, muscle, and certain fat tissue.
  • Two isoforms of RORy have been identified and are referred to as y1 and y2 (also referred to as RORyt).
  • Expression of the y2 isoform has been reported to appear in, for example, double-positive thymocytes.
  • Compounds capable of modulating RORyt activity are contemplated to provide a therapeutic benefit in the treatment of multiple medical disorders, including immune and inflammatory disorders.
  • Psoriasis is a T cell- mediated inflammatory disease that affects approximately 2% to 3% of adults and has a substantial adverse impact on the quality of life for patients suffering from this disorder. Plaques resulting from psoriasis can be painful and are visually unappealing.
  • Various therapeutics have been developed in an attempt to treat psoriasis. However, the traditional therapies for psoriasis often have toxic adverse effects. Accordingly, a need exists for improved treatments for psoriasis as well as other immune and inflammatory disorders.
  • the present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORy activity and/or reducing the amount of I L-17 in a subject, and methods of treating various medical disorders using such compounds.
  • one aspect of the invention relates to compounds represented by Formula I:
  • R 1 , X and W are as defined in the Detailed Description.
  • Another aspect of the invention provides a method of treating a subject suffering from a medical disorder.
  • the method comprises administering to the subject a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, as described in the Detailed Description.
  • a large number of disorders may be treated using the compounds described herein.
  • the compounds described herein may be used to treat an immune disorder or inflammatory disorder, such as rheumatoid arthritis, psoriasis, chronic graft- versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic
  • thrombocytopenic thrombotic purpura myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, epidermal hyperplasia, and other medical disorders described herein.
  • the invention provides compounds, pharmaceutical compositions, methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and therapeutic uses of said compounds and pharmaceutical compositions.
  • the practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in "Comprehensive Organic Synthesis” (B.M. Trost & I. Fleming, eds., 1991-1992); “Handbook of experimental immunology” (D.M. Weir & C.C. Blackwell, eds.); “Current protocols in molecular biology” (F.M.
  • Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates.
  • ROR stands for Retinoic acid receptor-related Orphan Receptor. There are three forms of ROR, ROR-a, - ⁇ , and - ⁇ and each is encoded by a separate gene (RORA, RORB, and RORC respectively). There are two subtypes of RORC: 1 and 2. Subtype 2 is also called “t”. The human RORC gene is also called TOR; RORG; RZRG; NRIF3; and RZR-GAMMA.
  • RORC nuclear receptor ROR-gamma
  • nuclear receptor RZR-gamma nuclear receptor RZR-gamma
  • retinoic acid-binding receptor gamma retinoid-related orphan receptor gamma
  • RAR-related orphan receptor C isoform a
  • RAR-related orphan nuclear receptor variant 2 nuclear receptor subfamily 1 group F member 3.
  • RORv and RORC2 are used interchangeably to refer to a protein from a RORC subtype 2 gene.
  • a modulator refers to a compound that alters an activity of a molecule.
  • a modulator can cause an increase or decrease in the magnitude of a certain activity of a molecule compared to the magnitude of the activity in the absence of the modulator.
  • a modulator is an inhibitor, which decreases the magnitude of one or more activities of a molecule.
  • an inhibitor completely prevents one or more activities of a molecule.
  • a modulator is an activator, which increases the magnitude of at least one activity of a molecule.
  • the presence of a modulator results in an activity that does not occur in the absence of the modulator.
  • alkyl refers to a substituent obtained by removing a hydrogen from a saturated, straight (i.e. unbranched) or branched carbon chain (or carbon), or combination thereof, which has the number of carbon atoms designated (i.e. C ⁇ C e means one to six carbons).
  • alkyl substituents include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and tert-butyl), pentyl, isoamyl, hexyl and the like.
  • haloalkyl is an alkyl in which at least one hydrogen on the alkyl is replaced with a halogen atom. In certain embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are all the same as one another. In other embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are not all the same as one another.
  • cycloalkyl refers to a substituent obtained by removing a hydrogen atom from a saturated carbocycle having the number of carbon atoms designated (i.e. C3-C 8 means three to eight carbons).
  • Cycloalkyl refers to both a radical of a single ring saturated carbocycle, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, as well as a radical of a two or three ring bridged, fused or spiro saturated carbocycle, such as bicyclo[4.2.0]octane and decalinyl.
  • five-membered heteroaryl is defined herein as a ring system having five ring atoms wherein at least one ring atom, alternatively 2 ring atoms, alternatively 3 ring atoms, alternatively 4 ring atoms, is a heteroatom independently selected in each instance from, unless otherwise indicated, the group consisting of nitrogen (N), oxygen (O), and sulfur (S), and wherein the ring is partially unsaturated.
  • the ring atom of the heteroaryl substituent that is bound to the group may be the at least one heteroatom, or it may be a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon may be in a different ring from the at least one heteroatom.
  • heteroaryl groups can be substituted.
  • the group or substituent may be bound to the heteroatom, or it may be bound to a ring carbon atom, where the ring carbon atom may be in the same ring as the heteroatom(s), or where the ring carbon atom may be in a different ring from the heteroatom(s).
  • Examples of monocyclic heteroaryl rings include, but are not limited to, 1 ,2,3,4-tetrazolyl, [1 ,2,3]triazolyl, [1 ,2,4]triazolyl, triazinyl, thiazol-2-yl, thiazol-4-yl, imidazol-1-yl, 1 H-imidazol-2-yl, 1 H-imidazol-4-yl, oxazolyl, isoxazolin-5-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, and thiophen-4-yl.
  • substituent refers to substituents that are collectively described as being optionally substituted by one or more of a list of substituents, the group may include: (1) unsubstitutable substituents, (2) substitutable substituents that are not substituted by the optional substituents, and/or (3) substitutable substituents that are substituted by one or more of the optional substituents.
  • a substituent such that it "may be substituted” or as being “optionally substituted” with up to a particular number of non-hydrogen substituents, that substituent may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen substituents or by up to the maximum number of substitutable positions on the substituent, whichever is less.
  • a substituent is described as a heteroaryl optionally substituted with up to 3 non-hydrogen substituents, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen substituents as the heteroaryl has substitutable positions.
  • tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen substituent.
  • an amino nitrogen is described as being optionally substituted with up to 2 non-hydrogen substituents, then the nitrogen will be optionally substituted with up to 2 non-hydrogen substituents if the amino nitrogen is a primary nitrogen, whereas the amino nitrogen will be optionally substituted with up to only 1 non-hydrogen substituent if the amino nitrogen is a secondary nitrogen.
  • compounds of Formula I may be referred to as a "compound(s) of the invention.” Such terms are also defined to include all forms of the Formula I including hydrates, solvates, isomers, crystalline and non-crystalline forms, isomorphs, polymorphs, and metabolites thereof.
  • the compounds of Formula I and pharmaceutically acceptable salts thereof may exist in unsolvated and solvated forms.
  • the solvent or water When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity.
  • the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non- stoichiometry will be the norm.
  • a “metabolite” of a compound disclosed herein is a derivative of that compound that is formed when the compound is metabolized.
  • active metabolite refers to a biologically active derivative of a compound that is formed when the compound is metabolized.
  • metabolism refers to the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes, such as, oxidation reactions) by which a particular substance is changed by an organism. Thus, enzymes may produce specific structural alterations to a compound.
  • cytochrome P450 catalyzes a variety of oxidative and reductive reactions while uridine diphosphate glucuronyl transferases catalyze the transfer of an activated glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulfhydryl groups. Further information on metabolism may be obtained from The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill (1996). Metabolites of the compounds disclosed herein can be identified either by administration of compounds to a host and analysis of tissue samples from the host, or by incubation of compounds with hepatic cells in vitro and analysis of the resulting compounds. Both methods are well known in the art. In some embodiments, metabolites of a compound are formed by oxidative processes and correspond to the corresponding hydroxy-containing compound. In some embodiments, a compound is metabolized to pharmacologically active metabolites.
  • prodrugs refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
  • An example, without limitation, of a prodrug would be a compound described herein, which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial.
  • a further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety.
  • a prodrug upon in vivo administration, is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound.
  • a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.
  • a pharmaceutically active compound is modified such that the active compound will be regenerated upon in vivo administration.
  • the prodrug can be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug.
  • prodrugs of the compound see, for example, Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392; Silverman (1992), The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc., San Diego, pages 352-401 , Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985).
  • Prodrug forms of the herein described compounds, wherein the prodrug is metabolized in vivo to produce a derivative as set forth herein are included within the scope of the claims.
  • some of the herein-described compounds may be a prodrug for another derivative or active compound.
  • Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not.
  • the prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
  • Prodrugs may be designed as reversible drug derivatives, for use as modifiers to enhance drug transport to site-specific tissues. In some embodiments, the design of a prodrug increases the effective water solubility. See, e.g.
  • the compounds of the invention may have asymmetric carbon atoms.
  • the carbon-carbon bonds of the compounds of the invention may be depicted herein using a solid line, a solid wedge or a dotted wedge.
  • the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers (e.g. specific enantiomers, racemic mixtures, etc.) at that carbon atom are included.
  • the use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom.
  • a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included.
  • the compounds of the invention can exist as enantiomers and diastereomers or as racemates and mixtures thereof.
  • the use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
  • Stereoisomers of compounds of the invention include cis and trans isomers, optical isomers such as R and S enantiomers, diastereomers, geometric isomers, rotational isomers,
  • conformational isomers, and tautomers of the compounds of the invention including compounds exhibiting more than one type of isomerism; and mixtures thereof (such as racemates and diastereomeric pairs).
  • acid addition or base addition salts wherein the counterion is optically active for example, D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL- arginine.
  • the first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts.
  • the second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
  • the present invention also includes isotopically-labeled compounds, which are identical to those recited in Formula I herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that may be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as, but not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 1s O, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 CI.
  • isotopically- labeled compounds of Formula (I) and Formula (II), for example those into which radioactive isotopes such as 3 H and 14 0 are incorporated, are useful in drug and/or substrate tissue distribution assays.
  • Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
  • substitution with heavier isotopes such as deuterium, i.e., 2 H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
  • Isotopically-labeled compounds the invention may generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting an isotopically-labeled reagent for a non-isotopically-labeled reagent.
  • the compounds of this invention may be used in the form of salts derived from inorganic or organic acids.
  • a salt of the compound may be
  • a salt of a compound also may be used as an aid in the isolation, purification, and/or resolution of the compound.
  • the salt preferably is pharmaceutically acceptable.
  • “pharmaceutically acceptable salt” refers to a salt prepared by combining a compound of Formula I with an acid whose anion, or a base whose cation, is generally considered suitable for human consumption.
  • Pharmaceutically acceptable salts are particularly useful as products of the methods of the present invention because of their greater aqueous solubility relative to the parent compound.
  • the salts of the compounds of this invention are non-toxic
  • salts encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
  • Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, hydrofluoric, boric, fluoroboric, phosphoric, metaphosphoric, nitric, carbonic, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric,
  • Suitable organic acids generally include but are not limited to aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.
  • suitable organic acids include but are not limited to acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, toluenesulfonate, 2-hydroxyethanesulfonate, sufanilate, cyclohexylaminosulfonate, algenic acid, ⁇ - hydroxy butyric acid, galactarate, galacturonate, adipate, alginate, butyrate, camphor
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, i.e., sodium or potassium salts; alkaline earth metal salts, e.g. , calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
  • base salts are formed from bases which form non-toxic salts, including aluminum, arginine, benzathine, choline, diethylamine, diolamine, glycine, lysine, meglumine, olamine, tromethamine and zinc salts.
  • Organic salts may be made from secondary, tertiary or quaternary amine salts, such as tromethamine, diethylamine, ⁇ , ⁇ '-benzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine.
  • Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl (Ci-C 6 ) halides (e.g. , methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (i.e.
  • halides i.e. , decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides
  • arylalkyl halides i.e., benzyl and phenethyl bromides
  • hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
  • the compounds of the invention described herein are selective for RORy over RORa and/or ROR .
  • an inhibitor compound of RORy used in the methods described herein is identified or characterized in an in vitro assay, e.g., an acellular biochemical assay or a cellular functional assay. Such assays are useful to determine an in vitro IC 50 for said compounds.
  • the RORy inhibitor compound used for the methods described herein inhibits RORy activity with an in vitro IC 50 of less than 25 ⁇ (e.g., less than 20 ⁇ , less than 10 ⁇ , less than 1 ⁇ , less than 0.5 ⁇ , less than 0.4 ⁇ , less than 0.3 ⁇ , less than 0.1 , less than 0.08 ⁇ , less than 0.06 ⁇ , less than 0.05 ⁇ , less than 0.04 ⁇ , less than 0.03 ⁇ , less than less than 0.02 ⁇ , less than 0.01 , less than 0.008 ⁇ , less than 0.006 ⁇ , less than 0.005 ⁇ , less than 0.004 ⁇ , less than 0.003 ⁇ , less than less than less than 0.002 ⁇ , less than 0.001 , less than 0.00099 ⁇ , less than 0.00098 ⁇ , less than 0.00097 ⁇ , less than 0.00096 ⁇ , less than 0.00095 ⁇ , less than 0.00094 ⁇ , less than 0.00093 ⁇ , less than 25 ⁇
  • Described herein are compounds of Formula I. Also described herein are pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically active metabolites, and pharmaceutically acceptable prodrugs of such compounds. Pharmaceutical compositions that include at least one such compound or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically active metabolite or pharmaceutically acceptable prodrug of such compound, are provided. In some embodiments, when compounds disclosed herein contain an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art. In certain embodiments, isomers and chemically protected forms of compounds having a structure represented by Formula I are also provided.
  • One aspect of the invention relates to a compound of Formula I:
  • X is phenyl or 5-membered hereroaryl, in each case optionally substituted with one, two, three, four or five substituents independently selected from the grou of -CH 3 , -CF 3 , -
  • R 1 is -CH or -CH 2 CH 3 ;
  • W is optionally substituted with one, two, three, four or five -CH 3 ;
  • R 2 is 10 )cycloalkyl, phenyl or isothiazolyl , optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C 1 -C 3 )alkyl, (CrC ⁇ haloalkyl and (C 3 -C 8 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 1 is -CH 3 .
  • the present invention relates to any of the aforementioned compounds, wherein R 1 is -CH 2 CH 3 .
  • the present invention relates to any of the aforementioned
  • W is optionally substituted with one, two, three, four or five -CH 3 .
  • the present invention relates to any of the aforementioned
  • the present invention relates to any of the aforementioned
  • the resent invention relates to any of the aforementioned
  • the present invention relates to any of the aforementioned compounds, wherein W with one -CH 3 .
  • the present invention relates to any of the aforementioned compounds, wherein W with two -CH 3 .
  • the present invention relates to any of the aforementioned
  • the present invention relates to any of the aforementioned compounds, wherein X is unsubstituted phenyl.
  • the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with one, two, three, four or five substituents independently selected from the group consi -CH 3 , -CF 3 , -CH 2 CH 3 , -OH, -OCH 3 ,
  • the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with one substituent selected from the group consisting of with -CH 3 , -CF 3 , -CH 2 CH 3 , -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 OH,
  • the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with two substituents independently selected from the group consisting -CH 3 , -CF 3 , -CH 2 CH 3 , -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 OH,
  • the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with three substituents independently selected from the group consisting of -CH 3 , -CF 3 , -CH 2 CH 3 , -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 OH,
  • the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with four substituents independently selected from the group consisting -CH 3 , -CH 2 CH 3 , -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 OI-l,
  • the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with five substituents independently selected from the group consisting -CH 3 , -CF 3 , -CH 2 CH 3 , -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 OH,
  • the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with -F and optionally substituted with one or two substituents independently selected from the group consisting of -CH 3 , -CF 3 , -CH 2 CH 3 , -OH,
  • the present invention relates to any of the aforementioned compounds, wherein X is phenyl optionally substituted with one, two, three, four or five substituents independently selected from the group consist -CH 3 , -CF 3 , -CH 2 CH 3 ,
  • n relates to any of the aforementioned
  • X one additional substituent selected from the group consisting of -CH 3 , -CF 3 , -CH 2 CH 3 , -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 OH,
  • the present invention relates to any of the aforementioned compounds, wherein X is 5-membered hereroaryl optionally substituted with one, two, three, or four substituents independently selected from the group consisting of -CH 3 , -CF 3 , -CH 2 CH 3 ,
  • the present invention relates to any of the aforementioned compounds, wherein X is isoxazolyl or pyrazolyl, in each case optionally substituted with one, two or three, substituents independently selected from the group consisting of -CH 3 , -CF 3 ,
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is (C 1 -C 6 )alkyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI,
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is unsubstituted (CrC ⁇ alkyl. In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R 2 is unsubstituted branched (d-Ce)alkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is (C 1 -C 3 )alkyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C 1 -C 3 )alkyl, (C C 3 )haloalkyl and (C 3 -C 10 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is methyl optionally substituted with one, two or three substitutents independently selected for each occurrence from the group consisting of -F, -CI,
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is ethyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI,
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is n-propyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (Ci-C 3 )alkyl, (C C 3 )haloalkyl and (C 3 -Ci 0 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is i-propyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C 1 -C 3 )alkyl, (C C 3 )haloalkyl and (C 3 -C 10 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is methyl substituted with (C 3 -C 6 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is propyl substituted with -CF 3 .
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is ethyl substituted with (C 3 -C 6 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is ethyl substituted with bicyclo[1.1.1]pentanyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is (C 3 -C 10 )cycloalkyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C 1 -C 3 )alkyl, (C C ⁇ haloalkyl and (C 3 -C 10 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is unsubstituted (C 3 -C 10 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is cyclopropyl optionally substituted with one, two, three or four substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, - OH, (C C 3 )alkyl, (C C ⁇ haloalkyl and (C 3 -C 10 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is cyclobutyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C 1 -C 3 )alkyl, (C C 3 )haloalkyl and (C 3 -C 10 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is cydopentyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C C ⁇ alkyl, (C C 3 )haloalkyl and (C 3 -C 10 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is cyclohexyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C C ⁇ alkyl, (C C 3 )haloalkyl and (C 3 -C 10 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is unsubstituted phenyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is phenyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (CrC ⁇ alkyl, (C C 3 )haloalkyl and (C 3 -C 10 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is phenyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH and -CH 3 .
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is unsubstituted isothiazolyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is isothiazolyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C 1 -C 3 )alkyl, (C C ⁇ haloalkyl and (C 3 -C 10 )cycloalkyl.
  • the present invention relates to any of the aforementioned compounds, wherein R 2 is isothiazolyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH and -CH 3 .
  • the present invention relates to any of the aforementioned
  • the present invention relates to any of the aforementioned
  • the resent invention relates to any of the aforementioned
  • the resent invention relates to any of the aforementioned
  • the present invention relates to any of the aforementioned
  • the present invention relates to any of the aforementioned
  • the present invention relates to any of the aforementioned compounds, wherein R
  • the present invention relates to any of the aforementioned
  • nt invention relates to any of the aforementioned
  • the present invention relates to any of the aforementioned
  • Another embodiment of the invention is a compound selected from the group consisting of the compounds of Examples 1-35 and pharmaceutically acceptable salts thereof.
  • one aspect of the invention provides a method of treating a disorder selected from the group consisting of an immune disorder or inflammatory disorder.
  • the method comprises administering a therapeutically effective amount of a compound of Formula I to a subject in need thereof to ameliorate a symptom of the disorder, wherein Formula I are as described above.
  • the particular compound of Formula I is a compound defined by one of the embodiments described above.
  • the disorder is an inflammatory disorder. In certain other embodiments, the disorder is an autoimmune disorder. In certain other embodiments, the disorder is rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, or epidermal hyperplasia.
  • the disorder is cartilage inflammation, bone degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myositis, polymyositis, osteoarthriti
  • the psoriasis is plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.
  • the disorder is noninfectious uveitis, Behcet's disease or
  • Another aspect of the invention provides for the use of a compound of Formula I in the manufacture of a medicament.
  • the medicament is for treating a disorder described herein.
  • Another aspect of the invention provides for the use of a compound of Formula I for treating a medical disorder, such a medical disorder described herein.
  • compounds of Formula I can inhibit the activity of RORy. Accordingly, another aspect of the invention provides a method of inhibiting the activity of RORy. The method comprises exposing a RORy to an effective amount of a compound of Formula I to inhibit said RORy, wherein Formula I is as described above. In certain embodiments, the particular compounds of Formula I are the compound defined by one of the embodiments described herein.
  • compounds of Formula I can reduce the amount of interleukin-17 (IL-17) in a subject.
  • IL-17 is a cytokine that affects numerous biological functions, including inducing and mediating pro-inflammatory responses.
  • another aspect of the invention provides a method of reducing the amount of IL-17 in a subject. The method comprises administering to a subject an effective amount of a compound of I to reduce the amount of IL-17 in the subject, wherein Formula I is as described above.
  • the particular compounds of Formula I are the compounds defined by one of the embodiments described herein.
  • the subject is a human.
  • administering the compound reduces the amount of IL-17 produced by Th-17 cells in the subject.
  • a change in the amount of IL-17 produced by, for example, Th-17 cells can be measured using procedures described in the literature, such as an ELISA assay or intracellular staining assay.
  • compounds of Formula I may inhibit the synthesis of IL-17 in a subject.
  • another aspect of the invention provides a method of inhibiting the synthesis IL-17 in a subject. The method comprises administering to a subject an effective amount of a compound of Formula I to inhibit the synthesis IL-17 in the subject, wherein Formula I is as described above.
  • the particular compounds of Formula I are the compounds defined by one of the embodiments described herein.
  • the compounds of Formula I or their pharmaceutically acceptable salts may be used in combination with additional therapeutic agents to treat medical disorders, such as medical disorders associated with inappropriate IL-17 pathway activity.
  • additional therapeutic agents include, for example, (1) a TNF-a inhibitor; (2) a non-selective COX-l/COX-2 inhibitor; (3) a selective COX-2 inhibitor, such as celecoxib and rofecoxib; (4) other agents for treating inflammatory disease and autoimmune disease including, for example, methotrexate, leflunomide, sulfasalazine,
  • azathioprine penicillamine, bucillamine, actarit, mizoribine, lobenzarit, hydroxychloroquine, d- penicillamine, aurothiomalate, auranofin, parenteral gold, oral gold, cyclophosphamide,
  • Lymphostat-B a BAFF/ APRIL inhibitor, CTLA-4-lg, or a mimetic of CTLA-4-lg; (5) a leukotriene biosynthesis inhibitor, such as a 5-lipoxygenase (5-LO) inhibitor, or a 5-lipoxygenase activating protein (FLAP) antagonist; (6) a LTD4 receptor antagonist; (7) a phosphodiesterase type IV (PDE- IV) inhibitor, such as cilomilast (ariflo) or roflumilast; (8) an antihistamine H1 receptor antagonist; (9) an od- and oc2-adrenoceptor agonist; (10) an anticholinergic agent; (1 1) a ⁇ -adrenoceptor agonist; (12) an insulin-like growth factor type I (IGF-1) mimetic; (13) a glucocorticosoid; (14) a kinase inhibitor such as an inhibitor of a Janus Kinase (e.g
  • the additional therapeutic agent is selected from the group consisting of corticosteroids, vitamin D3, anthralin and retinoids. In certain embodiments, the additional therapeutic agent is a corticosteroid. In certain embodiments, the additional therapeutic agent is vitamin D3. In certain embodiments, the additional therapeutic agent is anthralin. In certain embodiments, the additional therapeutic agent is a retinoid.
  • the amount of the compounds of Formula I and additional therapeutic agent and the relative timing of administration may be selected in order to achieve a desired combined therapeutic effect.
  • the therapeutic agents in the combination, or a pharmaceutical composition or compositions comprising the therapeutic agents may be administered in any order such as, for example, sequentially, concurrently, together, simultaneously and the like.
  • a compound of Formula I may be administered during a time when the additional therapeutic agent(s) exerts its prophylactic or therapeutic effect, or vice versa.
  • the doses and dosage regimen of the active ingredients used in the combination therapy may be determined by an attending clinician.
  • the compound of Formula I and the additional therapeutic agent(s) are administered in doses commonly employed when such agents are used as monotherapy for treating the disorder.
  • the compound of Formula I and the additional therapeutic agent(s) are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating the disorder.
  • a compound of Formula I and the additional therapeutic agent(s) are present in the same composition, which is suitable for oral administration.
  • the compound of Formula I and the additional therapeutic agent(s) may act additively or synergistically.
  • a synergistic combination may allow the use of lower dosages of one or more agents and/or less frequent administration of one or more agents of a combination therapy.
  • a lower dosage or less frequent administration of one or more agents may lower toxicity of the therapy without reducing the efficacy of the therapy.
  • Another aspect of this invention is a kit comprising a therapeutically effective amount of a compound of Formula I, a pharmaceutically acceptable carrier, vehicle or diluent, and optionally at least one additional therapeutic agent listed above.
  • a compound of the invention is administered in an amount effective to treat a condition as described herein.
  • the compounds of the invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • Therapeutically effective doses of the compounds required to treat the progress of the medical condition are readily ascertained by one of ordinary skill in the art using preclinical and clinical approaches familiar to the medicinal arts.
  • the term "therapeutically effective amount” as used herein refers to that amount of the compound being administered which will relieve to some extent one or more of the symptoms of the disorder being treated.
  • treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating as “treating” is defined immediately above.
  • treating also includes adjuvant and neo-adjuvant treatment of a subject.
  • the invention provides pharmaceutical compositions, which comprise a therapeutically-effective amount of one or more of the compounds described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
  • the pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
  • oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
  • Formulations of the present invention include those suitable for oral, nasal, topical
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 0.1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
  • a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the present invention.
  • an aforementioned formulation renders orally bioavailable a compound of the present invention.
  • Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
  • a compound of the present invention may also be administered as a bolus, electuary or paste.
  • the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxa
  • pharmaceutically-acceptable carriers such as sodium citrate or dicalcium phosphate
  • compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried.
  • compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • embedding compositions which can be used include polymeric substances and waxes.
  • the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
  • Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
  • Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically- acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
  • the invention also includes pharmaceutical compositions utilizing one or more of the present compounds along with one or more pharmaceutically acceptable carriers, excipients, vehicles, etc.
  • Topical formulations of the presently disclosed compounds may be administered topically, (intra)dermally, or transdermal ⁇ to the skin or mucosa.
  • Topical administration using such preparations encompasses all conventional methods of administration across the surface of the body and the inner linings of body passages including epithelial and mucosal tissues, including transdermal, epidermal, buccal, pulmonary, ophthalmic, intranasal, vaginal and rectal modes of administration.
  • Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, colloid, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions.
  • Liposomes may also be used.
  • Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol.
  • Such topical formulations may be prepared in combination with additional pharmaceutically acceptable excipients.
  • a penetration enhancer may be used.
  • penetration enhancers include, for example, saturated C10-C18 fatty alcohols (such as decyl alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol and stearyl alcohol), cis-unsaturated C10-C18 fatty alcohols (such as oleyl alcohol, linoleyl alcohol, ⁇ -linolenyl alcohol and linolenyl alcohol), C10-C18 fatty acids (which when saturated may include capric acid, lauric acid, myristic acid, palmitic acid, stearic acid and arachidic acid), cis-unsaturated fatty acids (such as palmitoleic acid (cis-9- hexadecenoic acid), oleic acid (cis-9-octadecenoic acid), cis-vaccenic acid (cis-11-octadecenoic acid), linoleic acid (cis
  • topical formulations which contain one or more compounds of the invention in therapeutically effective amounts that may be given in daily or twice daily doses to patients in need.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients which enhance the stability of the formulations include aldehyde scavengers, such as glycerine and propylene glycol, and antioxidants, such as butyl hydroxyanisole (BHA), butyl hydroxytoluene (BHT), propyl gallate, ascorbic acid (Vitamin C), polyphenols, tocopherols (Vitamin E), and their derivatives.
  • Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
  • dosage forms can be made by dissolving or dispersing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
  • Formulations suitable for topical administration to the eye include, for example, eye drops wherein the compound of this invention is dissolved or suspended in a suitable carrier.
  • a typical formulation suitable for ocular or aural administration may be in the form of drops of a micronised suspension or solution in isotonic, pH- adjusted, sterile saline.
  • formulations suitable for ocular and aural administration include ointments, biodegradable (i.e., absorbable gel sponges, collagen) and non-biodegradable (i.e., silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes.
  • a polymer such as crossed-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methylcellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride.
  • Such formulations may also be delivered by iontophoresis.
  • the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant.
  • Formulations suitable for intranasal administration are typically administered in the form of a dry powder (either alone; as a mixture, for example, in a dry blend with lactose; or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1 ,1 ,1 ,2-tetrafluoroethane or 1 ,1 , 1 ,2,3,3,3-heptafluoropropane.
  • the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
  • compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more
  • sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
  • Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly
  • Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
  • the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
  • the preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred.
  • parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
  • systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
  • These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
  • the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
  • the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg.
  • the effective amount may be less than when the agent is used alone.
  • the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
  • preferred dosing is one administration per day.
  • the invention further provides a unit dosage form (such as a tablet or capsule) comprising a compound of Formula I or a specific compound described herein, or pharmaceutically acceptable salts thereof, in a therapeutically effective amount for the treatment of an immune or inflammatory disorder, such as one of the particular immune disorders or inflammatory disorders described herein.
  • a unit dosage form such as a tablet or capsule
  • an immune or inflammatory disorder such as one of the particular immune disorders or inflammatory disorders described herein.
  • the compounds of Formula I may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and derivatizations that are familiar to those of ordinary skill in the art.
  • the starting materials used herein are commercially available or may be prepared by routine methods known in the art (such as those methods disclosed in standard reference books such as the COMPENDIUM OF ORGANIC
  • Compounds of Formula I may be prepared as single enantiomer or as a mixture of individual enantiomers which includes racemic mixtures.
  • Methods to obtain preferentially a single enantiomer from a mixture of individual enantiomers or a racemic mixture are well known to those ordinarily skilled in the art of organic chemistry. Such methods include but are not limited to preferential crystallization of diastereomeric salts (e.g. tartrate or camphor sulfonate), covalent derivatization by a chiral, non-racemic reagent followed by separation of the resulting
  • Compounds of Formula A-6 can be prepared as described in Scheme A.
  • Aryl halides A-1 can be converted to boronates of Formula A-2.
  • Boronates A-2 can be coupled with vinyl triflate B- 3 (prepared as described in Scheme B) to afford compounds of the Formula A-3.
  • the resulting amine of compounds of Formula A-4 can be transformed to the corresponding sulfonamides by the reaction with sulfonyl chlorides in the presence of base to afford compounds of Formula A-5.
  • the Boc group within componds of Formula A- 5 could be removed through use of acid, and subsequently the piperidine nitrogen could be coupled with an appropriate acid chloride or carboxylic acid to furnish compounds of Formula A-6.
  • Carboxylic acids of the Formula R 2 C0 2 H employed in Scheme A, C, D, and F may be commercially available, prepared by procedures described in the literature, or prepared as described in Scheme F.
  • (R)-2,3,3-Trimethylbutanoic acid and (S)-2,3,3-trimethylbutanoic acid may be prepared as described by Kido, M. et al Tetrahedron: Asym. 2007, 18, 1934-1947; and thietane acid (see WO2013/7582, which is hereby incorporated by reference for the preparation of thietane acid).
  • carboxylic acids that may be prepared by Scheme F include (R)-2- cyclopentylpropanoic acid, and (S)-2-cyclopentylpropanoic acid.
  • R 2 C0 2 H according to the Formula F-4 can be prepared from acids F-1 where R may be alkyl, cycloalkyl or aryl which are reacted with an optically active chiral oxazolidinone (e.g. (R)-benzyl oxazolidinone, (R)-4-lsopropyl-2-oxazolidinone) to provide compounds of the Formula F-2.
  • an optically active chiral oxazolidinone e.g. (R)-benzyl oxazolidinone, (R)-4-lsopropyl-2-oxazolidinone
  • Base mediated alkylation and subsequent removal of the oxazolidinone auxiliary furnishes acids of the Formula F- 4 in high optical purity.
  • a chiral oxazolidinone of a different absolute configuration e.g. (S)-benzyl oxazolidinone, (S)-4-lsopropyl-2-oxazolidinone
  • chiral acids F-4 of both configurations can be obtained.
  • Chiral purity of scalemic compounds was determined by chiral SFC (super-critical fluid chromatography) employing one of the following conditions: HPLC Method A: XBridge C18, 2.1x50 mm, 5 urn, CH3CN/H20 (0.0375% TFA), 10-100%, 0.8 mL/min, 4min; and HPLC Method B: XBridge C18, 2.1x50 mm, 5 urn, CH3CN/H20 (0.0375% TFA), 1-100%, 0.8 mL/min, 4min.
  • Method C Ultimate XB-C18, 3 ⁇ , 3.0x50mm, CH3CN/H20 (0.1 % TFA), 1-5%, 1.2 mL/min, 10 min.
  • Method D Xtimate C18, 3 ⁇ , 5.0x50mm, CH3CN/H2Q (0.1 % TFA), 1-100%, 1.2 mL/min, 10 min.
  • Method E Ultimate XB-C18, 3 ⁇ , 3.0x50mm, CH3CN/H20 (0.1 % TFA), 1-100%, 1.2 mL/min, 10 min.
  • reaction conditions length of reaction and temperature
  • reactions were followed by thin layer
  • eluants/gradients were chosen to provide appropriate Rf s or retention times (RetT).
  • DCM dichloromethane
  • DEA diethylamine
  • DIPEA diisopropylethylamine
  • DME 1 ,2-dimethoxyethane
  • DMF dimethylformamide
  • EtOAc ethyl acetate
  • EtOH ethanol
  • HATU 1-[bis(dimethylamino)-methylene]-1 H-1 ,2,3-triazolo[4,5- b]pyridinium 3-oxid hexafluorophosphate
  • MeOH methanol
  • MTBE methyl t-butyl ether
  • PE PE:
  • Step 1 3-Bromo-1-methyl-5-nitro-1 /-/-indole.
  • 3-bromo-5-nitro-1 H-indole 5.5 g, 20.6 mmol
  • THF 50ml_
  • NaH 1.9 g, 41.3 mmol, 60% w/w in mineral oil.
  • methyl iodide 6.4 ml_, 103.3 mmol
  • the reaction mixture was warmed to room temperature and stirred for 16 h. After completion, the reaction mixture was cooled, quenched with addition of ice-cooled water and extracted using EtOAc.
  • Step 3 te/ -Butyl 3-methyl-4-oxopiperidine-1-carboxylate.
  • Boc-anhydride 8 g, 36.9 mmol
  • Pd(OH) 2 2.4 g, 40% wt of ketone
  • the reaction mixture was stirred under hydrogen atmosphere (100 psi) in autoclave for 6 h at room temperature.
  • the reaction mixture was concentrated in vacuo to obtain a crude residue which was purified by silica gel column chromatography (10-15% EtOAc in hexane) to afford the title compound (8.8 g, 78%).
  • Step 4 tert-Butyl 3-methyl-4-(((trifluoromethyl) sulfonyl)oxy)-3,6-dihydropyridine-1 (2H)- carboxylate.
  • te/ -Butyl 3-methyl-4-oxopiperidine-1-carboxylate 7 g, 32.8mmol
  • NaHMDS 66 mL, 65.7 mmol, 1 M in THF
  • 1 ,1 ,1-trifluoro-/V-phenyl-/V- ((trifluoromethyl)sulfonyl)methanesulfonamide 23.4 g, 65.7 mmol
  • Step 5 tert-butyl 3-methyl-4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridine-1 (2H)- carboxylate.
  • a solution of 1-methyl-5-nitro-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H- indole (1 g, 3.32 mmol) in dioxane: water (40 mL: 5 mL) was degassed using nitrogen for 10min.
  • tert-butyl 5-methyl-4-(trifluoromethylsulfonyloxy)-5,6-dihydropyridine-1 (2H)-carboxylate 1.g, 4.05 mmol
  • K 3 P0 4 1.5g, 7.1 mmol
  • tetrakis (triphenyl phosphine) palladium(O) 375 mg, 0.32 mmol) were added, degassed for another 10 min.
  • Step 6 tert-butyl 4-(5-amino-1-methyl-1 H-indol-3-yl)-3-methylpiperidine-1-carboxylate.
  • tert-butyl 5-methyl-4-(1-methyl-5-nitro-1 H-indol-3-yl)-5,6-dihydropyridine-1 (2H)- carboxylate (1 g, 2.6 mmol) in EtOH (25 mL) were added Pd(OH) 2 (1 g, 100% w/w), ammonium formate (1.7 g, 26.9 mmol) and the reaction mixture was heated at 80 °C for 4h.
  • Step 7 tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1 H-indol-3-yl)-3- methylpiperidine-1-carboxylate.
  • te/ -butyl 4-(5-amino-1-methyl-1 H-indol-3-yl)-3- methylpiperidine-1-carboxylate 900 mg, 2.62 mmol
  • pyridine 0.32 mL, 3.93 mmol
  • 4-fluorobenzenesulfonyl chloride (613 mg, 3.14 mmol) solution in DCM (25 mL) dropwise at 0-5 °C and the resulting reaction mixture was stirred at 0-5 °C for 30 min.
  • the reaction mixture was basified with 10% aqueous NaHC0 3 solution and extracted using DCM. The combined organic layer was dried over anhydrous Na 2 S0 4
  • Step 8 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methylpiperidin-4-yl)-1 H-indol-5- yl)benzenesulfonamide.
  • Step 9 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methylpiperidin-4-yl)-1 H-indol-5- yl)benzenesulfonamide.
  • 3R,4R)-tert-butyl 4-(5-(4-fluorophenylsulfonamido)-1- methyl-1 H-indol-3-yl)-3-methylpiperidine-1-carboxylate (273 mg. 0.544 mmol) in DCM (10.9 ml_, 0.05 mmol) was added 4M HCI in dioxane (2.04 ml_, 8.16 mmol) at room temperature.
  • Step 10 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methyl-1-((R)-2,3,3-trimethylbutanoyl)-piperidin- 4-yl)-1 H-indol-5-yl)benzenesulfonamide.
  • Step 1 (R)-3-(2-cyclopentylacetyl)-4-isopropyloxazolidin-2-one.
  • Step 2 (R)-3-((R)-2-cyclopentylpropanoyl)-4-isopropyloxazolidin-2-one.
  • Mel (3.55 mL, 56.6 mmol) was added and the reaction was allowed to warm to 0 °C over 1 h and allowed to stir at 0 °C for 3 h.
  • Step 3 (R)-2-cyclopentylpropanoic acid.
  • the resulting solution was allowed to stir at room temperature overnight.
  • the reaction was quenched with 1.0 M KHS0 4 (8 mL) and extracted with EtOAc (3x).
  • Step 4 N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)-3-methylpiperidin-4-yl)-1-methyl-1 H- indol-5-yl)-4-fluorobenzenesulfonamide.
  • Example 3-5 and 32-35 were prepared analogous to Example 1 employing the appropriate sulfonyl chloride in step 7 and the appropriate carboxylic acid coupling reagent in step 10. However, chiral separation was conducted on the final product. Separation conditions: Method AA: Luxe Cellulose-4, 250x21.2 mm, 5 ⁇ , 40% EtOH/C0 2 , 80.0 mL/min; Method AB: ChiralTech IC, 250x21.2 mm, 5 ⁇ , 60-40% (3: 1) EtOAc-MeOH/C0 2 , 80.0 mL/min.
  • Method AC ChiralPak AD-3, 50 x 4 mm, 3 ⁇ , EtOH (0.05% DEA)/C0 2 , 4 mL/min.
  • Method AD ChiralPak AS- H, 150 x 4 mm, 5 ⁇ , EtOH (0.05% DEA)/C0 2 , 3 mL/min.
  • Method AE ChiralPak AD-3, 50 x 4.6 mm, 3 ⁇ , EtOH (0.05% DEA)/C0 2 , 4 mL/min.
  • Method AF ChiralPak AS-H, 150 x 4.6 mm, 5 ⁇ , EtOH (0.05% DEA)/C0 2 , 3 mL/min.
  • Step 1 tert-butyl 4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridine-1 (2H)-carboxylate.
  • Step 2 tert-butyl 4-(5-amino-1-methyl-1 H-indol-3-yl)piperidine-1-carboxylate.
  • a dry hydrogenation bottle was added dry Pd(OH) 2 /C (1600 mg) under an Ar atmosphere, followed by a solution of tert-butyl 4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridine-1 (2H)-carboxylate (8050 mg, 22.5 mmol) in EtOH (500 mL) and DCM (50 ml_).
  • the mixture was degassed and refilled with H 2 3 times, then the mixture was stirred under a hydrogen atmosphere (50 Psi) at 50 °C for 48 hours.
  • the mixture was filtered through a pad of Celite®, and the filtrate was concentrated to give the crude product (7700 mg, 100%) as a purple solid, which wasn't hydrogenated completely according to proton NMR.
  • the material was resubjected as follows: To a dry hydrogenation bottle was added dry Pd(OH) 2 /C (1500 mg) under an Ar atmosphere, followed by a solution of crude starting material (7700 mg, 23.5 mmol) in EtOH (400 mL).
  • Step 3 tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1 H-indol-3-yl)piperidine-1- carboxylate.
  • tert-butyl 4-(5-amino-1-methyl-1 H-indol-3- yl)piperidine-1-carboxylate 2200 mg, 6.678 mmol
  • 4-fluorobenzensulfonyl chloride (1950 mg, 10.0 mmol)
  • pyridine 30 mL
  • Step 4 4-fluoro-N-(1-methyl-3-(piperidin-4-yl)-1 H-indol-5-yl)benzenesulfonamide.
  • tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1 H-indol-3-yl)piperidine-1 - carboxylate (1200 mg, 2.461 mmol) in DCM (15 mL) was added HCI/dioxane (7 mL, 4 M) at 0-5 °C in an ice/water bath. The brown solution was stirred at 20 °C for 2 hours. The reaction was combined with three other batches for workup.
  • Step 5 4-fluoro-N-(3-(1-(isothiazole-5-carbonyl)piperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide.
  • the title compound was prepared in an analogous manner to Example 1 , step 10 employing isothiazole-5-carboxylic acid .
  • LC/MS [M+H] + : 499; Rt 2.93 (Method A).
  • Step 1 tert-butyl 2,2-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1 (2H)- carboxylate.
  • tert-butyl 2,2-dimethyl-4-oxopiperidine-1-carboxylate 7.76 g, 34.1 mmol
  • dry THF 130 mL
  • sodium bistrimethyldisilazide 7.51 g 41.0 mmol
  • Step 2 tert-butyl 2,2-dimethyl-4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridine-1 (2H)- carboxylate.
  • Step 3 tert-butyl 4-(5-amino-1-methyl-1 H-indol-3-yl)-2,2-dimethylpiperidine-1 -carboxylate.
  • Pd/C 200 mg
  • tert-butyl 2,2-dimethyl-4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridine-1 (2H)- carboxylate 1000 mg, 2.594 mmol
  • EtOH 75 mL
  • DCM 15 mL
  • Step 4 tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1 H-indol-3-yl)-2,2- dimethylpiperidine-1-carboxylate.
  • tert-butyl 4-(5-amino-1-methyl-1 H-indol-3-yl)- 2,2-dimethylpiperidine-1-carboxylate 900 mg, 2.52 mmol
  • 4-fluorobenzenesulfonyl chloride 735 mg, 3.78 mmol
  • TEA 764 mg, 7.55 mmol
  • Step 5 N-(3-(2,2-dimethylpiperidin-4-yl)-1 -methyl-1 H-indol-5-yl)-4- fluorobenzenesulfonamide.
  • tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl- 1 H-indol-3-yl)-2,2-dimethylpiperidine-1-carboxylate 900 mg, 1.75 mmol
  • DCM 25 mL
  • HCI/Dioxane 15 mL
  • the solvent was removed under reduced pressure to give the title compound (800 mg, 100%) as a white solid, which was used directly without further purification.
  • Step 6 4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide.
  • N-(3-(2, 2-dimethylpiperidin-4-yl)-1 -methyl-1 H-indol-5- yl)-4-fluorobenzenesulfonamide 400 mg, 0.885 mmol
  • DCM 25 mL
  • TEA 269 mg, 2.65 mmol
  • Step 6 (R)-4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide.
  • the first eluting isomer (7.33 min) was arbitrarily assigned as (S)-4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide (65 mg) as a white solid.
  • Step 1 N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5-yl)- 4-fluorobenzenesulfonamide.
  • N-(3-(2,2-dimethylpiperidin-4-yl)-1-methyl-1 H- indol-5-yl)-4-fluorobenzenesulfonamide prepared as described in Example 18) (400 mg, 0.885 mmol) in DCM (25 mL) was added TEA (269 mg, 2.65 mmol) at 0 °C and the mixture was stirred untill the solution turned clear.
  • Step 2 (R)-N-(3-(1 -(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5- yl)-4-fluorobenzenesulfonamide.
  • the first eluting isomer (4.99 min) was arbitrarily assigned as (S)-N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1- methyl-1 H-indol-5-yl)-4-fluorobenzenesulfonamide (92 mg, 46 %) as a white solid.
  • the second eluting isomer (5.34 min) was arbitrarily assigned as (R)- N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1 -methyl-1 H-indol-5-yl)-4- fluorobenzenesulfonamide (95 mg, 48 %) as a white solid.
  • 1 H NMR 400 MHz, DMSO-d 6 ) ⁇ 9.78 (br.
  • Steps 1 (S)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-one.
  • a flask with a mixture of benzyl (S)-2-methyl-4-oxopiperidine-1-carboxylate (500 mg, 2.02 mmol) and Pd/C (5% by weight, 215 mg) in EtOH (10 mL) was evacuated with water aspiration and then put under hydrogen gas.
  • the mixture was stirred under 1.1 bar hydrogen over-pressure for 1 h.
  • the mixture was filtered through a Celite® plug, and the filtrate was concentrated in vacuo.
  • Step 2 (S)-1-(cyclopentanecarbonyl)-2-methyl-1 ,2,3,6-tetrahydropyridin-4-yl
  • Step 3 (S)-cyclopentyl(2-methyl-4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridin- 1 (2H)-yl)methanone.
  • Steps 4 N-(3-((2S,4S)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-yl)-1 -methyl-1 H-indol- 5-yl)-4-fluorobenzenesulfonamide.
  • the reaction mixture was filtered through a PTFE filter, and concentrated in vacuo.
  • the reduced product was unstable and used immediantly.
  • the residue was dissolved in pyridine (3 mL).
  • 4-Fluorobenzenesulfonyl chloride (40 mg, 0.20 mmol) was then added at room temperature, and the mixture was stirred for 90 min.
  • the mixture was concentrated in vacuo, and the residue was purified by prep-HPLC to provide the title compound (3.7 mg, 5.5%).
  • Step 1 tert-butyl 4-(5-((4-fluoro-3-methoxyphenyl)sulfonamido)-1 -methyl-1 H-indol-3- yl)piperidine-1-carboxylate.
  • Step 3 4-fluoro-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-1 H-indol-5-yl)-3- methoxybenzenesulfonamide.
  • isobutyryl chloride 4.7 mL, 44.7 mmol.
  • the reaction mixture was stirred at room temperature for 1 h.
  • the pyridine was evaporated, and 1 M HCI and DCM were added.
  • the phases were separated and the organic layer was concentrated.
  • the residue was purified by flash chromatography
  • Example 25-31 were prepared in an analogous manner to Example 22 employing the necessary benzenesulfonyl chloride in step 1 and the appropriate carboxylic acid in step 5.
  • the activity of compound of the invention can be determined by a co-activator recruitment by TR-FRET (time- resolved fluorescence resonance energy transfer) assay.
  • TR-FRET time- resolved fluorescence resonance energy transfer
  • the assay is based on the interaction between N-terminally Six-Histidine-tagged-RORC2 ligand binding domain (6-His-RORC2 LBD), expressed in E. coli and purified by affinity chromatography, and biotin-coactivator peptide SRC1-2 (biotin-aminohexanoic acid-
  • Streptavidin-APC (Ex. 620 nm, Em. 665 nm, which binds to biotin).
  • FRET close proximity
  • this signal is measured at 665 nm. Due to the long lasting fluorescence emission of Europium, the non-specific, short-lived fluorescence is time-resolved (TR) from the fluorescence of interest.
  • Inhibitors of the interaction of receptor and coactivator peptide are detected by a decrease in TR-FRET signal.
  • the aforementioned assay was performed as outlined below.
  • the assay was carried out in black polystyrene, 384-well plates in a total assay volume of 50.5 ⁇ _.
  • the assay buffer contained 50 mM TRIS-HCL pH 7.5, 1 mM NaCI, 2 mM MgCI 2 , 0.5 mg/mL bovine serum albumin, and 5 mM dithiothreitol.
  • the final concentration of reagents was 6.3 nM RORC2 LBD, 200 nM SRC1-2, 50 nM streptavidin APC, 1 nM Europium-labeled anti-His antibody, and varying concentrations of compounds such that final concentration of DMSO is 1 % (v/v).
  • the assay steps were: (1) dispensing 500 ⁇ compound at 100x final concentration in DMSO (test wells) or DMSO only (control wells for no inhibition); and (2) dispensing 50 ⁇ mixture of the other assay components including receptor (test wells) or excluding receptor (control wells for maximal inhibition).
  • TR-FRET signal was determined by calculating the ratio of 665 nm by 615 nm and IC 50 values of compounds of the invention (Table 1) were determined by the non-linear regression analysis of dose response curves.
  • Example ICso (nM) Example ICso (nM)
  • Example ICso (nM) Example ICso (nM)
  • the activity of compound of the invention can be also be determined by a luciferase reporter Gal4-RORC2 activity assay.
  • Neuro2A cells murine neuroblastoma cell line obtained from HPACC, cat #89121404
  • pM mammalian expression vector
  • Gal4-RORC2 LBD is constitutively active in the transfected Neuro2a cells, resulting in a robust luciferase response in the absence of stimulation.
  • RORC2 inhibitor Upon treatment with an RORC2 inhibitor the transcriptional response is decreased and the magnitude of the decrease in response is dose-dependently related to the intrinsic efficacy of the inhibitor.
  • the growth medium was composed by MEM EBS w/o L-glutamine, 10% (v/v) FBS, 2 mM L-glutamine and 1x non-essential aminoacid (NEAA);
  • the seeding medium was composed by MEM EBS w/o L-glutamine, w/o phenol red, 4% (v/v) FBS, 2 mM L-glutamine, 1x NEAA, 1 % Penicillin (10,000 U/mL)/Streptomycin (10,000 ⁇ g/mL);
  • the assay medium was composed by MEM EBS w/o L-glutamine, w/o phenol red, 4% (v/v) FBS, 2 mM L-glutamine, 1x NEAA, 1 % Penicillin (10,000 U/mL)/Streptomycin (10,000 g/mL).
  • Neuro2A cells were cultured in growth medium in humidified chambers at 37°C and 5% C0 2 using standard tissue culture procedures.
  • Neuro2A cells were suspended in seeding medium and mixed with plasmids and transfection reagent which was dissolved in OptiMEM I reduced serum medium (InVitrogen), and then seeded to 384-well plates (Corning, Black, Clear bottom) in 40 ⁇ _/ ⁇ containing 12,500 cells, 17.25 ng Gal4-Luc3, 5.75 ng either empty pM vector ('no receptor control' wells) or pM-Gal4RORgamma-LBD, and 0.1 1 ⁇ _ Lipofectamine2000.
  • the treatment was started 20-24 hr after seeding and transfection of the cells.
  • the activity of compound of the invention can be also be determined by an IL-17 production from human Th17 cells assay.
  • this assay measures blockade of IL-17 production, the signature cytokine of T helper 17 (Th17) cells, by compounds.
  • Purified human CD4+ T cells are stimulated with anti-CD3 + anti-CD28 and incubated with a cytokine cocktail that induce their differentiation into Th17 in the absence or presence of various concentrations of compound. After 6 days, IL-17A concentration is measured in the cell culture supernatant with an ELISA kit (MSD).
  • MSD ELISA kit
  • CD4+ T cells were purified from buffy coats from healthy donors (obtained from Massachusetts General Hospital) by negative selection the following procedure: Mixing 25 mL of blood with 1 mL of Rosette Sep CD4+ T cell enrichment cocktail
  • Ficoll Paque Plus (Amersham GE Healthcare) followed by application of a layer of 14 mL Ficoll Paque Plus (Amersham GE Healthcare) and subsequent centrifugation at 1200 g for 20 min at room temperature. The Ficoll layer was then harvested and washed with phosphate saline buffer containing 2% (v/v) fetal bovine serum and cells were resuspended with RPMI medium containing 10 % (v/v) fetal bovine serum and 10% (v/v) DMSO, frozen and kept in LN2 until used.
  • a vial containing 10 7 CD4+ T cells is thawed rapidly in 37°C water bath, immediately transferred into 20 mL X-Vivo 15 medium (Lonza), is spun for 6 min at 300xg, the supernatant is discarded, and the resulting pellet is re-suspended at 10 6 cells/mL in 50 mL fresh X-Vivo 15 medium, followed by storage overnight in a tissue culture vessel in a humidified chamber at 37°C and 5% C0 2 .
  • Serial dilutions of compounds of the invention are prepared at 10x final concentration in X-Vivo15 medium containing 3% (v/v) DMSO.
  • a 384-well tissue culture plate was coated with 10 ⁇ g mL anti-hCD3 (eBioscience) at 50 L/well. After 2 hr at 37°C, the supernatant is discarded and the coated plates are kept in a sterile tissue culture hood.
  • Cytokine plus anti-CD28 cocktail is prepared by mixing 25 ng/mL hlL-6 (Peprotech), 5 ng/mL hTGFbetal (Peprotech), 12.5 ng/mL IL-1 beta (Peprotech), 25 ng/mL hlL-21 , 25 ng/mL hlL- 23 (R&D Systems), and 1 ug/mL anti-hCD28 (eBioscience) in X-Vivo 15 medium.
  • the cytokine plus anti-CD28 cocktail with CD4+ cells is prepared such that the cocktail is diluted 10-fold and cell density is 0.22 x 10 6 /mL. The mixture is incubated 1 hr at 37°C.
  • Measurement is carried out in a Sector Imager 6000 by the same manufacturer. Signal units from the instrument are converted to pg/mL using a calibration curve with known amounts of IL-17A. IC 50 values of test compounds (Table 2) are determined by the non-linear regression analysis of dose response curves.
  • Example IC 50 (nM) Example IC 50 (nM) Example IC 50 (nM) Example IC 50 (nM)
  • Example ICso (nM) Example ICso (nM)
  • Example ICso (nM) Example ICso (nM)
  • Superantigens bind to the cell surface of major histocompatibilty complex (MHC) molecules, without intracellular processing. They stimulate T cells via the T cell receptor, irrespective of the antigen specificities. Therefore, bacterial superantigens are able to activate a large pool of CD4+ as well as CD8+ T cells in contrast to the low T cell frequency for conventional antigens.
  • CD4+ T cells can be classified into various subsets (ThO, Th1 , Th2, Th17) based on their respective cytokine secretion profiles. ThO cells are uncommitted naive precursor cells that primarily produce IL-2 upon stimulation. ThO cells upon activation can differentiate into Th1 , Th2, or the Th17 subset depending on the local cytokine milieu.
  • Th1 cells mainly produce lnf- ⁇ ; Th2 cells, IL-4, IL-5, and IL- 13, and Th17 cells, IL-17, and IL-22.
  • T helper subset occurs over days, or longer.
  • the various cytokines i.e. IL-2, IL-4, lnf- ⁇ , IL-17
  • ThO Th1 , Th2
  • C57BL/6, Balb/c, or C3H/HeJ mice which are dosed orally with compound 1 to 2 hr prior to superantigen injection on the day of the experiment (Day 0) based on the pharmacokinetic (PK) profile of the compound.
  • An optional dose may be given the day before superantigen injection (Day -1) to further inhibit the response if necessary.
  • C57BL/6 and Balb/c mice will be sensitized 1 hr prior to supernatigen injection with approximately 25 mg/mouse D-Galactosamine intraperitoneally (C3H/HeJ mice do not need to be sensitized). Based on the literature superantigen is typically given at 10 ⁇ g/mouse intraperitoneally. Mice will be sacrificed at 3 hr for RNA analysis or up to 6 hr for cytokine analysis.
  • 5% imiquimod (IMQ) cream (3M Pharmaceuticals) is applied to the back and right ear of each experimental mouse for two consecutive days. Control mice are treated similarly with a commercially available vehicle cream. The experimental mice are then
  • ear thickness is measured on all days by digital micrometer (Mitutoyo). Tissues, such as ears and speens, are harvested on Day 5 for RNA analysis. Ear swelling and serum measurements are also made.
  • mice Ears from BALB/c mice were each injected intra-dermally every other day with 150 ng of mouse recombinant IL-23 (eBiosciences) or PBS in a total volume of 25 ⁇ . Ear swelling was measured in triplicate using a micrometer (Mitutoyo) right before each IL-23 challenge. On Day 14, mice were euthanized and ears were collected for measurement of cytokine levels, gene expression levels and hystopathological evaluation. Mice were administered 3 - 100 mg/kg of an RORC2 modulator or vehicle once daily orally for the duration of the study. Alternatively, the RORC2 modulator was applied topically once or twice daily using a standard formulation

Abstract

The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.

Description

Sulfonamide-Substituted Indole Modulators of RORC2 and Methods of Use Thereof
BACKGROUND OF THE INVENTION
Retinoid-related orphan receptors (ROR) are reported to have an important role in numerous biological processes. Scientific investigations relating to each of retinoid-related orphan receptors RORa, ROR , and RORY have been described in the literature. Continuing research in this field is spurred by the promise of developing new therapeutic agents to treat medical disorders associated with retinoid-related orphan receptor activity.
RORy has been reported to be expressed in high concentration in various tissues, such as thymus, kidney, liver, muscle, and certain fat tissue. Two isoforms of RORy have been identified and are referred to as y1 and y2 (also referred to as RORyt). Expression of the y2 isoform has been reported to appear in, for example, double-positive thymocytes. Compounds capable of modulating RORyt activity are contemplated to provide a therapeutic benefit in the treatment of multiple medical disorders, including immune and inflammatory disorders.
Numerous immune and inflammatory disorders continue to afflict millions of patients worldwide. Significant advances have been made in treating these disorders. However, current therapies do not provide satisfactory results for all patients due to, for example, detrimental side effects or insufficient efficacy. Treatments for immune and inflammatory disorders vary depending on the particular medical disorder, and often involve use of immunosuppressive drugs. Surgery (e.g. , splenectomy), plasmapheresis, or radiation can be used in certain instances.
One exemplary immune disorder in need of better therapy is psoriasis. Psoriasis is a T cell- mediated inflammatory disease that affects approximately 2% to 3% of adults and has a substantial adverse impact on the quality of life for patients suffering from this disorder. Plaques resulting from psoriasis can be painful and are visually unappealing. Various therapeutics have been developed in an attempt to treat psoriasis. However, the traditional therapies for psoriasis often have toxic adverse effects. Accordingly, a need exists for improved treatments for psoriasis as well as other immune and inflammatory disorders.
SUMMARY
The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORy activity and/or reducing the amount of I L-17 in a subject, and methods of treating various medical disorders using such compounds. In particular, one aspect of the invention relates to compounds represented by Formula I:
Figure imgf000003_0001
I
and pharmaceutically acceptable salts, pharmaceutically active metabolites, pharmaceutically acceptable prodrugs, and pharmaceutically acceptable solvates thereof; wherein R1, X and W are as defined in the Detailed Description.
Another aspect of the invention provides a method of treating a subject suffering from a medical disorder. The method comprises administering to the subject a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, as described in the Detailed Description. A large number of disorders may be treated using the compounds described herein. For example, the compounds described herein may be used to treat an immune disorder or inflammatory disorder, such as rheumatoid arthritis, psoriasis, chronic graft- versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic
thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, epidermal hyperplasia, and other medical disorders described herein.
DETAILED DESCRIPTION
The invention provides compounds, pharmaceutical compositions, methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and therapeutic uses of said compounds and pharmaceutical compositions. The practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in "Comprehensive Organic Synthesis" (B.M. Trost & I. Fleming, eds., 1991-1992); "Handbook of experimental immunology" (D.M. Weir & C.C. Blackwell, eds.); "Current protocols in molecular biology" (F.M. Ausubel et al., eds., 1987, and periodic updates); and "Current protocols in immunology" (J.E. Coligan et al., eds., 1991), each of which is herein incorporated by reference in its entirety.
Various aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section. Further, when a variable is not accompanied by a definition, the previous definition of the variable controls.
It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any subject matter claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and/or" unless stated otherwise. Furthermore, use of the term "including" as well as other forms, such as "include", "includes," and "included," is not limiting.
It is to be understood that the methods and compositions described herein are not limited to the particular methodology, protocols, cell lines, constructs, and reagents described herein and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods and compositions described herein, which will be limited only by the appended claims.
All publications and patents mentioned herein are incorporated herein by reference in their entirety for the purpose of describing and disclosing, for example, the constructs and
methodologies that are described in the publications, which might be used in connection with the methods, compositions and compounds described herein.
Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates.
Definitions
"ROR" stands for Retinoic acid receptor-related Orphan Receptor. There are three forms of ROR, ROR-a, -β, and -γ and each is encoded by a separate gene (RORA, RORB, and RORC respectively). There are two subtypes of RORC: 1 and 2. Subtype 2 is also called "t". The human RORC gene is also called TOR; RORG; RZRG; NRIF3; and RZR-GAMMA. The human protein RORC is also called nuclear receptor ROR-gamma; nuclear receptor RZR-gamma; retinoic acid-binding receptor gamma; retinoid-related orphan receptor gamma; RAR-related orphan receptor C, isoform a; RAR-related orphan nuclear receptor variant 2; nuclear receptor subfamily 1 group F member 3. As used herein, "RORv" and "RORC2" are used interchangeably to refer to a protein from a RORC subtype 2 gene.
As used herein, the term "modulator" refers to a compound that alters an activity of a molecule. For example, a modulator can cause an increase or decrease in the magnitude of a certain activity of a molecule compared to the magnitude of the activity in the absence of the modulator. In certain embodiments, a modulator is an inhibitor, which decreases the magnitude of one or more activities of a molecule. In certain embodiments, an inhibitor completely prevents one or more activities of a molecule. In certain embodiments, a modulator is an activator, which increases the magnitude of at least one activity of a molecule. In certain embodiments the presence of a modulator results in an activity that does not occur in the absence of the modulator.
The term "alkyl" refers to a substituent obtained by removing a hydrogen from a saturated, straight (i.e. unbranched) or branched carbon chain (or carbon), or combination thereof, which has the number of carbon atoms designated (i.e. C^Ce means one to six carbons). Examples of alkyl substituents include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and tert-butyl), pentyl, isoamyl, hexyl and the like.
The term "haloalkyl" is an alkyl in which at least one hydrogen on the alkyl is replaced with a halogen atom. In certain embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are all the same as one another. In other embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are not all the same as one another.
The term "cycloalkyl" refers to a substituent obtained by removing a hydrogen atom from a saturated carbocycle having the number of carbon atoms designated (i.e. C3-C8 means three to eight carbons). Cycloalkyl refers to both a radical of a single ring saturated carbocycle, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, as well as a radical of a two or three ring bridged, fused or spiro saturated carbocycle, such as bicyclo[4.2.0]octane and decalinyl.
The term "five-membered heteroaryl" whether used alone or as part of another group, is defined herein as a ring system having five ring atoms wherein at least one ring atom, alternatively 2 ring atoms, alternatively 3 ring atoms, alternatively 4 ring atoms, is a heteroatom independently selected in each instance from, unless otherwise indicated, the group consisting of nitrogen (N), oxygen (O), and sulfur (S), and wherein the ring is partially unsaturated. In a group that has a heteroaryl substituent, unless otherwise indicated, the ring atom of the heteroaryl substituent that is bound to the group may be the at least one heteroatom, or it may be a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon may be in a different ring from the at least one heteroatom. Where so indicated, heteroaryl groups can be substituted. If the heteroaryl substituent is substituted with a group or substituent, the group or substituent may be bound to the heteroatom, or it may be bound to a ring carbon atom, where the ring carbon atom may be in the same ring as the heteroatom(s), or where the ring carbon atom may be in a different ring from the heteroatom(s). Examples of monocyclic heteroaryl rings include, but are not limited to, 1 ,2,3,4-tetrazolyl, [1 ,2,3]triazolyl, [1 ,2,4]triazolyl, triazinyl, thiazol-2-yl, thiazol-4-yl, imidazol-1-yl, 1 H-imidazol-2-yl, 1 H-imidazol-4-yl, oxazolyl, isoxazolin-5-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, and thiophen-4-yl.
This specification uses the terms "substituent," "radical," and "group" interchangeably. If a group of substituents are collectively described as being optionally substituted by one or more of a list of substituents, the group may include: (1) unsubstitutable substituents, (2) substitutable substituents that are not substituted by the optional substituents, and/or (3) substitutable substituents that are substituted by one or more of the optional substituents.
If a substituent is described such that it "may be substituted" or as being "optionally substituted" with up to a particular number of non-hydrogen substituents, that substituent may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen substituents or by up to the maximum number of substitutable positions on the substituent, whichever is less. Thus, for example, if a substituent is described as a heteroaryl optionally substituted with up to 3 non-hydrogen substituents, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen substituents as the heteroaryl has substitutable positions. To illustrate, tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen substituent. To illustrate further, if an amino nitrogen is described as being optionally substituted with up to 2 non-hydrogen substituents, then the nitrogen will be optionally substituted with up to 2 non-hydrogen substituents if the amino nitrogen is a primary nitrogen, whereas the amino nitrogen will be optionally substituted with up to only 1 non-hydrogen substituent if the amino nitrogen is a secondary nitrogen.
As used herein compounds of Formula I may be referred to as a "compound(s) of the invention." Such terms are also defined to include all forms of the Formula I including hydrates, solvates, isomers, crystalline and non-crystalline forms, isomorphs, polymorphs, and metabolites thereof. For example, the compounds of Formula I and pharmaceutically acceptable salts thereof, may exist in unsolvated and solvated forms. When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non- stoichiometry will be the norm.
A "metabolite" of a compound disclosed herein is a derivative of that compound that is formed when the compound is metabolized. The term "active metabolite" refers to a biologically active derivative of a compound that is formed when the compound is metabolized. The term "metabolized," as used herein, refers to the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes, such as, oxidation reactions) by which a particular substance is changed by an organism. Thus, enzymes may produce specific structural alterations to a compound. For example, cytochrome P450 catalyzes a variety of oxidative and reductive reactions while uridine diphosphate glucuronyl transferases catalyze the transfer of an activated glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulfhydryl groups. Further information on metabolism may be obtained from The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill (1996). Metabolites of the compounds disclosed herein can be identified either by administration of compounds to a host and analysis of tissue samples from the host, or by incubation of compounds with hepatic cells in vitro and analysis of the resulting compounds. Both methods are well known in the art. In some embodiments, metabolites of a compound are formed by oxidative processes and correspond to the corresponding hydroxy-containing compound. In some embodiments, a compound is metabolized to pharmacologically active metabolites.
In some embodiments, compounds described herein could be prepared as prodrugs. A "prodrug" refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. An example, without limitation, of a prodrug would be a compound described herein, which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound. In certain embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound. To produce a prodrug, a pharmaceutically active compound is modified such that the active compound will be regenerated upon in vivo administration. The prodrug can be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. By virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo, those of skill in this art, once a pharmaceutically active compound is known, can design prodrugs of the compound, (see, for example, Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392; Silverman (1992), The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc., San Diego, pages 352-401 , Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985).
Prodrug forms of the herein described compounds, wherein the prodrug is metabolized in vivo to produce a derivative as set forth herein are included within the scope of the claims. In some cases, some of the herein-described compounds may be a prodrug for another derivative or active compound. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. Prodrugs may be designed as reversible drug derivatives, for use as modifiers to enhance drug transport to site-specific tissues. In some embodiments, the design of a prodrug increases the effective water solubility. See, e.g. , Fedorak et al., Am. J. Physiol., 269:G210-218 (1995); McLoed et al., Gastroenterol, 106:405-413 (1994); Hochhaus et al., Biomed. Chrom., 6:283-286 (1992); J. Larsen and H. Bundgaard, Int. J. Pharmaceutics, 37, 87 (1987); J. Larsen et al., Int. J. Pharmaceutics, 47, 103 (1988); Sinkula et al., J. Pharm. Sci. , 64: 181-210 (1975); T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series; and Edward B. Roche, Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, all incorporated herein in their entirety.
The compounds of the invention may have asymmetric carbon atoms. The carbon-carbon bonds of the compounds of the invention may be depicted herein using a solid line, a solid wedge or a dotted wedge. The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers (e.g. specific enantiomers, racemic mixtures, etc.) at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included. For example, unless stated otherwise, it is intended that the compounds of the invention can exist as enantiomers and diastereomers or as racemates and mixtures thereof. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
Stereoisomers of compounds of the invention include cis and trans isomers, optical isomers such as R and S enantiomers, diastereomers, geometric isomers, rotational isomers,
conformational isomers, and tautomers of the compounds of the invention, including compounds exhibiting more than one type of isomerism; and mixtures thereof (such as racemates and diastereomeric pairs). Also included are acid addition or base addition salts wherein the counterion is optically active, for example, D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL- arginine.
When any racemate crystallizes, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
The present invention also includes isotopically-labeled compounds, which are identical to those recited in Formula I herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that may be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as, but not limited to, 2H, 3H, 13C, 14C, 15N, 1sO, 170, 31P, 32P, 35S, 18F, and 36CI. Certain isotopically- labeled compounds of Formula (I) and Formula (II), for example those into which radioactive isotopes such as 3H and 140 are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically-labeled compounds the invention may generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting an isotopically-labeled reagent for a non-isotopically-labeled reagent.
The compounds of this invention may be used in the form of salts derived from inorganic or organic acids. Depending on the particular compound, a salt of the compound may be
advantageous due to one or more of the salt's physical properties, such as enhanced
pharmaceutical stability in differing temperatures and humidities, or a desirable solubility in water or oil. In some instances, a salt of a compound also may be used as an aid in the isolation, purification, and/or resolution of the compound.
Where a salt is intended to be administered to a patient (as opposed to, for example, being used in an in vitro context), the salt preferably is pharmaceutically acceptable. The term
"pharmaceutically acceptable salt" refers to a salt prepared by combining a compound of Formula I with an acid whose anion, or a base whose cation, is generally considered suitable for human consumption. Pharmaceutically acceptable salts are particularly useful as products of the methods of the present invention because of their greater aqueous solubility relative to the parent compound. For use in medicine, the salts of the compounds of this invention are non-toxic
"pharmaceutically acceptable salts." Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, hydrofluoric, boric, fluoroboric, phosphoric, metaphosphoric, nitric, carbonic, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric,
ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic, malic,
methanesulfonic, trifluoromethanesulfonic, succinic, toluenesulfonic, tartaric, and trifluoroacetic acids. Suitable organic acids generally include but are not limited to aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.
Specific examples of suitable organic acids include but are not limited to acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, toluenesulfonate, 2-hydroxyethanesulfonate, sufanilate, cyclohexylaminosulfonate, algenic acid, β- hydroxy butyric acid, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycerophosphate, heptanoate, hexanoate, nicotinate, 2-naphthalesulfonate, oxalate, palmoate, pectinate, 3- phenylpropionate, picrate, pivalate, thiocyanate, and undecanoate.
Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, i.e., sodium or potassium salts; alkaline earth metal salts, e.g. , calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts. In another embodiment, base salts are formed from bases which form non-toxic salts, including aluminum, arginine, benzathine, choline, diethylamine, diolamine, glycine, lysine, meglumine, olamine, tromethamine and zinc salts.
Organic salts may be made from secondary, tertiary or quaternary amine salts, such as tromethamine, diethylamine, Ν, Ν'-benzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl (Ci-C6) halides (e.g. , methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (i.e. , dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (i.e. , decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (i.e., benzyl and phenethyl bromides), and others.
In one embodiment, hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
Compounds
In the following description of compounds suitable for use in the methods described herein, definitions of referred-to standard chemistry terms may be found in reference works (if not otherwise defined herein), including Carey and Sundberg "Advanced Organic Chemistry 4th Ed." Vols. A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the ordinary skill of the art are employed. Unless specific definitions are provided, the nomenclature employed in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those known in the art. Standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.
In certain embodiments, the compounds of the invention described herein are selective for RORy over RORa and/or ROR .
Generally, an inhibitor compound of RORy used in the methods described herein is identified or characterized in an in vitro assay, e.g., an acellular biochemical assay or a cellular functional assay. Such assays are useful to determine an in vitro IC50 for said compounds. In some embodiments, the RORy inhibitor compound used for the methods described herein inhibits RORy activity with an in vitro IC50 of less than 25 μΜ (e.g., less than 20 μΜ, less than 10 μΜ, less than 1 μΜ, less than 0.5 μΜ, less than 0.4 μΜ, less than 0.3 μΜ, less than 0.1 , less than 0.08 μΜ, less than 0.06 μΜ, less than 0.05 μΜ, less than 0.04 μΜ, less than 0.03 μΜ, less than less than 0.02 μΜ, less than 0.01 , less than 0.008 μΜ, less than 0.006 μΜ, less than 0.005 μΜ, less than 0.004 μΜ, less than 0.003 μΜ, less than less than 0.002 μΜ, less than 0.001 , less than 0.00099 μΜ, less than 0.00098 μΜ, less than 0.00097 μΜ, less than 0.00096 μΜ, less than 0.00095 μΜ, less than 0.00094 μΜ, less than 0.00093 μΜ, less than 0.00092, or less than 0.00090 μΜ). In some embodiments, the RORy inhibitor compound is a compound described in the
Exemplification.
Described herein are compounds of Formula I. Also described herein are pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically active metabolites, and pharmaceutically acceptable prodrugs of such compounds. Pharmaceutical compositions that include at least one such compound or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically active metabolite or pharmaceutically acceptable prodrug of such compound, are provided. In some embodiments, when compounds disclosed herein contain an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the art. In certain embodiments, isomers and chemically protected forms of compounds having a structure represented by Formula I are also provided.
One aspect of the invention relates to a compound of Formula I:
Figure imgf000012_0001
I
or a pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, wherein,
X is phenyl or 5-membered hereroaryl, in each case optionally substituted with one, two, three, four or five substituents independently selected from the grou of -CH3, -CF3, -
CH2CH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2OH, -OCH2CH2OCH3,
Figure imgf000012_0002
and -CN;
R1 is -CH or -CH2CH3;
W is optionally substituted with one, two, three, four or five -CH3; and
R2 is
Figure imgf000012_0003
10)cycloalkyl, phenyl or isothiazolyl , optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C1-C3)alkyl, (CrC^haloalkyl and (C3-C8)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R1 is -CH3.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R1 is -CH2CH3.
In certain embodiments, the present invention relates to any of the aforementioned
Figure imgf000012_0004
compounds, wherein W is optionally substituted with one, two, three, four or five -CH3.
In certain embodiments, the present invention relates to any of the aforementioned
Figure imgf000012_0005
compounds, wherein W is optionally substituted with one, two, three, four or five -CH3; and R1 is -CH3. In certain embodiments, the present invention relates to any of the aforementioned
Figure imgf000013_0001
compounds, wherein W is
In cetrain embodiments, the resent invention relates to any of the aforementioned
Figure imgf000013_0002
compounds, wherein W is ; and R1 is -CH3
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein W with one -CH3.
In certain embod lates to any of the aforementioned
compounds, wherein W
Figure imgf000013_0003
In certain embod nvention relates to any of the aforementioned
compounds, wherein W
Figure imgf000013_0004
; and R1 is -CH3.
In certain ention relates to any of the aforementioned
compounds, whe
In certain ention relates to any of the aforementioned
compounds, whe
Figure imgf000013_0005
nd R1 is -CH3.
In certain embodi vention relates to any of the aforementioned
compounds, wherein W i
Figure imgf000013_0006
In certain vention relates to any of the aforementioned
compounds, whe
Figure imgf000014_0001
and R is -CH3.
In certain embod nvention relates to any of the aforementioned
compounds, wherein W
In certain embod nvention relates to any of the aforementioned
compounds, wherein W
Figure imgf000014_0002
; and R1 is -CH3.
In certain on relates to any of the aforementioned
compounds, whe
In certain on relates to any of the aforementioned
compounds, whe
Figure imgf000014_0003
R1 is -CH3.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein W with two -CH3.
In certain embod lates to any of the aforementioned
compounds, wherein W
Figure imgf000014_0004
In certain embodiments, the present invention relates to any of the aforementioned
Figure imgf000014_0005
compounds, wherein ; and R1 is -CH In certain ention relates to any of the aforementioned
compounds, whe
Figure imgf000015_0001
In certain embodi on relates to any of the aforementioned
compounds, wherein W i
Figure imgf000015_0002
R1 is -CH3.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is unsubstituted phenyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with one, two, three, four or five substituents independently selected from the group consi -CH3, -CF3, -CH2CH3, -OH, -OCH3,
-OCH2CH3, -OCH2CH2OH, -OCH2CH2OCH3,
Figure imgf000015_0003
-F, -CI, -Br and -CN.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with one substituent selected from the group consisting of with -CH3, -CF3, -CH2CH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2OH,
Figure imgf000015_0004
-OCH2CH2OCH3, w , -F, -CI, -Br and -CN.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with two substituents independently selected from the group consisting -CH3, -CF3, -CH2CH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2OH,
Figure imgf000015_0005
-OCH2CH2OCH3, w , -F, -CI, -Br and -CN.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with three substituents independently selected from the group consisting of -CH3, -CF3, -CH2CH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2OH,
-OCH2CH2OCH3, -F, -CI, -Br and -CN.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with four substituents independently selected from the group consisting -CH3, -CH2CH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2OI-l,
-OCH2CH2OCH3,
Figure imgf000016_0001
-F, -CI, -Br and -CN.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with five substituents independently selected from the group consisting -CH3, -CF3, -CH2CH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2OH,
-OCH2CH2OCH3,
Figure imgf000016_0002
-F, -CI, -Br and -CN.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl substituted with -F and optionally substituted with one or two substituents independently selected from the group consisting of -CH3, -CF3, -CH2CH3, -OH,
-OCH3, -OCH2CH3, -OCH2CH2OH, -OCH2CH2OCH3,
Figure imgf000016_0003
-F, -CI, -Br and -CN.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is phenyl optionally substituted with one, two, three, four or five substituents independently selected from the group consist -CH3, -CF3, -CH2CH3,
-OCH3, -OCH2CH3, -OCH2CH2OH, -OCH2CH2OCH3,
Figure imgf000016_0004
-F, -CI, -Br and -CN In certain embod n relates to any of the aforementioned
compounds, wherein X i
Figure imgf000016_0005
substituted with one additional substituent selected from the group consistin -CH3, -CF3, -CH2CH3, -OH, -OCH3, -OCH2CH3,
-OCH2CH2OH, -OCH2CH2OCH3,
Figure imgf000016_0006
-F, -CI, -Br and -CN.
In certain embo relates to any of the aforementioned
compounds, wherein X
Figure imgf000016_0007
one additional substituent selected from the group consisting of -CH3, -CF3, -CH2CH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2OH,
-OCH2CH2OCH3, wkm , -F, -CI, -Br and -CN.
In certain embo
compounds, wherein X
Figure imgf000017_0001
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is 5-membered hereroaryl optionally substituted with one, two, three, or four substituents independently selected from the group consisting of -CH3, -CF3, -CH2CH3,
-OH, -OCH3, -OCH2CH3, -OCH2CH2OH, -OCH2CH2OCH3, «JLft , -F, -CI, -Br and -CN.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein X is isoxazolyl or pyrazolyl, in each case optionally substituted with one, two or three, substituents independently selected from the group consisting of -CH3, -CF3,
-CH2CH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2OH, -OCH2CH2OCH3, «J XL»> , -F, -CI, -Br and -CN.
In certain embod lates to any of the aforementioned
compounds, wherein X i
Figure imgf000017_0002
certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is (C1-C6)alkyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI,
-Br, -OH, (C C^alkyl, (C C3)haloalkyl and (C3-C10)cycloalkyl. In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is unsubstituted (CrC^alkyl. In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is unsubstituted branched (d-Ce)alkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is (C1-C3)alkyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C1-C3)alkyl, (C C3)haloalkyl and (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is methyl optionally substituted with one, two or three substitutents independently selected for each occurrence from the group consisting of -F, -CI,
-Br, -OH, (C1-C3)alkyl, (C C3)haloalkyl and (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is ethyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI,
-Br, -OH, (C1-C3)alkyl, (C C3)haloalkyl and (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is n-propyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (Ci-C3)alkyl, (C C3)haloalkyl and (C3-Ci0)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is i-propyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C1-C3)alkyl, (C C3)haloalkyl and (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is methyl substituted with (C3-C6)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is propyl substituted with -CF3.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is ethyl substituted with (C3-C6)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is ethyl substituted with bicyclo[1.1.1]pentanyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is (C3-C10)cycloalkyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C1-C3)alkyl, (C C^haloalkyl and (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is unsubstituted (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is cyclopropyl optionally substituted with one, two, three or four substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, - OH, (C C3)alkyl, (C C^haloalkyl and (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is cyclobutyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C1-C3)alkyl, (C C3)haloalkyl and (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is cydopentyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C C^alkyl, (C C3)haloalkyl and (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is cyclohexyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C C^alkyl, (C C3)haloalkyl and (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is unsubstituted phenyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is phenyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (CrC^alkyl, (C C3)haloalkyl and (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is phenyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH and -CH3.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is unsubstituted isothiazolyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is isothiazolyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C1-C3)alkyl, (C C^haloalkyl and (C3-C10)cycloalkyl.
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R2 is isothiazolyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH and -CH3.
In certain embodiments, the present invention relates to any of the aforementioned
compounds, wherein R is,
Figure imgf000020_0001
, ,
Figure imgf000020_0002
In certain embodim the present invention relates to any of the aforementioned
compounds, wherein R2 is
Figure imgf000020_0003
In certain embodiments, the resent invention relates to any of the aforementioned
Figure imgf000020_0004
compounds, wherein R2 is
In certain embodiments, the resent invention relates to any of the aforementioned
Figure imgf000020_0005
compounds, wherein R2 is In certain embodiments, the present invention relates to any of the aforementioned
Figure imgf000021_0001
compounds, wherein R2 is .
In certain embod t invention relates to any of the aforementioned compounds, wherein R2
In certain embod t invention relates to any of the aforementioned compounds, wherein R
In certain embod t invention relates to any of the aforementioned compounds, wherein R2
In certain embod t invention relates to any of the aforementioned
compounds, wherein R2
In certain embod t invention relates to any of the aforementioned
compounds, wherein R2
In certain embod t invention relates to any of the aforementioned
compounds, wherein R
In certain embod invention relates to any of the aforementioned
compounds, wherein R
Figure imgf000021_0002
is In certain embod ent invention relates to any of the aforementioned compounds, wherein R
Figure imgf000022_0001
In certain embodiments, the present invention relates to any of the aforementioned
compounds, wherein R
Figure imgf000022_0002
In certain embodiments, the present invention relates to any of the aforementioned
compounds, wherein R
In certain embod t invention relates to any of the aforementioned
compounds, wherein R
In certain embod t invention relates to any of the aforementioned
compounds, wherein R
Figure imgf000022_0003
In certain embodiments, the present invention relates to any of the aforementioned compounds, wherein R
Figure imgf000022_0004
In certain embodiments, the present invention relates to any of the aforementioned
compounds, wherein R2 is 4> In certain embodim nt invention relates to any of the aforementioned
compounds, wherein R is
In certain embodim nt invention relates to any of the aforementioned
compounds, wherein R2 is
Figure imgf000023_0001
In certain embodiments, the present invention relates to any of the aforementioned
compounds, wherein R2 is
Figure imgf000023_0002
Another embodiment of the invention is a compound selected from the group consisting of the compounds of Examples 1-35 and pharmaceutically acceptable salts thereof.
Therapeutic Applications
It is contemplated that the compounds of Formula I provide therapeutic benefits to subjects suffering from an immune disorder or inflammatory disorder. Accordingly, one aspect of the invention provides a method of treating a disorder selected from the group consisting of an immune disorder or inflammatory disorder. The method comprises administering a therapeutically effective amount of a compound of Formula I to a subject in need thereof to ameliorate a symptom of the disorder, wherein Formula I are as described above. In certain embodiments, the particular compound of Formula I is a compound defined by one of the embodiments described above.
In certain embodiments, the disorder is an immune disorder. In certain other
embodiments, the disorder is an inflammatory disorder. In certain other embodiments, the disorder is an autoimmune disorder. In certain other embodiments, the disorder is rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, or epidermal hyperplasia.
In certain other embodiments, the disorder is cartilage inflammation, bone degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myositis, polymyositis, osteoarthritis, polyarteritis nodossa, Wegener's granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, atherosclerosis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, psoriatic epidermal hyperplasia, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, giant cell arteritis, nonalcoholic hepatic steatosis, or an immune disorder associated with or arising from activity of pathogenic lymphocytes.
In certain embodiments, the psoriasis is plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.
In certain other embodiments, the disorder is noninfectious uveitis, Behcet's disease or
Vogt-Koyanagi-Harada syndrome.
Another aspect of the invention provides for the use of a compound of Formula I in the manufacture of a medicament. In certain embodiments, the medicament is for treating a disorder described herein.
Another aspect of the invention provides for the use of a compound of Formula I for treating a medical disorder, such a medical disorder described herein.
Further, it is contemplated that compounds of Formula I can inhibit the activity of RORy. Accordingly, another aspect of the invention provides a method of inhibiting the activity of RORy. The method comprises exposing a RORy to an effective amount of a compound of Formula I to inhibit said RORy, wherein Formula I is as described above. In certain embodiments, the particular compounds of Formula I are the compound defined by one of the embodiments described herein.
Further, it is contemplated that compounds of Formula I can reduce the amount of interleukin-17 (IL-17) in a subject. IL-17 is a cytokine that affects numerous biological functions, including inducing and mediating pro-inflammatory responses. Accordingly, another aspect of the invention provides a method of reducing the amount of IL-17 in a subject. The method comprises administering to a subject an effective amount of a compound of I to reduce the amount of IL-17 in the subject, wherein Formula I is as described above. In certain embodiments, the particular compounds of Formula I are the compounds defined by one of the embodiments described herein.
In certain embodiments, the subject is a human. In certain embodiments, administering the compound reduces the amount of IL-17 produced by Th-17 cells in the subject. A change in the amount of IL-17 produced by, for example, Th-17 cells can be measured using procedures described in the literature, such as an ELISA assay or intracellular staining assay.
Further, it is contemplated that compounds of Formula I may inhibit the synthesis of IL-17 in a subject. Accordingly, another aspect of the invention provides a method of inhibiting the synthesis IL-17 in a subject. The method comprises administering to a subject an effective amount of a compound of Formula I to inhibit the synthesis IL-17 in the subject, wherein Formula I is as described above. In certain embodiments, the particular compounds of Formula I are the compounds defined by one of the embodiments described herein.
The description above describes multiple embodiments providing definitions for variables used herein. The application specifically contemplates all combinations of such variables.
Combination Therapy
Another aspect of the invention provides for combination therapy. For example, the compounds of Formula I or their pharmaceutically acceptable salts may be used in combination with additional therapeutic agents to treat medical disorders, such as medical disorders associated with inappropriate IL-17 pathway activity. Exemplary additional therapeutic agents include, for example, (1) a TNF-a inhibitor; (2) a non-selective COX-l/COX-2 inhibitor; (3) a selective COX-2 inhibitor, such as celecoxib and rofecoxib; (4) other agents for treating inflammatory disease and autoimmune disease including, for example, methotrexate, leflunomide, sulfasalazine,
azathioprine, penicillamine, bucillamine, actarit, mizoribine, lobenzarit, hydroxychloroquine, d- penicillamine, aurothiomalate, auranofin, parenteral gold, oral gold, cyclophosphamide,
Lymphostat-B, a BAFF/ APRIL inhibitor, CTLA-4-lg, or a mimetic of CTLA-4-lg; (5) a leukotriene biosynthesis inhibitor, such as a 5-lipoxygenase (5-LO) inhibitor, or a 5-lipoxygenase activating protein (FLAP) antagonist; (6) a LTD4 receptor antagonist; (7) a phosphodiesterase type IV (PDE- IV) inhibitor, such as cilomilast (ariflo) or roflumilast; (8) an antihistamine H1 receptor antagonist; (9) an od- and oc2-adrenoceptor agonist; (10) an anticholinergic agent; (1 1) a β-adrenoceptor agonist; (12) an insulin-like growth factor type I (IGF-1) mimetic; (13) a glucocorticosoid; (14) a kinase inhibitor such as an inhibitor of a Janus Kinase (e.g., JAK 1 and/or JAK2 and/or JAK 3 and/or TYK2), p38 MAPK, Syk or IKK2; (15) a B-cell target biologic such as rituximab; (16) a selective co-stimulation modulator such as abatacept; (17) an interleukin inhibitor or interleukin receptor inhibitor, such as the IL-1 inhibitor anakinra, IL-6 inhibitor tocilizumab, and IL12/IL-23 inhibitor ustekimumab; (18) an anti-IL17 antibody, anti-IL21 antibody, or anti-IL22 antibody (19) a S1 P1 agonist, such as fingolimod; (20) an interferon, such as interferon beta 1 ; (21) an integrin inhibitor such as natalizumab; (22) a mTOR inhibitor such as rapamycin, cyclosporin and tacrolimus; (23) a non-steroidal antiinflammatory agent (NSAID), such as propionic acid derivatives (alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivatives (flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicams (isoxicam, piroxicam, sudoxicam and tenoxican), salicylates (acetyl salicylic acid, sulfasalazine) and pyrazolones (apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone, phenylbutazone); (24) a NRF2 pathway activator, such as the fumaric acid derivative, BG-12; and (25) a chemokine or chemokine receptor inhibitor, such as a CCR9 antagonist.
In certain embodiments, the additional therapeutic agent is selected from the group consisting of corticosteroids, vitamin D3, anthralin and retinoids. In certain embodiments, the additional therapeutic agent is a corticosteroid. In certain embodiments, the additional therapeutic agent is vitamin D3. In certain embodiments, the additional therapeutic agent is anthralin. In certain embodiments, the additional therapeutic agent is a retinoid.
The amount of the compounds of Formula I and additional therapeutic agent and the relative timing of administration may be selected in order to achieve a desired combined therapeutic effect. For example, when administering a combination therapy to a patient in need of such administration, the therapeutic agents in the combination, or a pharmaceutical composition or compositions comprising the therapeutic agents, may be administered in any order such as, for example, sequentially, concurrently, together, simultaneously and the like. Further, for example, a compound of Formula I may be administered during a time when the additional therapeutic agent(s) exerts its prophylactic or therapeutic effect, or vice versa.
The doses and dosage regimen of the active ingredients used in the combination therapy may be determined by an attending clinician. In certain embodiments, the compound of Formula I and the additional therapeutic agent(s) are administered in doses commonly employed when such agents are used as monotherapy for treating the disorder. In other embodiments, the compound of Formula I and the additional therapeutic agent(s) are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating the disorder. In certain embodiments, a compound of Formula I and the additional therapeutic agent(s) are present in the same composition, which is suitable for oral administration.
In certain embodiments, the compound of Formula I and the additional therapeutic agent(s) may act additively or synergistically. A synergistic combination may allow the use of lower dosages of one or more agents and/or less frequent administration of one or more agents of a combination therapy. A lower dosage or less frequent administration of one or more agents may lower toxicity of the therapy without reducing the efficacy of the therapy. Another aspect of this invention is a kit comprising a therapeutically effective amount of a compound of Formula I, a pharmaceutically acceptable carrier, vehicle or diluent, and optionally at least one additional therapeutic agent listed above.
Pharmaceutical Compositions and Dosing Considerations
Typically, a compound of the invention is administered in an amount effective to treat a condition as described herein. The compounds of the invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds required to treat the progress of the medical condition are readily ascertained by one of ordinary skill in the art using preclinical and clinical approaches familiar to the medicinal arts. The term "therapeutically effective amount" as used herein refers to that amount of the compound being administered which will relieve to some extent one or more of the symptoms of the disorder being treated.
The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above. The term "treating" also includes adjuvant and neo-adjuvant treatment of a subject.
As indicated above, the invention provides pharmaceutical compositions, which comprise a therapeutically-effective amount of one or more of the compounds described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. The pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
Formulations of the present invention include those suitable for oral, nasal, topical
(including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 0.1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
In certain embodiments, a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the present invention. In certain embodiments, an aforementioned formulation renders orally bioavailable a compound of the present invention.
Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.
In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules, trouches and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxamer and sodium lauryl sulfate; (7) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non- ionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof; (10) coloring agents; and (11) controlled release agents such as crospovidone or ethyl cellulose. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically- acceptable carrier, and with any preservatives, buffers, or propellants which may be required. The invention also includes pharmaceutical compositions utilizing one or more of the present compounds along with one or more pharmaceutically acceptable carriers, excipients, vehicles, etc.
Topical formulations of the presently disclosed compounds may be administered topically, (intra)dermally, or transdermal^ to the skin or mucosa. Topical administration using such preparations encompasses all conventional methods of administration across the surface of the body and the inner linings of body passages including epithelial and mucosal tissues, including transdermal, epidermal, buccal, pulmonary, ophthalmic, intranasal, vaginal and rectal modes of administration. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, colloid, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Such topical formulations may be prepared in combination with additional pharmaceutically acceptable excipients.
In certain embodiments, a penetration enhancer may be used. Examples of penetration enhancers include, for example, saturated C10-C18 fatty alcohols (such as decyl alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol and stearyl alcohol), cis-unsaturated C10-C18 fatty alcohols (such as oleyl alcohol, linoleyl alcohol, γ-linolenyl alcohol and linolenyl alcohol), C10-C18 fatty acids (which when saturated may include capric acid, lauric acid, myristic acid, palmitic acid, stearic acid and arachidic acid), cis-unsaturated fatty acids (such as palmitoleic acid (cis-9- hexadecenoic acid), oleic acid (cis-9-octadecenoic acid), cis-vaccenic acid (cis-11-octadecenoic acid), linoleic acid (cis-9,12-octadecadienoic acid), γ-linolenic acid (cis-6,9,12-octadecatrienoic acid), linolenic acid (cis-9,12, 15-octadecatrienoic acid) and arachidonic acid (cis-5,8,1 1 ,14- eicosatetraenoic acid)). In certain embodiments, the penetration enhancers may be used amounts ranging from about 0.1 to about 5% (w/v).
In certain embodiments, topical formulations which contain one or more compounds of the invention in therapeutically effective amounts that may be given in daily or twice daily doses to patients in need.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Other excipients which enhance the stability of the formulations include aldehyde scavengers, such as glycerine and propylene glycol, and antioxidants, such as butyl hydroxyanisole (BHA), butyl hydroxytoluene (BHT), propyl gallate, ascorbic acid (Vitamin C), polyphenols, tocopherols (Vitamin E), and their derivatives. Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention. Formulations suitable for topical administration to the eye include, for example, eye drops wherein the compound of this invention is dissolved or suspended in a suitable carrier. A typical formulation suitable for ocular or aural administration may be in the form of drops of a micronised suspension or solution in isotonic, pH- adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, biodegradable (i.e., absorbable gel sponges, collagen) and non-biodegradable (i.e., silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methylcellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.
For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant. Formulations suitable for intranasal administration are typically administered in the form of a dry powder (either alone; as a mixture, for example, in a dry blend with lactose; or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1 ,1 ,1 ,2-tetrafluoroethane or 1 ,1 , 1 ,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more
pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly
(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
When the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
The preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred.
The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
The phrases "systemic administration," "administered systemically," "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Preferably, the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg.
When the compounds described herein are co-administered with another agent (e.g. , as sensitizing agents), the effective amount may be less than when the agent is used alone.
If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In certain embodiments, preferred dosing is one administration per day.
The invention further provides a unit dosage form (such as a tablet or capsule) comprising a compound of Formula I or a specific compound described herein, or pharmaceutically acceptable salts thereof, in a therapeutically effective amount for the treatment of an immune or inflammatory disorder, such as one of the particular immune disorders or inflammatory disorders described herein.
General Synthetic Schemes and Procedures
The compounds of Formula I may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and derivatizations that are familiar to those of ordinary skill in the art. The starting materials used herein are commercially available or may be prepared by routine methods known in the art (such as those methods disclosed in standard reference books such as the COMPENDIUM OF ORGANIC
SYNTHETIC METHODS, Vol. I-VI (published by Wiley-lnterscience)). Preferred methods include, but are not limited to, those described below.
During any of the following synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981 ; T. W. Greene and P. G. M. Wuts,
Protective Groups in Organic Chemistry, John Wiley & Sons, 1991 , and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference. Compounds of Formula I or their pharmaceutically acceptable salts, can be prepared according to the reaction Schemes discussed herein below. Unless otherwise indicated, the substituents in the Schemes are defined as above. Isolation and purification of the products is accomplished by standard procedures, which are known to a chemist of ordinary skill.
It will be understood by one skilled in the art that the various symbols, superscripts and subscripts used in the schemes, methods and examples are used for convenience of
representation and/or to reflect the order in which they are introduced in the schemes, and are not intended to necessarily correspond to the symbols, superscripts or subscripts in the appended claims. The schemes are representative of methods useful in synthesizing the compounds of the present invention. They are not to constrain the scope of the invention in any way.
Compounds of Formula I may be prepared as single enantiomer or as a mixture of individual enantiomers which includes racemic mixtures. Methods to obtain preferentially a single enantiomer from a mixture of individual enantiomers or a racemic mixture are well known to those ordinarily skilled in the art of organic chemistry. Such methods include but are not limited to preferential crystallization of diastereomeric salts (e.g. tartrate or camphor sulfonate), covalent derivatization by a chiral, non-racemic reagent followed by separation of the resulting
diastereomers by common methods (e.g. crystallization, chromatographic separation, or distillation) and chemical reversion to scalemic compound, Simulated Moving Bed technology, or high/medium-pressure liquid chromatography or supercritical fluid chromatography employing a chiral stationary phase. These techniques may be performed on the final compounds of the invention or on any intermediates to compounds of the invention which bear a stereogenic center. Also, to facilitate separation by any of the methods described above, the compounds of the invention or any intermediates to the compounds of the invention which bear a stereogenic center may be transiently reacted with an achiral reagent, separated, and then reverted to scalemic compound by standard synthetic techniques.
Compounds of Formula A-6 can be prepared as described in Scheme A. Aryl halides A-1 can be converted to boronates of Formula A-2. Boronates A-2 can be coupled with vinyl triflate B- 3 (prepared as described in Scheme B) to afford compounds of the Formula A-3. Subsequent reduction of the nitro group and the olefin concomitantly furnished compounds of Formula A-4. The resulting amine of compounds of Formula A-4 can be transformed to the corresponding sulfonamides by the reaction with sulfonyl chlorides in the presence of base to afford compounds of Formula A-5. The Boc group within componds of Formula A- 5 could be removed through use of acid, and subsequently the piperidine nitrogen could be coupled with an appropriate acid chloride or carboxylic acid to furnish compounds of Formula A-6. SCHEME A
Figure imgf000037_0001
A-4 A-5 A-6
Compounds of formula B-3 can be prepared as exemplified by the synthetic route described in Scheme B. Hydrogenolysis of B-1 in the presence of Boc anhydride removed the benzyl group from the piperidine nitrogen and this was followed by immediate carbamate formation in situ to form carbamate B-2. Next, treatment with a strong base such as lithium
hexamethyldisilylazide at cryogenic temperatures generated the kinetically controlled enolate, and this was trapped by treatment with /V-phenyl triflamide to form vinyl triflate B-3.
SCHEME B
Figure imgf000037_0002
B-1 B-2 B-3
Compounds of Formula C-5 can be prepared as in the route described in Scheme C. Iodide C-1 was coupled with Boc-protected piperidine boronate C-6 through the use of
conventional Suzuki conditions employing palladium tetrakistriphenylphoshine. Next,
hydrogenation conditions could be used to convert nitroolefin C-2 to the corresponding aniline C-3. This aniline could be substituted with various sulfonyl chlorides to provide structures of the formula C-4. The Boc group within C-4 could be removed through use of acid, and subsequently the piperidine nitrogen coupled with the an appropriate acid chloride or carboxylic acid to furnish compounds of Formula C-5.
SCHEME C
Figure imgf000038_0001
C-5
Compounds of Formula D-5 can be prepared as exemplified by the synthetic route described in Scheme D. The boronate A-2 prepared as described in Scheme A was coupled to Boc protected E-2 prepared as described in Scheme E through the use of conventional Suzuki conditions. Next hydrogenation could be used to convert nitroolefin D-2 to the corresponding aniline D-3. The resulting aniline could be substituted with various sulfonyl chlorides to provide compounds of Formula D-4. The Boc group within C-4 could be removed through use of acid, and subsequently the piperidine nitrogen could be coupled with an appropriate acid chloride or carboxylic acid to furnish compounds of Formula D-5. SCHEME D
Figure imgf000039_0001
D-4 D-5
Compounds of formula E-2 can be prepared as exemplified by the synthetic route described in Scheme E. Treatment of piperidone E-1 with a strong base such as lithium hexamethyldisilylazide at cryogenic temperatures generated the kinetically controlled enolate, and this was trapped by treatment with /V-phenyl triflamide to form vinyl triflate E-2.
SCHEME E
Figure imgf000039_0002
E-1 E-2
Compounds of Formula F-5 can be prepared as exemplified by the synthetic route described in Scheme F. The boronate A-2 prepared as described in Scheme A is coupled to Boc protected G-2 through the use of conventional Suzuki conditions. Next hydrogenation could be used to convert nitroolefin F-2 to the corresponding aniline F-3. The resulting aniline could be substituted with various sulfonyl chlorides to provide compounds of the Formula F-4. The Boc group within F-4 could be removed through use of acid, and subsequently the piperidine nitrogen could be coupled with an appropriate acid chloride or carboxylic acid to furnish compounds of Formula F-5. SCHEME F
Figure imgf000040_0001
F-4 F-5
Compounds of formula G-2 can be prepared as exemplified by the synthetic route described in Scheme G. Treatment of piperidone G-1 with a strong base such as lithium hexamethyldisilylazide at cryogenic temperatures generated the kinetically controlled enolate, and this was trapped by treatment with /V-phenyl triflamide to form vinyl triflate G-2.
SCHEME G
Figure imgf000040_0002
G-1 G-2
Carboxylic acids of the Formula R2C02H employed in Scheme A, C, D, and F may be commercially available, prepared by procedures described in the literature, or prepared as described in Scheme F. (R)-2,3,3-Trimethylbutanoic acid and (S)-2,3,3-trimethylbutanoic acid may be prepared as described by Kido, M. et al Tetrahedron: Asym. 2007, 18, 1934-1947; and thietane acid (see WO2013/7582, which is hereby incorporated by reference for the preparation of thietane acid). Specific examples of carboxylic acids that may be prepared by Scheme F include (R)-2- cyclopentylpropanoic acid, and (S)-2-cyclopentylpropanoic acid. Specific examples of R2C02H according to the Formula F-4 can be prepared from acids F-1 where R may be alkyl, cycloalkyl or aryl which are reacted with an optically active chiral oxazolidinone (e.g. (R)-benzyl oxazolidinone, (R)-4-lsopropyl-2-oxazolidinone) to provide compounds of the Formula F-2. Base mediated alkylation and subsequent removal of the oxazolidinone auxiliary furnishes acids of the Formula F- 4 in high optical purity. By employing a chiral oxazolidinone of a different absolute configuration (e.g. (S)-benzyl oxazolidinone, (S)-4-lsopropyl-2-oxazolidinone), chiral acids F-4 of both configurations can be obtained.
SCHEME F
Figure imgf000041_0001
F-1 F-2 F-3 F-4
EXEMPLIFICATION
The invention now being generally described, will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention. The following illustrates the synthesis of various compounds of the present invention. Additional compounds within the scope of this invention may be prepared using the methods illustrated in these Examples, either alone or in combination with techniques generally known in the art.
Experiments were generally carried out under inert atmosphere (nitrogen or argon), particularly in cases where oxygen- or moisture-sensitive reagents or intermediates were employed. Commercial solvents and reagents were generally used without further purification, including anhydrous solvents where appropriate. Mass spectrometry data is reported from either liquid chromatography-mass spectrometry (LCMS), atmospheric pressure chemical ionization (APCI) or gas chromatography-mass spectrometry (GCMS) instrumentation. Chemical shifts for nuclear magnetic resonance (NMR) data are expressed in parts per million (ppm, δ) referenced to residual peaks from the deuterated solvents employed. Coupling constants (J values) are reported in Hertz.
Chiral purity of scalemic compounds was determined by chiral SFC (super-critical fluid chromatography) employing one of the following conditions: HPLC Method A: XBridge C18, 2.1x50 mm, 5 urn, CH3CN/H20 (0.0375% TFA), 10-100%, 0.8 mL/min, 4min; and HPLC Method B: XBridge C18, 2.1x50 mm, 5 urn, CH3CN/H20 (0.0375% TFA), 1-100%, 0.8 mL/min, 4min. Method C: Ultimate XB-C18, 3μπι, 3.0x50mm, CH3CN/H20 (0.1 % TFA), 1-5%, 1.2 mL/min, 10 min. Method D: Xtimate C18, 3μπι, 5.0x50mm, CH3CN/H2Q (0.1 % TFA), 1-100%, 1.2 mL/min, 10 min. Method E: Ultimate XB-C18, 3μπι, 3.0x50mm, CH3CN/H20 (0.1 % TFA), 1-100%, 1.2 mL/min, 10 min.
For syntheses referencing procedures in other Examples, reaction conditions (length of reaction and temperature) may vary. In general, reactions were followed by thin layer
chromatography or mass spectrometry, and subjected to work-up when appropriate. Purifications may vary between experiments: in general, solvents and the solvent ratios used for
eluants/gradients were chosen to provide appropriate Rf s or retention times (RetT).
The chemical names for the compounds of the invention described below were generated using CambridgeSoft's ChemBioDraw Ultra version 13.0.2 (CambridgeSoft Corp., Cambridge Mass.).
The following abbreviations are used herein: DCM: dichloromethane; DEA: diethylamine; DIPEA: diisopropylethylamine; DME: 1 ,2-dimethoxyethane; DMF: dimethylformamide; EtOAc: ethyl acetate; EtOH: ethanol; HATU: 1-[bis(dimethylamino)-methylene]-1 H-1 ,2,3-triazolo[4,5- b]pyridinium 3-oxid hexafluorophosphate; MeOH: methanol; MTBE: methyl t-butyl ether; PE:
petroleum ether; TEA: triethylamine; and THF: tetrahydrofuran.
Example 1
Preparation of 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methyl-1-((R)-2,3,3- trimethylbutanoyl)piperidin-4-yl)-1 H-indol-5-yl)benzenesulfonamide
Figure imgf000042_0001
Step 1 : 3-Bromo-1-methyl-5-nitro-1 /-/-indole. To a solution 3-bromo-5-nitro-1 H-indole (5.5 g, 20.6 mmol) in THF (50ml_) at 0 °C was added NaH (1.9 g, 41.3 mmol, 60% w/w in mineral oil). The mixture was stirred for 15 min and methyl iodide (6.4 ml_, 103.3 mmol) was added. The reaction mixture was warmed to room temperature and stirred for 16 h. After completion, the reaction mixture was cooled, quenched with addition of ice-cooled water and extracted using EtOAc. The combined organic layer was dried over anhydrous Na2S04i filtered and concentrated to obtain a crude product which was purified by triturating with diethyl ether to afford the title compound (5 g, 86%). 1H NMR (400 MHz, CDCI3) δ 8.55 (d, J = 2.4 Hz, 1 H), 8.17 (dd, J = 8.8, 2.0 Hz, 1 H), 7.36 (d, J = 8.8 Hz, 1 H), 7.25 (s, 1 H), 3.87 (s, 3H). Step 2: 1-Methyl-5-nitro-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 --indole. A solution of 3-bromo-1-methyl-5-nitro-1 H-indole (3 g, 11.7 mmol) in dioxane (100 mL) was degassed using nitrogen for 10 min. K2C03 (4.8 g, 35.1 mmol), S-Phos (480 mg, 1.17 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1 ,3,2-dioxaborolane) (4.46 g, 17.5 mmol) and Pd2(dba)3 (533 mg, 0.58 mmol) were added, degassed with nitrogen for another 10 min and heated at 60 °C for 5h. After completion, the reaction mixture was cooled to room temperature, quenched with the addition of saturated NH4CI solution and extracted using EtOAc. The combined organic layer was dried over anhydrous Na2S04 filtered and concentrated to obtain a crude product which was purified by flash silica gel column chromatography (5-7% EtOAc in hexane) to afford the title compound (1 g, 28%). 1H NMR (400 MHz, CDCI3) δ 8.93 (d, J = 2.0 Hz, 1 H), 8.14 (dd, J = 9.2, 2.0 Hz, 1 H), 7.64 (s, 1 H), 7.33 (d, J = 9.2 Hz, 1 H), 3.86 (s, 3H), 1.38 (s, 12H); LCMS: m/e 303
[M+H]+.
Step 3: te/ -Butyl 3-methyl-4-oxopiperidine-1-carboxylate. To a solution of 1-benzyl-3- methylpiperidin-4-one (6 g, 29.5 mmol) in ethanol was added Boc-anhydride (8 g, 36.9 mmol), Pd(OH)2 (2.4 g, 40% wt of ketone) and the reaction mixture was stirred under hydrogen atmosphere (100 psi) in autoclave for 6 h at room temperature. After completion, the reaction mixture was concentrated in vacuo to obtain a crude residue which was purified by silica gel column chromatography (10-15% EtOAc in hexane) to afford the title compound (8.8 g, 78%). 1 H NMR (400 MHz, CDCI3): δ 4.20-4.16 (m, 2H), 3.29-3.22 (m, 1 H), 2.85 (br.s, 1 H), 2.57-2.38 (m, 3H), 1.49 (s, 9H), 1.04 (d, J = 6.4 Hz, 3H); LCMS: m/e 235 [M+Na]+
Step 4: tert-Butyl 3-methyl-4-(((trifluoromethyl) sulfonyl)oxy)-3,6-dihydropyridine-1 (2H)- carboxylate. To a solution of te/ -Butyl 3-methyl-4-oxopiperidine-1-carboxylate (7 g, 32.8mmol) in THF (70 mL) was added a solution of NaHMDS (66 mL, 65.7 mmol, 1 M in THF) dropwise at -78 °C, stirred for 1.5 h at the same temperature, 1 ,1 ,1-trifluoro-/V-phenyl-/V- ((trifluoromethyl)sulfonyl)methanesulfonamide (23.4 g, 65.7 mmol) was added, the reaction mixture was warmed to room temperature and stirred for 16 h. After completion, the reaction mixture was quenched with addition of ice-cooled water and extracted using EtOAc. The combined organic layer was washed with 10% citric acid followed by 2N NaOH solution, dried over anhydrous Na2S04 filtered and concentrated to obtain a crude product which was purified by silica gel column chromatography (3-5% EtOAc in hexane) to afford the title compound (8.8 g, 78%). 1H NMR (400 MHz, CDCI3): δ 5.73-5.72 (m, 1 H), 4.12-3.96 (m, 2H), 3.61-3.40 (m, 2H), 2.62-2.61 (m, 1 H), 1.47 (s, 9H), 1.14 (d, J = 6.8 Hz, 3H).
Step 5: tert-butyl 3-methyl-4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridine-1 (2H)- carboxylate. A solution of 1-methyl-5-nitro-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H- indole (1 g, 3.32 mmol) in dioxane: water (40 mL: 5 mL) was degassed using nitrogen for 10min., tert-butyl 5-methyl-4-(trifluoromethylsulfonyloxy)-5,6-dihydropyridine-1 (2H)-carboxylate (1.4g, 4.05 mmol), K3P04 (1.5g, 7.1 mmol), tetrakis (triphenyl phosphine) palladium(O) (375 mg, 0.32 mmol) were added, degassed for another 10 min. and the reaction mixture was heated at 90 °C for 5h. After completion, the reaction mixture was cooled to room temperature, diluted with water and extracted using EtOAc. The combined organic layer was dried over anhydrous Na2S04, filtered and concentrated to obtain a crude product which was purified by flash silica gel column chromatography (1 % MeOH in DCM) to afford a pure title compound (1 g, 82%). 1 H NMR (400 MHz, CDCI3): δ 8.75 (br.s, 1 H), 8.14 (dd, J = 8.8, 2.0 Hz, 1 H), 7.31 (d, J = 8.8 Hz, 1 H), 6.01 (br.s, 1 H), 7.26-7.25 (m, 1 H,), 4.52-4.35 (m, 1 H), 4.05-3.84 (m, 5H), 3.30-3.29 (m, 1 H), 2.78-2.75 (m, 1 H), 1.51 (s, 9H), 1.09 (d, J = 6.8 Hz, 3H); LCMS: m/e 435.4 [M+Na+CH3CN]+.
Step 6: tert-butyl 4-(5-amino-1-methyl-1 H-indol-3-yl)-3-methylpiperidine-1-carboxylate. To a solution of tert-butyl 5-methyl-4-(1-methyl-5-nitro-1 H-indol-3-yl)-5,6-dihydropyridine-1 (2H)- carboxylate (1 g, 2.6 mmol) in EtOH (25 mL) were added Pd(OH)2 (1 g, 100% w/w), ammonium formate (1.7 g, 26.9 mmol) and the reaction mixture was heated at 80 °C for 4h. After completion, the reaction mixture was cooled to room temperature, filtered through celite® and washed with EtOH. The filtrate was concentrated to afford the title compound (900 mg, 97%) which was used in the next step without further purification. 1 H NMR (400 MHz, CDCI3): δ 7.09 (d, J = 8.4 Hz, 1 H), 6.92-6.91 (m, 1 H), 6.72 (d, J = 8.4 Hz, 1 H), 6.67 (s, 1 H), 4.29-3.96 (m, 2H), 3.76-3.68 (m, 4H), 3.16-2.88 (m, 3H), 2.22-2.19 (m, 1 H), 1.98-1.96 (m, 1 H), 1.66-1.63 (m, 2H), 1.47 (s, 9H), 0.69 (d, J = 6.4 Hz, 3H); LCMS: m/e 344.35 [M+H]+.
Step 7: tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1 H-indol-3-yl)-3- methylpiperidine-1-carboxylate. To a solution of te/ -butyl 4-(5-amino-1-methyl-1 H-indol-3-yl)-3- methylpiperidine-1-carboxylate (900 mg, 2.62 mmol) in DCM (25 mL) was added pyridine (0.32 mL, 3.93 mmol), followed by 4-fluorobenzenesulfonyl chloride (613 mg, 3.14 mmol) solution in DCM (25 mL) dropwise at 0-5 °C and the resulting reaction mixture was stirred at 0-5 °C for 30 min. After completion, the reaction mixture was basified with 10% aqueous NaHC03 solution and extracted using DCM. The combined organic layer was dried over anhydrous Na2S04, filtered and concentrated to obtain the crude compound which was purified by silica gel column
chromatography (1-2% MeOH in DCM) to afford the title compound (1 g, 68%). 1H NMR (400 MHz, CDCI3): δ 7.66 (d, J = 5.6 Hz, 1 H), 7.65 (d, J = 5.6 Hz, 1 H), 7.20 (br.s, 1 H), 7.12 (d, J = 8.4 Hz, 1 H), 7.05 (d, J = 8.0 Hz, 1 H), 6.84 (d, J = 8.0 Hz, 1 H), 6.75 (s, 1 H), 6.37 (s, 1 H), 4.29-3.95 (m, 2H), 3.71 (s, 3H), 3.12-2.85 (m, 3H), 2.02-1.93 (m, 2H), 1.65-1.58 (m, 1 H), 1.48 (s, 9H), 0.62 (d, J = 6.4 Hz, 3H).
Step 8: 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methylpiperidin-4-yl)-1 H-indol-5- yl)benzenesulfonamide. Racemic tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1 -methyl- 1 H-indol- 3-yl)-3-methylpiperidine-1-carboxylate (1.1 g) was separated by chiral SFC (Column: Lux
Cellulose-4, 250 x 21.2 mm, 5 μηι, 80% CO2/20% MeOH + 0.2% NH4 +, 80 mL/min) to give two major peaks for which absolute stereochemistry were arbitrarily assigned. The first eluting isomer (Rt = 8.89 min) was arbitrarily assigned as tert-butyl (3S,4S)-4-(5-((4-fluorophenyl)sulfonamido)-1- methyl-1 H-indol-3-yl)-3-methylpiperidine-1-carboxylate. The second eluting isomer (Rt = 9.78 min) was arbitrarily assigned tert-butyl (3R,4R)-4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1 H-indol-3- yl)-3-methylpiperidine-1-carboxylate. 1 H NMR (400 MHz, CDCI3): δ 7.66 (d, J = 5.6 Hz, 1 H), 7.65 (d, J = 5.6 Hz, 1 H), 7.20 (br.s, 1 H), 7.12 (d, J = 8.4 Hz, 1 H), 7.05 (d, J = 8.0 Hz, 1 H), 6.84 (d, J =
8.0 Hz, 1 H), 6.75 (s, 1 H), 6.37 (s, 1 H), 4.29-3.95 (m, 2H), 3.71 (s, 3H), 3.12-2.85 (m, 3H), 2.02- 1.93 (m, 2H), 1.65-1.58 (m, 1 H), 1.48 (s, 9H), 0.62 (d, J = 6.4 Hz, 3H).
Step 9: 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methylpiperidin-4-yl)-1 H-indol-5- yl)benzenesulfonamide. To a solution of (3R,4R)-tert-butyl 4-(5-(4-fluorophenylsulfonamido)-1- methyl-1 H-indol-3-yl)-3-methylpiperidine-1-carboxylate (273 mg. 0.544 mmol) in DCM (10.9 ml_, 0.05 mmol) was added 4M HCI in dioxane (2.04 ml_, 8.16 mmol) at room temperature. The resulting mixture was allowed to stir for 90 min.. The solvent was removed in vacuo to afford the crude product as a black solid, which was used without further purification (238 mg, >99%). 1 H NMR (400 MHz, MeOD) δ 7.66 (dd, 2 H, J=8. 8, 5.3 Hz), 7.35 - 7.07 (m, 4 H), 7.05 (s, 1 H), 6.82 (d, 1 H, J=8.6 Hz), 3.74 (s, 3 H), 3.48 - 3.25 (m, 7 H), 2.45-2.33 (m, 1 H), 2.26-2.1 1 (m, 1 H), 2.07- 1.96 (m, 1 H), 0.79 (d, 3 H, J=7.4 Hz).
Step 10: 4-fluoro-N-(1-methyl-3-((3R,4R)-3-methyl-1-((R)-2,3,3-trimethylbutanoyl)-piperidin- 4-yl)-1 H-indol-5-yl)benzenesulfonamide. To a solution of (R)-2,3,3-trimethylbutanoic acid (152.0 mg, 0.347 mmol) in DMF (3.47 mL) was added successively 4-fluoro-N-(1-methyl-3-((3R,4R)-3- methylpiperidin-4-yl)-1 H-indol-5-yl)benzenesulfonamide (152 mg, 0.347 mmol), HATU (160 mg, 0.416 mmol) and DIPEA (453 mg, 3.47 mmol). The resulting yellow solution was allowed to stir at room temperature. LC/MS showed that the reaction was complete after 1 h. The reaction was quenched with sat. NaHC03, extracted with EtOAc (3x100 mL), washed with brine, dried over MgS04, filtered and. The crude product was purified silica gel column chromatography (0 to 100% EtOAc in heptane) to afford the title compound (172 mg, 97%) as a white fluffy powder consisting of a mixture or rotamers (approximately 1.5: 1.0 ratio). 1 H NMR (400 MHz, CDCI3) δ 7.65 (dd, J=8.6, 5.1 Hz, 2H), 7.18 - 7.1 1 (m, 4H), 7.08 - 6.94 (m, 2H), 6.92 - 6.77 (m, 1 H), 6.77 - 6.66 (m, 1 H), 6.55 - 6.42 (m, 1 H), 4.65 - 4.53 (m, 1 H) 4.21 - 4.09 (m, 0.6H), 3.83-3.80 (m, 0.4 H), 3.37-3.34 (m, 0.4H), 3.28 - 3.08 (m, 1.6H), 3.00 - 2.70 (m, 1.9H), 2.59 - 2.52 (m, 0.4 H), 2.10 (br. s., 1 H), 2.00 - 1.80 (m, 1 H), 1.76 - 1.70 (m, 1 H), 1.58 (s, 0.9H), 1.36 - 1.17 (m, 8.3H), 1.17 - 1.04 (m,
3.1 H), 1.04 - 0.91 (m, 8.6H), 0.66 (d, J=7.0 Hz, 1.3H), 0.58 (d, J=7.0 Hz, 1.7H) ppm.
Example 2
Preparation of N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)-3-methylpiperidin-4-yl)-1- methyl-1 H-indol-5-yl)-4-fluorobenzenesulfonamide
Figure imgf000046_0001
Step 1 : (R)-3-(2-cyclopentylacetyl)-4-isopropyloxazolidin-2-one. To a solution of (R)-4- isopropyloxazolidin-2-one (2.0 g, 10 mmol) in THF (55 mL) at -78 °C was added dropwsie n-BuLi (2.5 M in hexanes, 4.92 mL, 12.3 mmol). The resulting solution was allowed to stir at the same temperature for 1 h, then cyclopentyl acetyl chloride (1 .86 g, 12.3 mmol) was added. The reaction turned pale yellow rapidly and was allowed to stir at -78 °C for 1 h. The reaction was quenched with sat. NaHC03 solution, extracted with EtOAc, dried over Na2S04, filtered and concentrated to afford the title compound (3.20 g, 99%) as a pale yellow oil that solidified on standing. 1 H NMR (400 MHz, CDCI3) δ 7.40-7.28 (m, 3H), 7.26-7.16 (m, 2H), 4.74-4.64 (m, 1 H), 4.24-4.12 (m, 2H), 3.32 (dd, J=13, 3 Hz, 1 H), 3.04 (dd, J=17, 7 Hz, 1 H), 2.92 (dd, J=17, 7 Hz, 1 H), 2.77 (dd, J=14, 10 Hz, 1 H), 2.41-2.28 (m, 1 H), 1 .95-1 .84 (m, 2H), 1 .72-1 .56 (m, 4H), 1 .30-1 .15 (m, 2H).
Step 2: (R)-3-((R)-2-cyclopentylpropanoyl)-4-isopropyloxazolidin-2-one. To a colorless solution of (R)-3-(2-cyclopentylacetyl)-4-isopropyloxazolidin-2-one (3250 mg, 1 1 .34 mmol) in THF (50 mL) at -78 °C was added dropwise LDA (2.0 M, 6.50 mL, 13.0 mmol). The resulting yellow solution was allowed to stir at the same temperature for 1 h. Mel (3.55 mL, 56.6 mmol) was added and the reaction was allowed to warm to 0 °C over 1 h and allowed to stir at 0 °C for 3 h. The reaction was quenched with sat. NH4CI and extracted with EtOAc. The combined organic extracts were washed with sat. NaHC03 and brine, dried over magnesium sulfate, filtered and concentrated in vacuo to afford a white solid. The crude product was purified by silica gel column
chromatography twice (EtOAc: Heptane, 5:95-60:40 then 5:95-50:50). The product was recrystallized from n-heptane to provide the title compound (680 mg, 20%) as colorless crystalline needles. 1 H NMR (400 MHz, CDCI3) δ 7.40-7.17 (m, 5H), 4.69 (ddt, J=10, 7, 3 Hz, 1 H), 4.25-4.1 1 (m, 2H), 3.63 (dg, J=9, 7 Hz, 1 H), 3.28 (dd, J= 14, 3 Hz, 1 H), 2.78 (dd, J=13, 9 Hz, 1 H), 2.21-2.08 (m, 1 H), 1.90-1 .73 (m, 2H), 1 .71-1 .48 (m, 4H), 1 .30-1 .17 (m, 4H), 1 .1 1 (ddd, J=12.0, 5.0, 4.0 Hz, 1 H).
Step 3: (R)-2-cyclopentylpropanoic acid. To a solution of (R)-3-((R)-2- cyclopentylpropanoyl)-4-isopropyloxazolidin-2-one (680 mg, 2.26 mmol) in THF/H20 (v/v = 1/1 , 12 mL) at room temperature was added LiOH H20 (142 mg, 3.38 mmol) followed by H202 (237 mL, 4.17 mmol, 50 wt%). The resulting solution was allowed to stir at room temperature overnight. The reaction was quenched with 1.0 M KHS04 (8 mL) and extracted with EtOAc (3x). The combined organic extracts were washed with brine and dried over Na2S04, filtered and concentrated. The crude product was purified by silica gel column chromatography (EtOAc: Heptane, 7:93-50:50) to afford the title compound (285 mg, 89%) as a colorless oil. 1H NMR (400 MHz, CDCI3) δ 2.29 (dq, J=9, 7 Hz, 1 H), 2.07-1.95 (m, 1 H), 1.87-1.76 (m, 2H), 1.69-1.51 (m, 4H), 1.31-1.24 (m, 1 H), 1.24-1.15 (m, 4H).
Step 4: N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)-3-methylpiperidin-4-yl)-1-methyl-1 H- indol-5-yl)-4-fluorobenzenesulfonamide. To a flask charged with 4-fluoro-N-(1-methyl-3-((3R,4R)-3- methylpiperidin-4-yl)-1 H-indol-5-yl)benzenesulfonamide (prepared as described in Step 9 of Example 1 , 33 mg, 0.075 mmol), (R)-2-cyclopentylpropanoic acid (12.9 mg, 0.090 mmol), HATU (37.4 mg, 0.090 mmol), DIPEA (98.4 mg, 0.753 mmol) was added DMF (1 mL). The mixture was allowed to stir for 2 h then the reaction was added to aq NaHC03 and extracted three times with EtOAc. The combined organic layers were concentrated to give the titled compound (1 1.6 mg, 90%) as a white solid: LCMS m/z [M + H+]: 526.1 ; (1 : 1.4 mixture of rotamers) 1H NMR (400 MHz, CDCI3) δ 7.68-7.65 (2 H, m), 7.25 (s, 0.66 H), 7.20 (s, 0.44H), 7.1 1 (d, J=8.6 Hz, 1 H), 7.07-6.98 (m, 2 H), 6.88 (d, J=8.6 Hz, 0.40 H), 6.81 (d, J=8.6 Hz, 0.60 H), 6.77-6.66 (m, 1.40 H), 6.61 (s, 0.60 H), 4.75 (d, J=13.3 Hz, 0.60 H), 4.50 (d, J=13.3 Hz, 0.40 H) 3.82 (d, J=13.3 Hz, 0.60 H), 3.70 (s, 3 H), 3.34 (d, J=13.3 Hz, 1 H), 3.26-3.11 (m, 1.60 H), 2.96 (m, 0.40 H), 2.77-2.65 (m, 0.60 H), 2.61-2.58 (m, 0.40 H), 2.50-2.38 (m, 0.60 H), 2.29-2.05 (m, 2.10 H), 1.99-1.42 (m, 9.4 H), 1.33- 0.90 (m, 10.6 H), 0.68 - 0.52 (m, 3.10 H)
Examples 3-5 and 32-35
The following Examples 3-5 and 32-35 were prepared analogous to Example 1 employing the appropriate sulfonyl chloride in step 7 and the appropriate carboxylic acid coupling reagent in step 10. However, chiral separation was conducted on the final product. Separation conditions: Method AA: Luxe Cellulose-4, 250x21.2 mm, 5 μηι, 40% EtOH/C02, 80.0 mL/min; Method AB: ChiralTech IC, 250x21.2 mm, 5 μπι, 60-40% (3: 1) EtOAc-MeOH/C02, 80.0 mL/min. Method AC: ChiralPak AD-3, 50 x 4 mm, 3 μπι, EtOH (0.05% DEA)/C02, 4 mL/min. Method AD: ChiralPak AS- H, 150 x 4 mm, 5 μπι, EtOH (0.05% DEA)/C02, 3 mL/min. Method AE: ChiralPak AD-3, 50 x 4.6 mm, 3 μηι, EtOH (0.05% DEA)/C02, 4 mL/min. Method AF: ChiralPak AS-H, 150 x 4.6 mm, 5 μηι, EtOH (0.05% DEA)/C02, 3 mL/min. Example Structure Name/Characterization
N-(3-((3R,4R)-1-(cyclopentanecarbonyl)-3- methylpiperidin-4-yl)-1 -methyl-1 H-indol-5-yl)- 4-fluorobenzenesulfonamide. Separation method AA (first eluting isomer, 8.58 min); LCMS: m/e 498.60 [M+H]+.1H NMR (400 MHz, DMSO-d6): δ 9.74 (s, 1H), 7.69-7.66 (m, 2H), 7.37-7.32 (m, 2H), 7.24 (d, J= 9.2 Hz,
3
1H), 7.11 (s, 1H), 7.06-7.04 (m, 1H), 6.84 (t, J = 6.8 Hz, 1H), 4.45 (d, J= 13.2 Hz, 0.5H), 4.28 (d, J= 12.4 Hz, 0.5H), 4.03 (d, J= 12.4 stereochemistry arbitrarily assigned Hz, 0.5H), 3.84 (d, J= 13.2 Hz, 0.5H), 3.67
(s, 3H), 3.37 (d, J= 10.8 Hz, 0.5H), 3.21-2.75 (m, 4H), 1.97-1.55 (m, 11 H), 0.49 (d, J = 6.8 Hz, 1.5H), 0.41 (d, J= 6.8 Hz, 1.5H)
N-(3-((3S,4S)-1-(cyclopentanecarbonyl)-3- methylpiperidin-4-yl)-1 -methyl-1 H-indol-5-yl)- 4-fluorobenzenesulfonamide. Separation method AA (second eluting isomer, 9.31 min); LCMS: m/e 498.60 [M+H]+.1H NMR (400 MHz, DMSO-d6): δ 9.74 (s, 1H), 7.69-7.66 (m, 2H), 7.37-7.32 (m, 2H), 7.24 (d, J= 9.2 Hz, 1H), 7.11 (s, 1H), 7.06-7.04 (m, 1H), 6.84 (t, J = 6.8 Hz, 1H), 4.45 (d, J= 13.2 Hz, 0.5H), 4.28 (d, J= 12.4 Hz, 0.5H), 4.03 (d, J= 12.4
4 Hz, 0.5H), 3.84 (d, J= 13.2 Hz, 0.5H), 3.67
(s, 3H), 3.37 (d, J= 10.8 Hz, 0.5H), 3.21- 2.75 (m, 4H), 1.97-1.55 (m, 11H), 0.49 (d, J = 6.8 Hz, 1.5H), 0.41 (d, J= 6.8 Hz, 1.5H); stereochemistry arbitrarily assigned
LCMS: m/e 498.60 [M+H]+. 1H NMR (400 MHz, DMSO-d6): δ 9.74 (s, 1H), 7.69-7.66 (m, 2H), 7.37-7.32 (m, 2H), 7.24 (d, J= 9.2 Hz, 1H), 7.11 (s, 1H), 7.06-7.04 (m, 1H), 6.84 (t, J = 6.8 Hz, 1H), 4.45 (d, J= 13.2 Hz, 0.5H), 4.28 (d, J= 12.4 Hz, 0.5H), 4.03 (d, J= 12.4 Hz, 0.5H), 3.84 (d, J= 13.2 Hz, 0.5H), 3.67 Example Structure Name/Characterization
(s, 3H), 3.37 (d, J = 10.8 Hz, 0.5H), 3.21- 2.75 (m, 4H), 1.97-1.55 (m, 11 H), 0.49 (d, J = 6.8 Hz, 1.5H), 0.41 (d, J = 6.8 Hz, 1.5H);
4-fluoro-N-(3-((3R,4R)-1 -isobutyryl-3- methylpiperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide. Separation method AB (first eluting isomer, 9.33 min); 1H NMR (400 MHz, CDCI3) δ ppm 7.68 (dd, J=8.2, 5.1 Hz, 1 H), 7.23 (br. s., 1 H), 7.15 (d, J=8.6 Hz,
5
1 H), 7.07 (t, J=8.4 Hz, 1 H), 6.73-6.91 (m, 1 H), 6.40 (d, J=9.4 Hz, 1 H), 4.44-4.84 (m, 1 H), 3.78-4.10 (m, 1 H), 3.15-3.46 (m, 2 H), stereochemistry arbitrarily assigned
2.68-3.03 (m, 2 H), 2.06-2.20 (m, 1 H), 1.66- 2.04 (m, 2 H), 1.09-1.24 (m, 4 H), 0.55-0.68 (m, 2 H)
N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)- 3-methylpiperidin-4-yl)-1 -methyl-1 H-indol-5- yl)-1 ,3,5-trimethyl-1 H-pyrazole-4- sulfonamide. Separation method AC (second eluting isomer, 2.05 min); 1H NMR (400 MHz, CD3OD) δ ppm 7.28-7.22 (m, 2H), 6.97 (s,
32 1 H), 6.89-6.87 (m, 1 H), 4.65-4.53 (m, 1 H),
4.04-4.00 (m, 1 H), 3.74 (s, 3H), 3.62 (s, 3H), 3.49-3.47 (m, 1 H), 3.33-3.26 (m, 1 H), 3.05- 3.03 (m, 1 H), 2.83-2.80 (m, 1 H), 2.65-2.63 stereochemistry arbitrarily assigned (m, 1 H), 2.24-1.57 (m, 16H), 1.21-1.1 1 (m,
5H), 0.68-0.59 (m, 3H); LCMS: m/e 540.2 [M + H+]. Example Structure Name/Characterization
N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)- 3-methylpiperidin-4-yl)-1 -methyl- 1 H-indol-5- yl)-2-ethoxybenzenesulfonamide. Separation method AD (second eluting isomer, 4.93 min); 1 H NMR (400 MHz, CD3OD) δ ppm
33 7.65-7.63 (m, 1 H), 7.47-7.28 (m, 1 H), 7.23- 6.86 (m, 6H), 4.67-4.51 (m, 1 H), 4.33-4.28 (m, 3H), 3.65 (s, 3H), 3.33-3.02 (m, 4H), 2.78-2.55 (m, 2H), 2.15-1.52 (m, 14H), 1.20- stereochemistry arbitrarily assigned 1.1 1 (m, 5H), 0.61-0.48 (m, 3H); LCMS: m/e
552.2 [M + H+].
N-(3-((3R,4R)-1-((R)-2-cyclopentylpropanoyl)- 3-methylpiperidin-4-yl)-1 -methyl-1 H-indol-5- yl)-2-fluorobenzenesulfonamide. Separation method AD (second eluting isomer, 2.36 min); 1 H NMR (400 MHz, CD3OD) δ ppm 7.66-7.65 (m, 1 H), 7.57-7.55 (m, 1 H), 7.30-
34
7.26 (m, 2H), 7.19-7.16 (m, 2H), 6.96-6.90 (m, 2H), 4.67-4.51 (m, 1 H), 4.33-4.28 (m, 3H), 3.65 (s, 3H), 3.33-3.02 (m, 4H), 2.78- stereochemistry arbitrarily assigned 2.55 (m, 2H), 2.15-1.52 (m, 10H), 1.20-1.1 1
(m, 5H), 0.63-0.51 (m, 3H); LCMS: m/e 526.1 [M + H+].
Figure imgf000051_0001
Example 6
Preparation of 4-fluoro-N-(3-(1-(isothiazole-5-carbonyl)piperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide
Figure imgf000051_0002
Step 1 : tert-butyl 4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridine-1 (2H)-carboxylate. A mixture of 3-iodo-1-methyl-5-nitro-1 H-indole (10.0 g, 33.1 mmol), fe/f-butyl 4-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1 (2H)-carboxylate (13.3 g, 43.0 mmol), K3PO4 (21.1 g, 99.3 mmol) in dioxane (200 mL) and water (20 mL) was degassed and purged with nitrogen three times. Pd(PPh3)4 (3.06 g, 2.65 mmol) was then added under a nitrogen atmosphere. The mixture was degassed and purged with N2 three times. The mixture was heated to 60 °C and stirred at this temperature for 14 h. The solvent was removed under reduced pressure andthe residue was partitioned with EtOAc (200 mL) and water (150 mL). The aqueous layer was extracted with EtOAc (150 ml_x2), the organic layers were combined, washed with brine, dried over anhydrous Na2S04, and concentrated. The crude product was purified by silica gel column chromatography (10-50% EtOAc in PE) to give the title compound (8.05 g, 68.0 %) as an orange solid. 1 H NMR (400 MHz, CDCI3): δ 8.82 (s, 1 H), 8.17-8.15 (m, 1 H), 7.37-7.32 (m, 1 H), 7.16 (s, 1 H), 6.18 (s, 1 H), 4.17 (s, br, 2H), 3.84 (s, 3H), 3.68 (s, br, 2H), 2.55 (s, br, 2H), 1.52 (s, 9H); LCMS: m/e 380.0 [M+Na]+.
Step 2: tert-butyl 4-(5-amino-1-methyl-1 H-indol-3-yl)piperidine-1-carboxylate. To a dry hydrogenation bottle was added dry Pd(OH)2/C (1600 mg) under an Ar atmosphere, followed by a solution of tert-butyl 4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridine-1 (2H)-carboxylate (8050 mg, 22.5 mmol) in EtOH (500 mL) and DCM (50 ml_). The mixture was degassed and refilled with H2 3 times, then the mixture was stirred under a hydrogen atmosphere (50 Psi) at 50 °C for 48 hours. The mixture was filtered through a pad of Celite®, and the filtrate was concentrated to give the crude product (7700 mg, 100%) as a purple solid, which wasn't hydrogenated completely according to proton NMR. The material was resubjected as follows: To a dry hydrogenation bottle was added dry Pd(OH)2/C (1500 mg) under an Ar atmosphere, followed by a solution of crude starting material (7700 mg, 23.5 mmol) in EtOH (400 mL). The mixture was degassed and refilled with H2 3 times, then the mixture was stirred under a hydrogen atmosphere (50 Psi) at 50 °C for 48 hours. H-NMR showed the starting material was consumed completely, and the desired product was formed. The mixture was filtered through a pad of Celite® and the filtrate was concentrated to give the crude product . The crude product was combined with another batch for purification by silica gel column chromatography (0-33% EtOAc inDCM) to give the title compound (3.79 g, 34.6%) as a purple solid. 1H NMR (400 MHz, CDCI3)
Figure imgf000052_0001
6.86 - 6.98 (m, 1 H) 6.54 - 6.80 (m, 2 H) 4.06 - 4.33 (m, 2 H) 3.68 (s, 3 H) 2.87 (t, J=1 1.54 Hz, 3 H) 1.99 (d, J=12.05 Hz, 2 H) 1.63 (d, J=13.05 Hz, 3 H) 1.43 - 1.53 (m, 10 H); LCMS: m/e 351.9 [M+Na]+.
Step 3: tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1 H-indol-3-yl)piperidine-1- carboxylate. To a round bottom flask was added tert-butyl 4-(5-amino-1-methyl-1 H-indol-3- yl)piperidine-1-carboxylate (2200 mg, 6.678 mmol), 4-fluorobenzensulfonyl chloride (1950 mg, 10.0 mmol) and pyridine (30 mL). The solution was stirred at 15 °C for 13 hours. The reaction was combined with two other batches for workup. The solvent was removed under reduced pressure andthe residue was partitioned with DCM (80 mL) and water (80 mL) The aqueous layer was extracted with DCM (40 mLx2). The combined organic layers were washed with aqueous citric acid and concentrated. The crude product was purified on by silica gel column chromatography (10- 60% EtOAc in PE) to give the title compound (3.20 g, 55.6%) as a yellow solid. 1 H NMR (400
MHz, CDCI3): δ 7.70-7.66 (m, m2H), 7.27-7.26 (m, 1 H), 7.15-7.05 (m, 3H), 6.84-6.81 (m, 2H), 6.39 (s, 1 H), 4.20 (s, br, 2H), 3.72 (s, 3H), 2.88-2.82 (m, 3H), 1.92-1.89 (m, 2H), 1.58-1.51 (m, 2H), 1.50 (s, 9H) ppm. LCMS: m/e 510.0 [M+Na]+.
Step 4: 4-fluoro-N-(1-methyl-3-(piperidin-4-yl)-1 H-indol-5-yl)benzenesulfonamide. To a solution of tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1 H-indol-3-yl)piperidine-1 - carboxylate (1200 mg, 2.461 mmol) in DCM (15 mL) was added HCI/dioxane (7 mL, 4 M) at 0-5 °C in an ice/water bath. The brown solution was stirred at 20 °C for 2 hours. The reaction was combined with three other batches for workup. The solvent was removed under reduced pressure to give the crude product as a gum, which was then dissoled with MeOH and DCM. The resulting solutionwas concentrated to afford the title compound (3.67 g, 100%) as a brown solid. 1H NMR (400 MHz, methanol-d4) δ 7.70-7.67 (m, 2H), 7.36 (s, 1 H), 7.22-7.15 (m, 3H), 7.06 (s, 1 H), 6.80- 6.78 (m, 1 H), 3.77-3.68 (m, 4H), 3.52-3.49 (m, 2H), 3.37-3.12 (m, 4H), 2.22-2.18 (m, 2H), 1.97- 1.86 (m, 2H) ppm. LCMS: m/e 388.0 [M+H]+.
Step 5: 4-fluoro-N-(3-(1-(isothiazole-5-carbonyl)piperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide. The title compound was prepared in an analogous manner to Example 1 , step 10 employing isothiazole-5-carboxylic acid . LC/MS [M+H]+: 499; Rt = 2.93 (Method A).
Examples 7-18
The following Examples 7-18 were prepared in an analogous manner to Example 6 employing the necessary carboxylic acid in step 5.
Example Structure Name/Characterization
(R)-N-(3-(1-(2-cyclopentylpropanoyl)piperidin-4-yl)- 1-methyl-1 H-indol-5-yl)-4- fluorobenzenesulfonamide; 1H NMR (400 MHz, DMSO-d6): δ 9.77 (s, 1 H), 7.70-7.67 (m, 2H), 7.37- 7.32 (m, 2H), 7.23 (d, J=8.8 Hz, 1 H), 7.12 (d,
7
J=10.0 Hz, 1 H), 7.08 (s, 1 H), 6.80 (t, J=7.6 Hz, 1 H), 4.52 (d, J=12.4 Hz, 1 H), 4.08 (d, J=12.4 Hz, 1 H), 3.65 (s, 3H), 3.17 (t, J=12.8 Hz, 1 H), 2.89 (t, J=12.8 Hz, 1 H), 2.67-2.65 (m, 2H), 1.99-1.0 (m, 16H); LC/MS [M+H]+ :512
N-(3-(1-(cyclopropanecarbonyl)piperidin-4-yl)-1-
8 methyl-1 H-indol-5-yl)-4-fluorobenzenesulfonamide.
LC/MS [M+H]+: 456; Rt = 3.1 1 (method B) Example Structure Name/Characterization
4-fluoro-N-(1-methyl-3-(1-(4,4,4-trifluoro-3- methylbutanoyl)piperidin-4-yl)-1 H-indol-5-
9
yl)benzenesulfonamide. LC/MS [M+H]+ :526; Rt =3.27 (method A)
(R)-4-fluoro-N-(1 -methyl-3-(1 -(2,3,3- trimethylbutanoyl)piperidin-4-yl)-1 H-indol-5- yl)benzenesulfonamide. 1 H NMR (400 MHz, DMSO-d6) δ ppm 9.76 (br. s., 1 H), 7.61 - 7.75 (m, 2 H), 7.36 (t, J=8.3 Hz, 2 H), 7.25 (d, J=9.0 Hz, 1
10
H), 7.02 - 7.17 (m, 2 H), 6.82 (d, J=8.53 Hz, 1 H), 4.60 (br. s., 1 H), 4.21 (d, J=12.05 Hz, 1 H), 3.66 (s, 3 H), 3.07 - 3.25 (m, 1 H), 2.54 - 2.95 (m, 3 H), 1.73 - 1.95 (m, 2 H), 1.21 - 1.52 (m, 2 H), 0.84 - 1.08 (m, 12 H); LCMS: m/e 522 [M+Na]+.
N-(3-(1-(cyclobutanecarbonyl)piperidin-4-yl)-1- methyl-1 H-indol-5-yl)-4-fluorobenzenesulfonamide. 1H NMR (400 MHz, DMSO-d6): δ 9.80 (s, 1 H), 7.68- 7.63 (m, 2H), 7.39-7.36 (m, 2H), 7.22-6.80 (m, 4H),
1 1
4.47-4.41 (m, 1 H), 3.76-3.65 (m, 2H), 3.63 (s, 3H), 3.10-3.03 (m, 1 H), 2.92-2.81 (m, 1 H), 2.73-2.61 (m, 1 H), 2.21-2.04 (m, 4H), 2.00-1.67 (m, 4H), 1.40- 1.30 (m, 2H). LCMS: m/e 470.15 [M+H]+
Example Structure Name/Characterization
4-Fluoro-N-(1-methyl-3-(1-(3- methylbutanoyl)piperidin-4-yl)-1 H-indol-5- yl)benzenesulfonamide. 1 H NMR (400 MHz, CDCI3): δ 7.69-7.66 (m, 2H), 7.28-7.26 (m, 1 H), 7.12 (d, J = 8.4 Hz, 1 H), 7.08-7.04 (m, 2H), 6.83-
12 6.80 (m, 2H), 6.47 (bs, 1 H), 4.76 (d, J = 13.2 Hz,
1 H), 3.96 (d, J = 13.2 Hz, 1 H), 3.71 (s, 3H), 3.17 (t, J = 12.4 Hz, 1 H), 2.96-2.92 (m, 1 H), 2.69 (t, J = 12.4 Hz, 1 H), 2.26 (t, J = 6.8 Hz, 2H), 2.18-1.94 (m, 3H), 1.58-1.48 (m, 2H), 0.99 (t, J = 6.8 Hz, 6H). LCMS: m/e 472.20 [M+H] +
N-(3-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-1- methyl-1 H-indol-5-yl)-4-fluorobenzenesulfonamide. 1H NMR (400 MHz, CDCI3): δ 7.69-7.66 (m, 2H), 7.29 (d, J = 1.6 Hz, 1 H), 7.12 (d, J = 8.8 Hz, 1 H), 7.08-7.04 (m, 2H), 6.83 (d, J = 1.6 Hz, 1 H), 6.81 (bs,1 H), 6.45 (bs, 1 H), 4.76 (d, J = 13.2 Hz, 1 H),
13
3.91 (d, J = 13.2 Hz, 1 H), 3.71 (s, 3H), 3.19 (t, J = 12.0 Hz, 1 H), 2.98-2.93 (m, 1 H), 2.71 (t, J = 12.8 Hz, 1 H), 2.32 (d, J = 6.8 Hz, 2H), 2.04-1.95 (m, 2H), 1.64-1.47 (m, 2H), 1.29-1.07 (m, 1 H), 0.58 (d, J = 7.6 Hz, 2H), 0.20 (d, J = 4.8 Hz, 2H). LCMS: m/e 470.20 [M+H] +
N-(3-(1-(cyclohexanecarbonyl)-piperidin-4-yl)-1- methyl-1 H-indol-5-yl)-4-fluorobenzenesulfonamide. 1H NMR (400 MHz, DMSO-d6): δ 9.77 (s, 1 H), 7.70- 7.67 (m, 2H), 7.34 (t, J=8.8 Hz, 2H), 7.23 (d, J=8.8 Hz, 1 H), 7.12 (d, J=2.0 Hz, 1 H), 7.08 (s, 1 H), 6.80
14
(dd, J=8.4, 2.0 Hz, 1 H), 4.48 (d, J=13.2 Hz, 1 H), 4.05 (d, J=13.2 Hz, 1 H), 3.65 (s, 3H), 3.12-3.15 (m, 1 H), 2.87-2.86 (m, 1 H), 2.64-2.60 (m, 2H), 1.85-1.65 (m, 8H), 1.43-1.10 (m, 6H); LCMS: m/e 498.55 [M+H] + Example Structure Name/Characterization
4-fluoro-N-(3-(1-(2-fluoro-6- methylbenzoyl)piperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide. 1 H NMR (400 MHz, DMSO-d6): δ 9.77 (s, 1 H), 7.70-7.65 (m, 2H), 7.36- 7.30 (m, 3H), 7.23 (d, J=8.8 Hz, 1 H), 7.17-7.10 (m,
15
4H), 6.80 (dd, J=8.4, 1.2 Hz, 1 H), 4.67 (d, J=13.4 Hz, 1 H), 3.66 (s, 1.5H), 3.65 (s, 1.5H), 3.32-3.15 (m, 2H), 2.95-2.92 (m, 2H), 2.29 (s, 1.5H), 2.22 (s, 1.5H), 1.94 (d, J=13.8 Hz, 1 H), 1.78 (d, J=13.8 Hz, 1 H), 1.52-1.38(m, 2H); LCMS: m/e 524.55 [M+H] +
(S)-N-(3-(1-(2,3-dimethylbutanoyl)piperidin-4-yl)-1 - methyl-1 H-indol-5-yl)-4-fluorobenzenesulfonamide. 1H NMR (400 MHz, DMSO-d6): δ 9.71 (s, 1 H), 7.69- 7.66 (m, 2H), 7.37-7.33 (m, 2H), 7.23 (d, J=8.8 Hz, 1 H), 7.12 (d, J=6.0 Hz, 1 H), 7.08 (s, 1 H), 6.79 (d,
16
J=8.4 Hz, 1 H), 4.56-4.54 (m, 1 H), 4.07 (d, J=13.2 Hz, 1 H), 3.65 (s, 3H), 3.16 (t, J=13.2 Hz, 1 H), 2.89 (d, J=13.2 Hz, 1 H), 2.67-2.57 (m, 2H), 1.87-1.76 (m, 3H), 1.43-1.37 (m, 2H), 0.99-0.84 (m, 9H); LCMS: m/e 486.45 [M+H] +
N-(3-(1-(cyclopentanecarbonyl)piperidin-4-yl)-1- methyl-1 H-indol-5-yl)-2-fluorobenzenesulfonamide 1H NMR (400 MHZ, CDCI3): δ 7.70 (t, J = 7.6 Hz, 1 H), 7.55-7.50 (m, 1 H), 7.35 (s, 1 H), 7.25-7.1 1 (m, 3H), 6.93 (t, J = 7.6 Hz, 1 H), 6.78 (s, 1 H), 6.70 (s,
17
1 H), 4.75 (d, J=13.6 Hz, 1 H), 4.07 (d, J = 13.6 Hz, 1 H), 3.68 (s, 3H), 3.19 (t, J=13.6 Hz, 1 H), 2.98-2.94 (m, 2H), 2.71 (d, J=12.8 Hz, 1 H), 2.05-1.47 (m, 12H). LCMS: m/e 484.1 [M+H] + Example 18
(R)^-fluoro-N-(3-(1-isobutyi7l-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide
Figure imgf000057_0001
Step 1 : tert-butyl 2,2-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1 (2H)- carboxylate. To a RB flask charged with tert-butyl 2,2-dimethyl-4-oxopiperidine-1-carboxylate (7.76 g, 34.1 mmol) in dry THF (130 mL) was added slowly dropwise at -70 °C a solution of sodium bistrimethyldisilazide (7.51 g 41.0 mmol) in THF (41 mL). Upon complete addition, a solution of N- phenyltriflamide (16.1 g, 41.0 mmol) in THF (10 mL) was added and the mixture was allowed to warm to room temperature over the course of 12 h. The reaction mixture was then concentrated and brought up in EtOAc:heptane (85:15,100 mL) and washed twice with water. The combined organics were collected and concentrated to give 12.0 g (98%) of the titled compound as a yellow oil. 1 HNMR (400 MHz, CDCI3) δ 5.78 (t, J=3.5 Hz, 1 H), 4.08 (q, J=2.7 Hz, 2 H), 2.40 (br s, 2 H), 1.37-1.58 (m, 14H).
Step 2: tert-butyl 2,2-dimethyl-4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridine-1 (2H)- carboxylate. A mixture of 1-methyl-5-nitro-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H- indole (prepared as described in Example 1) (1.25 g, 4.137 mmol), tert-butyl 2,2-dimethyl-4- (((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1 (2H)-carboxylate (1.63 g, 4.55 mmol) and K3PO4 (1.76 g, 8.27 mmol) in dioxane/H20 (40 mL/4 mL) was purged and degassed with N2 three times. Pd(PPh3)4 (478 mg, 0.414 mmol) under nitrogen atmosphere was then added. The mixture was purged and degassed with N2 for 5 mins and then heated to 60 °C overnight. The reaction mixture was concentrated and the residue was purified by silica gel column chromatography (0- 66% EtOAc in PE =0-66%) to provide the title compound (1.45 g, 91.2%) as a yellow solid. 1H NMR (400 MHz, CDCI3) δ ppm 8.83 (d, J=2.0 Hz, 1 H), 8.17 (dd, J=9.0, 2.0 Hz, 1 H), 7.34 (d, J=9.0 Hz, 1 H), 7.17 (s, 1 H), 6.35 (t, 1 H), 4.15 (d, J=4.0 Hz, 2 H), 3.85 (s, 3 H), 2.53 (s, 2 H), 1.43 - 1.56 (m, 9 H), 1.24 (s, 6 H).
Step 3: tert-butyl 4-(5-amino-1-methyl-1 H-indol-3-yl)-2,2-dimethylpiperidine-1 -carboxylate. To a dry hydrogenation bottle was added Pd/C (200 mg) under Ar atmosphere, followed by a solution of tert-butyl 2,2-dimethyl-4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridine-1 (2H)- carboxylate (1000 mg, 2.594 mmol) in EtOH (75 mL) and DCM (15 mL). The mixture was degassed and purged with H2 for 3 times and the mixture was stirred under hydrogen atmosphere (50 Psi) at 40 °C for 3 hours. The reaction solution was filtered through a pad of Celite® and the cake was washed with MeOH three times. The combined filtrate was concentrated to give the title compound (900 mg, 97%) as a lavender oil, which was used directly without further purification. LCMS: m/e 380 [M+Na]+.
Step 4: tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl-1 H-indol-3-yl)-2,2- dimethylpiperidine-1-carboxylate. To a solution of tert-butyl 4-(5-amino-1-methyl-1 H-indol-3-yl)- 2,2-dimethylpiperidine-1-carboxylate (900 mg, 2.52 mmol) and 4-fluorobenzenesulfonyl chloride (735 mg, 3.78 mmol) in DCM (20 mL) was added TEA (764 mg, 7.55 mmol) and the mixture was stirred at 15 °C for 2 hours. The reaction mixture was concentrated and the residue was purified by silica gel column chromatography (10-25% EtOAc in PE) to give the title compound (1 100 mg, 84.7 %) as a brown solid. LCMS: m/e 538 [M+Na]+.
Step 5: N-(3-(2,2-dimethylpiperidin-4-yl)-1 -methyl-1 H-indol-5-yl)-4- fluorobenzenesulfonamide. To a solution of tert-butyl 4-(5-((4-fluorophenyl)sulfonamido)-1-methyl- 1 H-indol-3-yl)-2,2-dimethylpiperidine-1-carboxylate (900 mg, 1.75 mmol) in DCM (25 mL) was added HCI/Dioxane (15 mL) and the resulting mixture was stirred for 6 hours at 15 °C. The solvent was removed under reduced pressure to give the title compound (800 mg, 100%) as a white solid, which was used directly without further purification. LCMS: m/e 416 [M+H]+.
Step 6: 4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide. To a suspension of N-(3-(2, 2-dimethylpiperidin-4-yl)-1 -methyl-1 H-indol-5- yl)-4-fluorobenzenesulfonamide (400 mg, 0.885 mmol) in DCM (25 mL) was added TEA (269 mg, 2.65 mmol) at 0 °C. A solution of isobutyryl chloride (141 mg, 1.33 mmol) in DCM (5 mL) was added dropwise at 0 °C and stirred for 6 hours at this temperature. Additional TEA (134 mg, 1.32 mmol) and isobutyryl chloride (94 mg, 0.885 mmol) was added. The resulting mixture was stirred at 15 °C overnight. The reaction mixture was quenched with water, extracted with DCM (20ml_x2). The combined organic layers were washed with brine, dried (Na2S04), and the solvent was removed under reduced pressure. The crude product was purified by prep-HPLC (Column: YMC- Actus Triart, C18 150 x 30 mm, 5 μηι; 52% MeCN/H20 to 72% MeCN/H20, 0.225% formic acid) to give the title compound (207 mg, 40.2 %) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 9.77 (br. s., 1 H), 7.69 (dd, J=8.8, 5.3 Hz, 2 H), 7.36 (t, J=8. 8 Hz, 2 H), 7.28 (d, J=8.5 Hz, 1 H), 7.00 - 7.16 (m, 2 H), 6.88 (d, =8.5 Hz, 1 H), 3.67 (s, 4 H), 2.78 - 3.05 (m, 2 H), 2.05-1.95 (m, 1 H), 1.48 - 1.74 (m, 3 H), 1.44 (d, J=12.6 Hz, 6 H), 0.84 - 1.06 (m, 6 H); LCMS: m/e 508.3 [M+Na]+.
Step 6: (R)-4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide. The racemic 4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1- methyl-1 H-indol-5-yl)benzenesulfonamide (190 mg) was resolved by prep-SFC (Column: OJ, 250x30 mm, 5 μηι; 25% EtOH/NH3/H20; 60 mL/min) to give two peaks for which absolte stereochemistry has been arbitrarily assigned. The first eluting isomer (7.33 min) was arbitrarily assigned as (S)-4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5- yl)benzenesulfonamide (65 mg) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 9.77 (br. s., 1 H), 7.69 (dd, J=8. 8, 5.3 Hz, 2 H), 7.36 (t, J=8. 8 Hz, 2 H), 7.28 (d, J=8.5 Hz, 1 H), 7.00 - 7.16 (m, 2 H), 6.88 (d, J=8. Hz, 1 H), 3.67 (s, 4 H), 2.78 - 3.05 (m, 2 H), 2.05-1.95 (m, 1 H), 1.48 - 1.74 (m, 3 H), 1.44 (d, J=12.6 Hz, 6 H), 0.84 - 1.06 (m, 6 H); LCMS: m/e 508 [M+Na]+. The second eluting isomer (7.57 min) was arbitrarily assigned as (R)-4-fluoro-N-(3-(1-isobutyryl-2,2-dimethylpiperidin-4-yl)-1- methyl-1 H-indol-5-yl)benzenesulfonamide (90 mg) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 9.77 (br. s., 1 H), 7.69 (dd, J=8.8, 5.3 Hz, 2 H), 7.36 (t, J=8.8 Hz, 2 H), 7.28 (d, J=8.5 Hz, 1 H), 7.00-7.16 (m, 2 H), 6.88 (d, J=8.5 Hz, 1 H), 3.67 (s, 4 H), 2.78-3.05 (m, 2 H), 2.05-1.95 (m, 1 H), 1.48-1.74 (m, 3 H), 1.44 (d, J=12.6 Hz, 6 H), 0.84-1.06 (m, 6 H); LCMS: m/e 508 [M+Na]+.
Example 19
(R)-N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5-yl)-4^ fluorobenzenesulfonamide
Figure imgf000059_0001
Step 1 : N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5-yl)- 4-fluorobenzenesulfonamide. To a suspension of N-(3-(2,2-dimethylpiperidin-4-yl)-1-methyl-1 H- indol-5-yl)-4-fluorobenzenesulfonamide (prepared as described in Example 18) (400 mg, 0.885 mmol) in DCM (25 mL) was added TEA (269 mg, 2.65 mmol) at 0 °C and the mixture was stirred untill the solution turned clear. A solution of cyclopentanecarbonyl chloride (176 mg, 1.33 mmol) in DCM (5 mL) was added dropwise at 0 °C, and the mixture was stirred for 3 hours at this temperature. The reaction mixture was quenched with water and extracted with DCM (20 ml_x2). The combined organic layers were washed with brine, dried (Na2S04) and the solvent was removed under reduced pressure. The crude product was purified by prep-HPLC (Column:
Phenomenex Gemini C18, 250x21.2 mm, 8 μηι; 51 % MeCN/H20 to 71 % MeCN/H20 w/ NH3 (pH 10)) to give the title compound (210 mg, 46.4 %) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 9.78 (br. s., 1 H), 7.69 (dd, J=8.5, 5.5 Hz, 2 H), 7.36 (d, J=17.6 Hz, 2 H), 7.28 (d, J=9.0 Hz, 1 H), 7.1 1 (s, 2 H), 6.87 (d, J=8.5 Hz, 1 H), 3.62 - 3.75 (m, 3 H), 2.89 - 3.07 (m, 2 H), 1.92 - 2.08 (m, 1 H), 1.48 - 1.84 (m, 12 H), 1.44 (d, J=16.1 Hz, 6 H); LCMS: m/e 534.1 [M+Na]+. Step 2: (R)-N-(3-(1 -(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5- yl)-4-fluorobenzenesulfonamide. The racemic N-(3-(1-(cyclopentanecarbonyl)-2,2- dimethylpiperidin-4-yl)-1-methyl-1 H-indol-5-yl)-4-fluorobenzenesulfonamide (200 mg) was resolved by prep-SFC (OJ (250x30 mm, 5 μηι; 28% MeOH, NH3/H20, 60 mL/min) to give two peaks for which the absolute stereochemistry has been aribitrarily assigned. The first eluting isomer (4.99 min) was arbitrarily assigned as (S)-N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1- methyl-1 H-indol-5-yl)-4-fluorobenzenesulfonamide (92 mg, 46 %) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 9.78 (br. s., 1 H), 7.69 (dd, J=8.53, 5.52 Hz, 2 H), 7.36 (d, J=17.6 Hz, 2 H), 7.28 (d, J=9.0 Hz, 1 H), 7.1 1 (s, 2 H), 6.87 (d, J=8.5 Hz, 1 H), 3.62 - 3.75 (m, 3 H), 2.89 - 3.07 (m, 2 H), 1.92 - 2.08 (m, 1 H), 1.48 - 1.84 (m, 12 H), 1.44 (d, J=16.1 Hz, 6 H); LC/MS (M+Na) = 534.1 ; LCMS: m/e 534.1 [M+Na]+. The second eluting isomer (5.34 min) was arbitrarily assigned as (R)- N-(3-(1-(cyclopentanecarbonyl)-2,2-dimethylpiperidin-4-yl)-1 -methyl-1 H-indol-5-yl)-4- fluorobenzenesulfonamide (95 mg, 48 %) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 9.78 (br. s., 1 H), 7.69 (dd, J=8.5, 5.5 Hz, 2 H), 7.36 (d, J=17.6 Hz, 2 H), 7.28 (d, J=9.0 Hz, 1 H), 7.1 1 (s, 2 H), 6.87 (d, J=8.5 Hz, 1 H), 3.62 - 3.75 (m, 3 H), 2.89 - 3.07 (m, 2 H), 1.92 - 2.08 (m, 1 H), 1.48 - 1.84 (m, 12 H), 1.44 (d, J=16.1 Hz, 6 H); LC/MS (M+Na)+ = 534.1.
Example 20
Preparation of N-(3-((2S,4S)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-yl)-1-methyl-1H- indol-5-yl)-4-fluorobenzenesulfonamide
Figure imgf000060_0001
Steps 1 : (S)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-one. A flask with a mixture of benzyl (S)-2-methyl-4-oxopiperidine-1-carboxylate (500 mg, 2.02 mmol) and Pd/C (5% by weight, 215 mg) in EtOH (10 mL) was evacuated with water aspiration and then put under hydrogen gas. The mixture was stirred under 1.1 bar hydrogen over-pressure for 1 h. The mixture was filtered through a Celite® plug, and the filtrate was concentrated in vacuo. To the residue was added DCM (10 ml) followed by triethylamine (1.41 mL, 10.1 mmol) and then cyclopentanecarbonyl chloride (492 μί, 4.04 mmol) dropwise. The reaction mixture was stirred at room temperature for 1 h, whereupon the reaction was quenched with 40 ml water followed by extraction in a phase separator (4 x DCM). The combined organic extracts were evaporated and the residue was purified by flash chromatography (EtOAc/heptane; 1 : 1) to provide the title compound (301 mg, 71 %) as a colorless oil. 1 H NMR (500 MHz, CDCI3): δ 5.24-4.84 (2 br s, 1 H), 4.64-4.10 (2 br s, 1 H), 3.55-3.1 1 (2 br s, 1 H), 2.95 (m, 1 H), 2.65 (dd, J=6.7, 14.4Hz, 1 H), 2.50-2.30 (m, 3H), 1.93-1.77 (m, 6H), 1.64-1.56 (m, 2H), 1.29-1.16 (m, 3H)
Step 2: (S)-1-(cyclopentanecarbonyl)-2-methyl-1 ,2,3,6-tetrahydropyridin-4-yl
tnfluoromethanesulfonate. n-BuLi (2.5M solution in hexanes, 1.15 mL, 2.87 mmol) was added drop wise to diisopropylamine (402 μί, 2.87 mmol) in dry THF (5 mL) under nitrogen at -78 °C.The mixture was stirred at -78 °C for 30 min, whereupon (S)-1-(cyclopentanecarbonyl)-2- methylpiperidin-4-one (300 mg, 1.43 mmol) in dry THF (4 mL) was added. The temperature was allowed to warm to room temperature. After stirring for 30 min, the reaction mixture was cooled to 0°C. The mixture was quenched with NaHC03 (50% sat.) and extracted with diethyl ether. The organic phase was washed with citric acid (10%), NaOH (1 M), water and brine. The organic phase was dried (Na2S04) and evaporated. The residue was purified by flash chromatography
(EtOAc/heptane, 15:85 - 2:8) to provide the title compound (329 mg, 67%) as an orange oil. NMR showed the two double bond isomers. 1H NMR (500 MHz, CDCI3): δ 5.81-5.74 (m, 1 H), 5.29-3.26 (m, 4H), 2.90-2.52 (m, 2H), 1.98-1.53 (m, 8H), 1.35-1.15 (m, 3H).
Step 3: (S)-cyclopentyl(2-methyl-4-(1-methyl-5-nitro-1 H-indol-3-yl)-3,6-dihydropyridin- 1 (2H)-yl)methanone. A mixture of 1-methyl-5-nitro-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)- 1 H-indole (prepared as described in Example 1) (100 mg, 0.33 mmol), (S)-1 - (cyclopentanecarbonyl)-2-methyl-1 ,2,3,6-tetrahydropyridin-4-yl tnfluoromethanesulfonate (1 19 mg, 0.35 mmol) and K3P04 (155 mg, 0.73 mmol) in dioxane/water (9: 1 , 3 mL) was flushed with nitrogen. Tetrakis triphenylphosphine Pd(0) (38 mg, 0.03 mmol) was added, the vial was flushed quickly with nitrogen, and the mixture was stirred at 60 °C overnight. Water was added, and the mixture was extracted with DCM (4 x). The combined organic layers were concentrated in vacuo. The residue was purified by prep-HPLC to provide the title compound (110 mg, 90%) as a yellow glass. LCMS: m/e 368.20 [M+H] +
Steps 4: N-(3-((2S,4S)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-yl)-1 -methyl-1 H-indol- 5-yl)-4-fluorobenzenesulfonamide. A mixture of (S)-cyclopentyl(2-methyl-4-(1-methyl-5-nitro-1 H- indol-3-yl)-3,6-dihydropyridin-1 (2H)-yl)methanone (50 mg, 0.14 mmol) and Pt02 (6.1 mg, 0.027 mg) in EtOH/AcOH 6:1 (3.5 mL) was stirred at room temperature under H2 (1 bar overpressure) for 18 h. The reaction mixture was filtered through a PTFE filter, and concentrated in vacuo. The reduced product was unstable and used immediantly. The residue was dissolved in pyridine (3 mL). 4-Fluorobenzenesulfonyl chloride (40 mg, 0.20 mmol) was then added at room temperature, and the mixture was stirred for 90 min. The mixture was concentrated in vacuo, and the residue was purified by prep-HPLC to provide the title compound (3.7 mg, 5.5%). 1 H NMR (500 MHz, (CD3)2CO): δ 8.63 (s, 1 H), 7.78-7.72 (m, 2H), 7.29-7.22 (m, 4H), 7.06 (s, 1 H), 7.03-6.98 (m, 1 H), 4.39-4.29 (m, 2H), 4.01 (br. s, 1 H), 3.74 (s, 3H), 3.28 (br. S, 1 H), 3.02 (quint., J = 8.43, 1 H), 2.22- 2.13 (m, 1 H), 2.01-1.95 (m, 1 H), 1.94-1.52 (m, 10H), 1.1 1 (d, J = 6.45, 3H), LCMS: m/e 498.29 [M+H] +.
Example 21
Preparation of N-(3-((2S,4R)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4-yl)-1 -methyl-1H- indol-5-yl)-4-fluorobenzenesulfonamide
Figure imgf000062_0001
Purification of the diastereomeric mixture produced in step 4 of Example 20 by preparative HPLC afford a second product as the title compound (6.3 mg, 9.3%). 1 H NMR (500 MHz, (CD3)2CO): δ 8.42 (s, 1 H), 7.75 (q, J = 5.4, 8.4 Hz, 2H), 7.32-7.21 (m, 4H), 7.02 (s, 1 H), 6.97 (d, J = 8.4 Hz, 1 H), 4.99 (m, 0.5H), 4.59 (m, 0.5H), 4.50 (m, 0.5H), 4.00 (m, 0.5H), 3.73 (s, 3H), 3.42- 2.98 (m, 3H), 2.0-1.51 (m, 12H), 1.40 (d, J = 6.7 Hz, 1.5H), 1.23 (d, J = 6.7 Hz, 1.5H), LCMS: m/e 498.28 [M+H] +.
Example 22
Preparation of 4-fluoro-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-1 H-indol-5-yl)-3- methoxybenzenesulfonamide
Figure imgf000062_0002
Step 1 : tert-butyl 4-(5-((4-fluoro-3-methoxyphenyl)sulfonamido)-1 -methyl-1 H-indol-3- yl)piperidine-1-carboxylate. A solution of tert-butyl 4-(5-amino-1-methyl-1 H-indol-3-yl)piperidine-1 carboxylate (prepared as described in Example 6) (3.0 g, 9.1 mmol) and 4-fluoro-3- methoxybenzenesulfonyl chloride (2.5 g, 10.9 mmol) in dry pyridine (20 ml) was stirred at room temperature overnight. The pyridine was evaporated, and 1 M HCI and DCM were added. The phases were separated and the organic layer was evaporated. The residue was purified by flash chromatography (heptane/EtOAc, 1 :4) to provide the title compound (3.9 g, 82%). LCMS: m/e 518.33 [M+H] +. Step 2: 4-fluoro-3-methoxy-N-(1-methyl-3-(piperidin-4-yl)-1 H-indol-5-yl)benzene- sulfonamide. To a solution of tert-butyl 4-(5-((4-fluoro-3-methoxyphenyl)sulfonamido)-1-methyl-1 H- indol-3-yl)piperidine-1-carboxylate (3.9 g, 7.5 mmol) in DCM (50 mL) was added TFA (5.7 mL), and the mixture was stirred at room temperature for 1 h. The volatiles were evaporated. The residue was dissolved in DCM, and sat. NaHC03 was added. The phases were separated and the organic layer evaporated to provide the title compound that was used in the subsequent step without further purification. LCMS: m/e 418.07 [M+H] +.
Step 3: 4-fluoro-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-1 H-indol-5-yl)-3- methoxybenzenesulfonamide. To the crude 4-fluoro-3-methoxy-N-(1-methyl-3-(piperidin-4-yl)-1 H- indol-5-yl)benzenesulfonamide from the previous step in dry pyridine (20 mL) was added isobutyryl chloride (4.7 mL, 44.7 mmol). The reaction mixture was stirred at room temperature for 1 h. The pyridine was evaporated, and 1 M HCI and DCM were added. The phases were separated and the organic layer was concentrated. The residue was purified by flash chromatography
(heptane/EtOAc, 1 : 1) to provide the title compound (2.0 g, 55% over two steps). 1 H NMR (500 MHz, (CD3)2CO): δ 7.24-7.20 (m, 2H), 7.19-7.12 (m, 3H), 6.97 (s, 1 H), 6.88 (dd, J = 2.0, 8.6 Hz, 1 H), 4.67-4.62 (m, 1 H), 4.16-4.10 (m, 1 H), 3.71 (s, 3H), 3.66 (s, 3H), 3.26-3.22 (m, 1 H), 3.03-2.95 (m, 2H), 2.81-2.73 (m, 1 H), 2.03-1.91 (m, 1 H), 1.62-1.48 (m, 2H), 1.35-1.22 (m, 2H), 1.13 (dd, J = 7.0, 10.9 Hz, 6H). LCMS: m/e 488.33 [M+H] +.
Example 23
Preparation of 4-fluoro-3-hydroxy-N-(3-(1-isobutyi^lpiperidin^-yl)-1-methyl-1H-indol-5- yl)benzenesulfonamide
Figure imgf000063_0001
A solution of BBr3 (24 mL, 1 M in DCM) in was added to a stirred solution of 4-fluoro-N-(3- (1-isobutyrylpiperidin-4-yl)-1-methyl-1 H-indol-5-yl)-3-methoxybenzenesulfonamide (prepared as described in Example 22) (1.97 g, 4.0 mmol) in DCM (30 mL) under an atmosphere of nitrogen at - 78 °C. The cooling bath was removed and the mixture was stirred at room temperature for 1 h. The reaction was quenched by adding MeOH (50 mL). Water and DCM were added and the phases were separated. The organic layer was concentrated and the residue was purified by prep-HPLC to provide the title compound (0.75 g, 39%). LCMS: m/e 474.33 [M+H] +. Example 24
Preparation of (R)-4-fluoro-N-(3-(1-isobutyi lpiperidin-4-yl)-1-methyl-1H-indol-5-yl)-3- ((tetrahydrofuran-3-yl)oxy)benzenesulfonamide
Figure imgf000064_0001
4-fluoro-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-1 H-indol-5-yl)-3- methoxybenzenesulfonamide (prepared as described in Example 22) (30 mg, 0.06 mmol), (S)- tetrahydrofuran-3-ol (18 mg, 0.19 mmol), triphenylphosphine (25 mg, 0.10 mmol) and di-tert- butyldiazene-1 ,2-dicarboxylate (22 mg, 0.10 mmol) were charged in an oven-dried vessel under an atmosphere of nitrogen. Dry DCM (2 mL) was added, and the reaction mixture was stirred at room temperature overnight. The volatiles were evaporated and the residue was purified by prep-HPLC to provide the title compound (13 mg, 40%). 1H NMR (500 MHz, CD3OD): δ 7.40-7.36 (m, 1 H), 7.27-7.21 (m, 2H), 7.12 (s, 1 H), 6.99 (s, 1 H), 6.90 (dd, J = 2.5, 9.0 Hz, 1 H), 6.87-6.84 (m, 1 H), 4.67-4.59 (m, 2H), 4.17-4.10 (m, 1 H), 3.77-3.64 (m, 5H), 3.62-3.50 (m, 2H), 3.29-3.21 (m, 1 H), 3.04-2.95 (m, 2H), 2.80-2.72 (m, 1 H), 2.04-1.90 (m, 2H), 1.86-1.75 (m, 1 H), 1.63-1.48 (m, 3H), 1.16-1.09 (m, 6H). LCMS: m/e 544.38 [M+H] +.
Examples 25-31
The following Examples 25-31 were prepared in an analogous manner to Example 22 employing the necessary benzenesulfonyl chloride in step 1 and the appropriate carboxylic acid in step 5. Example Structure Name/Characterization
(R)-4-methyl-N-(1 -methyl-3-(1 -(2,3,3- trimethylbutanoyl)piperidin-4-yl)-1 H-indol-5- yl)benzenesulfonamide; Rt = 5.02 (Method C); 1H NMR (400 MHz, MeOD-d4): δ 7.51-7.49 (m, 2H),
25 7.22- 7.14 (m, 4H), 6.91 (s, 1 H), 6.86-6.85 (m, 1 H),
4.70-4.67 (m, 1 H), 4.29-4.26 (m, 1 H), 3.66 (s, 3H),
3.23- 3.22 (m, 1 H), 2.95-2.72 (m, 3H), 2.35 (s, 3H), 2.01-1.91 (m, 2H), 1.48-1.45 (m, 2H), 1.12-1.07 (m, 3H), 1.02-0.99 (m, 9H) ; LC/MS [M+H]+ :496.1
(R)-1 ,3,5-trimethyl-N-(1-methyl-3-(1-(2,3,3- trimethylbutanoyl)piperidin-4-yl)-1 H-indol-5-yl)-1 H- pyrazole-4-sulfonamide. Rt = 4.56 (Method C); 1 H NMR (400 MHz, MeOD-d4): δ 7.25-7.21 (m, 2H),
26 6.98 (s, 1 H), 6.89-6.87 (m, 1 H), 4.74-4.71 (m, 1 H),
4.34-4.31 (m, 1 H), 3.72 (s, 3H), 3.62 (s, 3H), 3.33- 3.28 (m, 1 H), 2.91-2.78 (m, 3H), 2.11 -2.00 (m, 8H), 1.64-1.54 (m, 2H), 1.14-1.1 1 (m, 3H), 1.09-1.01 (m, 9H); LC/MS [M+H]+: 514.1 ;
(R)-2-ethoxy-N-(1 -methyl-3-(1 -(2,3,3- trimethylbutanoyl)piperidin-4-yl)-1 H-indol-5- yl)benzenesulfonamide. Rt =4.63 (Method D); 1 H NMR (400 MHz, MeOD-d4): δ 7.65-7.62 (m, 1 H),
27 7.45-7.26 (m, 2H), 7.12-7.09 (m, 2H), 6.92-6.84 (m,
3H), 4.69-4.66 (m, 1 H), 4.30-4.28 (m, 3H), 3.66 (s, 3H), 3.30-3.21 (m, 2H), 2.93-2.72 (m, 3H), 1.99- 1.96 (m, 2H), 1.55-1.46 (m, 5H), 1.12-0.99 (m, 12H). LC/MS [M+H]+ :526.1 ; Example Structure Name/Characterization
(R)-2-fluoro-N-(1 -methyl-3-(1 -(2,3,3- trimethylbutanoyl)piperidin-4-yl)-1 H-indol-5- yl)benzenesulfonamide. Rt =4.91 (Method E); 1H NMR (400 MHz, MeOD-d4) δ ppm 7.66-7.64 (m, 1 H), 7.58-7.54 (m, 1 H), 7.27-7.13 (m, 4H), 6.94-
28
6.91 (m, 2H), 4.70-4.67 (m, 1 H), 4.31 -4.28 (m, 1 H), 3.64 (s, 3H), 3.31-3.24 (m, 1 H), 2.97-2.73 (m, 3H), 2.08-1.90 (m, 2H), 1.73-1.46 (m, 2H), 1.55-1.46 (m, 5H), 1.12-0.99 (m, 12H) . LCMS: m/e 522.1
[M+Na]+.
(R)-N-(1-methyl-3-(1-(2,3,3-
29 trimethylbutanoyl)piperidin-4-yl)-1 H-indol-5- yl)benzenesulfonamide. LCMS: m/e 482.2 [M+H]+
(R)-3,5-dimethyl-N-(1 -methyl-3-(1 -(2,3,3- trimethylbutanoyl)piperidin-4-yl)-1 H-indol-5-
30
yl)isoxazole-4-sulfonamide. ). LCMS: m/e 501.1 [M+H]+
(R)-N-(3-(1-(2-(bicyclo[1.1.1]pentan-1- yl)propanoyl)piperidin-4-yl)-1-methyl-1 H-indol-5-yl)-
31
4-fluorobenzenesulfonamide. LCMS: m/e 510.2 [M+H]+
Example 36
Assay of co-activator recruitment by TR-FRET The activity of compound of the invention can be determined by a co-activator recruitment by TR-FRET (time- resolved fluorescence resonance energy transfer) assay. In general, the assay is based on the interaction between N-terminally Six-Histidine-tagged-RORC2 ligand binding domain (6-His-RORC2 LBD), expressed in E. coli and purified by affinity chromatography, and biotin-coactivator peptide SRC1-2 (biotin-aminohexanoic acid-
CPSSHSSLTERHKILHRLLQEGSPS-NH2; SEQ ID NO: 1) containing the LXXLL consensus domain which is responsible for receptor binding. This interaction is detected by addition of Europium labeled-anti-His antibody (Ex. 337 nm, Em. 620 nm, which binds to 6His) and
Streptavidin-APC (Ex. 620 nm, Em. 665 nm, which binds to biotin). When receptor and coactivator are bound to each other, upon shining light at 337 nm on the sample, the Europium emits fluorescence that excites APC due to close proximity (FRET) and this signal is measured at 665 nm. Due to the long lasting fluorescence emission of Europium, the non-specific, short-lived fluorescence is time-resolved (TR) from the fluorescence of interest. Inhibitors of the interaction of receptor and coactivator peptide are detected by a decrease in TR-FRET signal.
Specifically, in one embodiment the aforementioned assay was performed as outlined below. The assay was carried out in black polystyrene, 384-well plates in a total assay volume of 50.5 μΙ_. The assay buffer contained 50 mM TRIS-HCL pH 7.5, 1 mM NaCI, 2 mM MgCI2, 0.5 mg/mL bovine serum albumin, and 5 mM dithiothreitol. The final concentration of reagents was 6.3 nM RORC2 LBD, 200 nM SRC1-2, 50 nM streptavidin APC, 1 nM Europium-labeled anti-His antibody, and varying concentrations of compounds such that final concentration of DMSO is 1 % (v/v). The assay steps were: (1) dispensing 500 μί compound at 100x final concentration in DMSO (test wells) or DMSO only (control wells for no inhibition); and (2) dispensing 50 μί mixture of the other assay components including receptor (test wells) or excluding receptor (control wells for maximal inhibition).
Assay mixtures were incubated are room temperature for 3 hr and read in EnVision 2100
Multilabel Reader (PerkinElmer Life Sciences) at Excitation Filter 320, Emission Europium Filter 615, Emission APC Filter 665, Dichroic Mirror D400/D630.
TR-FRET signal was determined by calculating the ratio of 665 nm by 615 nm and IC50 values of compounds of the invention (Table 1) were determined by the non-linear regression analysis of dose response curves.
References which relate to the above-referenced assay include: Kallen et al. Structure, 2002, 10, 1697-1707; Stehlin et al. EMBO J 2001 , 20, 5822-5831 ; and Zhou et al. Mol Endocrinol 1998, 12, 1594-1604.
Table 1. Example ICso (nM) Example ICso (nM) Example ICso (nM)
1 8.2 13 16.9 25 2.1
2 1 1.4 14 5.6 26 1.3
3 5.3 15 6.8 27 1.7
4 33.8 16 3.1 28 1.0
5 5.1 17 5.9 29 8.7
6 75.9 18 7.0 30 10.0
7 4.5 19 3.7 31 2.4
8 17.1 20 91.3 32 2.5
9 14.8 21 9.0 33 1.1
10 5.6 22 10.6 34 0.9
11 28.8 23 19.9 35 1.0
12 7.8 24 5.7
Example 37
Assay of Gal4-RORC2 activity by luciferase reporter
The activity of compound of the invention can be also be determined by a luciferase reporter Gal4-RORC2 activity assay. In general, Neuro2A cells (murine neuroblastoma cell line obtained from HPACC, cat #89121404) are transiently transfected with a mammalian expression vector (pM) containing Gal4-RORC2 LBD and a Gal4-responsive reporter gene containing firefly luciferase (5xGAL4UAS-Luc3). Gal4-RORC2 LBD is constitutively active in the transfected Neuro2a cells, resulting in a robust luciferase response in the absence of stimulation. Upon treatment with an RORC2 inhibitor the transcriptional response is decreased and the magnitude of the decrease in response is dose-dependently related to the intrinsic efficacy of the inhibitor.
Specifically, the growth medium was composed by MEM EBS w/o L-glutamine, 10% (v/v) FBS, 2 mM L-glutamine and 1x non-essential aminoacid (NEAA); the seeding medium was composed by MEM EBS w/o L-glutamine, w/o phenol red, 4% (v/v) FBS, 2 mM L-glutamine, 1x NEAA, 1 % Penicillin (10,000 U/mL)/Streptomycin (10,000 μg/mL); and the assay medium was composed by MEM EBS w/o L-glutamine, w/o phenol red, 4% (v/v) FBS, 2 mM L-glutamine, 1x NEAA, 1 % Penicillin (10,000 U/mL)/Streptomycin (10,000 g/mL). In addition, Neuro2A cells were cultured in growth medium in humidified chambers at 37°C and 5% C02 using standard tissue culture procedures.
On day one of the assay, cells were seeded and transfected. Specifically, Neuro2A cells were suspended in seeding medium and mixed with plasmids and transfection reagent which was dissolved in OptiMEM I reduced serum medium (InVitrogen), and then seeded to 384-well plates (Corning, Black, Clear bottom) in 40 μΙ_/ννβΙΙ containing 12,500 cells, 17.25 ng Gal4-Luc3, 5.75 ng either empty pM vector ('no receptor control' wells) or pM-Gal4RORgamma-LBD, and 0.1 1 μΙ_ Lipofectamine2000.
On day two of the assay, the cells were treated with compounds of the invention.
Specifically, the treatment was started 20-24 hr after seeding and transfection of the cells.
Compounds of the invention were serially diluted in a 384-well polypropylene plate with assay medium containing 0.5% (v/v) DMSO at 5x final assay concentration. 10 μΙ_ of the compounds (or 0.5% DMSO in assay medium for 'no compound control' wells) were transferred from the dilution plate to the 384-format cell plate such that final assay volume was 50 μΙ_ and final DMSO concentration was 0.1 % (v/v), followed by incubation for 20-24 hr in humidified chambers at 37°C and 5% C02
On day three of the assay, luminescence was measured and the results analyzed.
Specifically, 10 μΙ_ of SteadyLite Plus reagent (Perkin Elmer) was added to each well. The cell plates were incubated at room temperature for 15 min in the dark before reading of luminescence on the MicroBeta Trilux (Wallac). IC50 values of the compounds tested were determined by the non-linear regression analysis of dose response curves.
References which relate to the above-referenced assay include: Stehlin-Gaon et al. Nature Structural Biology 2003, 10, 820-825; Wang et al. J Biol Chem. 2010, 285(7), 5013-5025; Kumar et al. Mol Pharmacol. 2010, 77(2), 228-36.
Example 38
Assay of IL-17 Production from human Th17 cells
The activity of compound of the invention can be also be determined by an IL-17 production from human Th17 cells assay. In general, this assay measures blockade of IL-17 production, the signature cytokine of T helper 17 (Th17) cells, by compounds. Purified human CD4+ T cells are stimulated with anti-CD3 + anti-CD28 and incubated with a cytokine cocktail that induce their differentiation into Th17 in the absence or presence of various concentrations of compound. After 6 days, IL-17A concentration is measured in the cell culture supernatant with an ELISA kit (MSD).
Preparation of human CD4+ T cells. CD4+ T cells were purified from buffy coats from healthy donors (obtained from Massachusetts General Hospital) by negative selection the following procedure: Mixing 25 mL of blood with 1 mL of Rosette Sep CD4+ T cell enrichment cocktail
(StemCell Technologies) followed by application of a layer of 14 mL Ficoll Paque Plus (Amersham GE Healthcare) and subsequent centrifugation at 1200 g for 20 min at room temperature. The Ficoll layer was then harvested and washed with phosphate saline buffer containing 2% (v/v) fetal bovine serum and cells were resuspended with RPMI medium containing 10 % (v/v) fetal bovine serum and 10% (v/v) DMSO, frozen and kept in LN2 until used. On the first day of the assay, a vial containing 107 CD4+ T cells is thawed rapidly in 37°C water bath, immediately transferred into 20 mL X-Vivo 15 medium (Lonza), is spun for 6 min at 300xg, the supernatant is discarded, and the resulting pellet is re-suspended at 106 cells/mL in 50 mL fresh X-Vivo 15 medium, followed by storage overnight in a tissue culture vessel in a humidified chamber at 37°C and 5% C02. Serial dilutions of compounds of the invention are prepared at 10x final concentration in X-Vivo15 medium containing 3% (v/v) DMSO.
On the second day of the assay, a 384-well tissue culture plate was coated with 10 μg mL anti-hCD3 (eBioscience) at 50 L/well. After 2 hr at 37°C, the supernatant is discarded and the coated plates are kept in a sterile tissue culture hood.
Cytokine plus anti-CD28 cocktail is prepared by mixing 25 ng/mL hlL-6 (Peprotech), 5 ng/mL hTGFbetal (Peprotech), 12.5 ng/mL IL-1 beta (Peprotech), 25 ng/mL hlL-21 , 25 ng/mL hlL- 23 (R&D Systems), and 1 ug/mL anti-hCD28 (eBioscience) in X-Vivo 15 medium. The cytokine plus anti-CD28 cocktail with CD4+ cells is prepared such that the cocktail is diluted 10-fold and cell density is 0.22 x 106/mL. The mixture is incubated 1 hr at 37°C.
90 μί (20,000 cells) dispensed per well in the anti-hCD3 coated plate prepared as noted above.
10μί 10x compound is added per well (final DMSO=0.3%) from the compound plate that was previously prepared, followed by 6 days of incubation in a tissue culture vessel in a humidified chamber at 37°C and 5% C02.
On day six of the assay, production of IL-17A in 10 μί of the supernatant is determined by sandwich ELISA using 384w hlL17 MSD plates following the manufacturer's protocol.
Measurement is carried out in a Sector Imager 6000 by the same manufacturer. Signal units from the instrument are converted to pg/mL using a calibration curve with known amounts of IL-17A. IC50 values of test compounds (Table 2) are determined by the non-linear regression analysis of dose response curves.
A reference which relates to the above-referenced assay is: Yang et al. Nature 2008, 454, 350-352.
Table 2.
Example IC50 (nM) Example IC50 (nM) Example IC50 (nM)
1 13.5 6 275.7 11 148.0
2 4.8 7 28.1 12 126.6
3 121.1 8 183.6 13 309.6
4 137.0 9 99.1 14 221.2
5 90.3 10 29.0 15 188.6 Example ICso (nM) Example ICso (nM) Example ICso (nM)
16 53.8 23 1457.9 30 19.8
17 1 14.4 24 69.5 31 26.0
18 19.0 25 10.6 32 3.3
19 191.3 26 5.1 33 8.4
20 633.0 27 16.0 34 4.2
21 88.7 28 1 1.4 35 8.4
22 267.1 29 28.5
Example 39
Inhibition of Superantigen-induced Th17 cytokine production
Exotoxins called "superantigens" are among the most powerful T cell activators.
Superantigens bind to the cell surface of major histocompatibilty complex (MHC) molecules, without intracellular processing. They stimulate T cells via the T cell receptor, irrespective of the antigen specificities. Therefore, bacterial superantigens are able to activate a large pool of CD4+ as well as CD8+ T cells in contrast to the low T cell frequency for conventional antigens. CD4+ T cells can be classified into various subsets (ThO, Th1 , Th2, Th17) based on their respective cytokine secretion profiles. ThO cells are uncommitted naive precursor cells that primarily produce IL-2 upon stimulation. ThO cells upon activation can differentiate into Th1 , Th2, or the Th17 subset depending on the local cytokine milieu. Th1 cells mainly produce lnf-γ; Th2 cells, IL-4, IL-5, and IL- 13, and Th17 cells, IL-17, and IL-22. During a classical immune response, the differentiation of T helper subset occurs over days, or longer. In the superantigen in-vivo model in mice injection of superantigen triggers a rapid transcription and translation of the various cytokines (i.e. IL-2, IL-4, lnf-γ, IL-17) of the different Th subsets after only 6 hr. A RORyt inhibitor given to animals prior to the superantigen stimulus would impair the Th17 cytokine profile without affecting the cytokine profile of the other Th subsets (ThO, Th1 , Th2). The model uses approximately 8 week old
C57BL/6, Balb/c, or C3H/HeJ mice which are dosed orally with compound 1 to 2 hr prior to superantigen injection on the day of the experiment (Day 0) based on the pharmacokinetic (PK) profile of the compound. An optional dose may be given the day before superantigen injection (Day -1) to further inhibit the response if necessary. C57BL/6 and Balb/c mice will be sensitized 1 hr prior to supernatigen injection with approximately 25 mg/mouse D-Galactosamine intraperitoneally (C3H/HeJ mice do not need to be sensitized). Based on the literature superantigen is typically given at 10 μg/mouse intraperitoneally. Mice will be sacrificed at 3 hr for RNA analysis or up to 6 hr for cytokine analysis.
A reference which relates to the above-referenced assay is: Rajagopalan, G. et. al. Physiol Genomics 2009, 37, 279. Example 40
Imiquimod Assay
Commercially available 5% imiquimod (IMQ) cream (3M Pharmaceuticals) is applied to the back and right ear of each experimental mouse for two consecutive days. Control mice are treated similarly with a commercially available vehicle cream. The experimental mice are then
administered with RORyt inhibitors, and the control mice with vehicle, for 4 days. The ear thickness is measured on all days by digital micrometer (Mitutoyo). Tissues, such as ears and speens, are harvested on Day 5 for RNA analysis. Ear swelling and serum measurements are also made.
References describing aspects of this assay include: Van der Fits, L. et al. J. Immunol.
2009, 182(9), 5836-45; Van Belle, A.B. et al. J Immunol. 2012, 188(1), 462-9; Cai, Y. et al.
Immunity 2011 , 35(4), 596-610; Fanti, P.A. et al. Int. J. Dermatol. 2006, 45(12), 1464-5; Swindell, W.R. et al. PLoS One 2011 , 6(4), e18266; and Roller, A. et al. J. Immunol. 2012, 189(9), 4612-20.
Example 41
IL-23 Injection Model of Mouse Skin Inflammation
Ears from BALB/c mice were each injected intra-dermally every other day with 150 ng of mouse recombinant IL-23 (eBiosciences) or PBS in a total volume of 25 μΙ. Ear swelling was measured in triplicate using a micrometer (Mitutoyo) right before each IL-23 challenge. On Day 14, mice were euthanized and ears were collected for measurement of cytokine levels, gene expression levels and hystopathological evaluation. Mice were administered 3 - 100 mg/kg of an RORC2 modulator or vehicle once daily orally for the duration of the study. Alternatively, the RORC2 modulator was applied topically once or twice daily using a standard formulation
(EtOH:propylene glycol:dimethyl isosorbide:DMSO, 38:30:15:15) at a concentration of 0.1 % to 5.0%.
References describing aspects of this assay include: Muramoto, K. et al. J. Pharmacol.
Exp. Ther. 2010, 335(1), 23-31 ; Fridman, J. S. et al. J. Invest. Dermatol. 2011 , 131 (9), 1838-1844.
INCORPORATION BY REFERENCE
All publications, patents and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference.

Claims

A compound of Formula I
Figure imgf000073_0001
I
or a pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, wherein,
X is phenyl or 5-membered heteroaryl, in each case optionally substituted with one, two, three, four or five substituents independently selected from the group consisting
-CHs, -CF3, -CH2CH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2OH, -OCH2CH2OCH3,
Figure imgf000073_0002
-CH or -CH2CH3;
W is
Figure imgf000073_0003
optionally substituted with one, two, three, four or five -CH3; and
R2 is (CrCe alkyl, (C3-C10)cycloalkyl, phenyl or isothiazolyl, optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C1-C3)alkyl, (C1-C3)haloalkyl and (C3-C10)cycloalkyl.
The compound of claim 1 , wherein R1 is -CH3.
The compound of claim 1 or 2, wherein W is KM
4. The compound of claim 1 or 2, wherein W is RM
5. The compound of claim 1 or 2, wherein W is KM
6. The compound of claim 1 or 2, wherein W
Figure imgf000074_0001
7. The compound of any one of claims 1-6, wherein X is phenyl substituted with one, two, three, four or five substituents independently selected from the group consisting
-CHs, -CF3, -CH2CH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2OH, -OCH2CH2OCH3,
Figure imgf000074_0002
The compound of any one of claims 1-6, wherein X is 5-membered heteroaryl optionally substituted with one additional substituent selected from the group consisti -CH3,
-CF3, -CH2CH3, -OH, -OCH3, -OCH2CH3, -OCH2CH2OH, -OCH2CH2OCH3,
Figure imgf000074_0003
-F, -CI, -Br and -CN.
Figure imgf000074_0004
10. The compound of any one of claims 1-6, wherein X is
Figure imgf000074_0005
1 1. The compound of any one of claims 1-10, wherein R2 is (C1-C6)alkyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C C3)alkyl, (Ci-C3)haloalkyl and (C3- C10)cycloalkyl.
The compound of any one of claims 1-10, wherein R2 is (C C6)alkyl.
13. The compound of any one of claims 1-10, wherein R2 is methyl substituted with (C3-C6)cycloalkyl.
14. The compound of any one of claims 1-10, wherein R2 is propyl substituted with -CF3.
15. The compound of any one of claims 1-10, wherein R2 is (C3-C10)cycloalkyl optionally
substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C C3)alkyl, (C C3)haloalkyl and (C3-C10)cycloalkyl.
16. The compound of any one of claims 1-10, wherein R2 is unsubstituted (C3-C10)cycloalkyl.
17. The compound of any one of claims 1-10, wherein R2 is phenyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (C C3)alkyl,
Figure imgf000075_0001
and (C3- C10)cycloalkyl.
18. The compound of any one of claims 1-10, wherein R2 is isothiazolyl optionally substituted with one, two, three, four or five substitutents independently selected for each occurrence from the group consisting of -F, -CI, -Br, -OH, (CrC^alkyl, (CrC^haloalkyl and (C3- C10)cycloalkyl.
19. The compound of any one of claims 1-13, wherein R2
Figure imgf000075_0002
Figure imgf000075_0003
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
21. A pharmaceutical composition comprising a compound according to any one of claims 1- 20, or a pharmaceutically acceptable salt, pharmaceutically active metabolite,
pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, admixed with a pharmaceutically acceptable carrier, excipient or dilutant.
22. A method of inhibiting RORC2 comprising of administering to a patient an effective amount of a pharmaceutical composition of claim 21.
23. A method for treating an immune disorder or inflammatory disorder comprising
administering to a subject in need thereof a pharmaceutical composition of claim 22.
24. The method of claim 23, wherein the disorder is an inflammatory disorder.
25. The method of claim 23, wherein the disorder is an autoimmune disorder.
26. The method of claim 23, wherein the disorder is rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, epidermal hyperplasia, cartilage inflammation, bone degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myositis, polymyositis, osteoarthritis, polyarteritis nodossa, Wegener's granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, atherosclerosis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, psoriatic epidermal hyperplasia, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, an immune disorder associated with or arising from activity of pathogenic lymphocytes, noninfectious uveitis, Behcet's disease, giant cell arteritis, nonalcoholic hepatic steatosis, or Vogt-Koyanagi-Harada syndrome.
27. A compound or pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof according to any one of claims 1-19 for use in medicine.
28. A compound or pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof according to any one of claims 1-19, or a pharmaceutical composition of claim 20, for use in treating or ameliorating an immune disorder or inflammatory disorder mediated by RORC2 and/or I L- 17.
29. The use of claim 28, wherein the disorder is an inflammatory disorder.
30. The use of claim 28, wherein the disorder is an autoimmune disorder.
31. The use of claim 28, wherein the disorder is rheumatoid arthritis, psoriasis, chronic graft- versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome,
scleroderma, ulcerative colitis, asthma, epidermal hyperplasia, cartilage inflammation, bone degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myositis, polymyositis, osteoarthritis, polyarteritis nodossa, Wegener's granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, atherosclerosis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, psoriatic epidermal hyperplasia, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythroderma psoriasis, an immune disorder associated with or arising from activity of pathogenic lymphocytes, noninfectious uveitis, Behcet's disease, giant cell arteritis, nonalcoholic hepatic steatosis, or Vogt-Koyanagi-Harada syndrome.
A compound or pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof according to any one of claims 1-20 for use in combination with another pharmaceutical agent.
PCT/IB2016/050477 2015-01-30 2016-01-29 Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof WO2016120850A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP16705819.7A EP3250561A1 (en) 2015-01-30 2016-01-29 Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof
US15/547,228 US10385036B2 (en) 2015-01-30 2016-01-29 Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof
JP2017539457A JP2018510131A (en) 2015-01-30 2016-01-29 RORC2 sulfonamide substituted indole modulator and method of use thereof
CA2975157A CA2975157C (en) 2015-01-30 2016-01-29 Sulfonamide-substituted indole modulators of rorc2 and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562110060P 2015-01-30 2015-01-30
US62/110,060 2015-01-30
US201562267350P 2015-12-15 2015-12-15
US62/267,350 2015-12-15

Publications (2)

Publication Number Publication Date
WO2016120850A1 true WO2016120850A1 (en) 2016-08-04
WO2016120850A9 WO2016120850A9 (en) 2017-07-20

Family

ID=55405379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/050477 WO2016120850A1 (en) 2015-01-30 2016-01-29 Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof

Country Status (5)

Country Link
US (1) US10385036B2 (en)
EP (1) EP3250561A1 (en)
JP (1) JP2018510131A (en)
CA (1) CA2975157C (en)
WO (1) WO2016120850A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018229079A1 (en) * 2017-06-14 2018-12-20 Ucb Biopharma Sprl Spirocyclic indolines as il-17 modulators
KR20190068946A (en) 2017-12-11 2019-06-19 씨제이헬스케어 주식회사 Intermediates of chiral piperidine derivatives and preparation method thereof
US10336748B2 (en) 2015-01-30 2019-07-02 Pfizer Inc. Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
KR20190120112A (en) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 Intermediates of chiral piperidine derivatives and preparation method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322105A (en) * 2021-05-11 2022-11-11 江苏润安制药有限公司 Method for synthesizing Iguratimod key intermediate

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013007582A2 (en) 2011-07-08 2013-01-17 Syngenta Participations Ag Processes for the preparation of thietanamine
WO2014026330A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026329A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2015015378A2 (en) * 2013-08-02 2015-02-05 Pfizer Inc. Rorc2 inhibitors and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742057A (en) 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
GB9211276D0 (en) * 1992-05-28 1992-07-15 Glaxo Lab Sa Pharmaceutical compositions
US5962473A (en) 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
DE69819903T2 (en) 1997-08-09 2004-11-11 Smithkline Beecham P.L.C., Brentford BICYCLIC COMPOUNDS AS LIGANDS OF 5-HT1 RECEPTORS
AU4425399A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
US7230011B2 (en) * 2001-01-30 2007-06-12 Eli Lilly And Company Benzenesulfonic acid indol-5-yl esters as antagonists of the 5ht6 receptor
MA40759A (en) 2014-09-26 2017-08-01 Pfizer PYRROLOPYRIDINE-SUBSTITUTED BY METHYL AND TRIFLUOROMETHYL RORC2 MODULATORS AND THEIR METHODS OF USE
CA2975060C (en) 2015-01-30 2019-09-03 Pfizer Inc. Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013007582A2 (en) 2011-07-08 2013-01-17 Syngenta Participations Ag Processes for the preparation of thietanamine
WO2014026330A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026329A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2015015378A2 (en) * 2013-08-02 2015-02-05 Pfizer Inc. Rorc2 inhibitors and methods of use thereof

Non-Patent Citations (38)

* Cited by examiner, † Cited by third party
Title
"COMPENDIUM OF ORGANIC SYNTHETIC METHODS", vol. I-VI, WILEY-INTERSCIENCE
"The Pharmacological Basis of Therapeutics, 9th Edition,", 1996, MCGRAW-HILL
B.M. TROST & . FLEMING,: "Comprehensive Organic Synthesis", 1991
CAI, Y. ET AL., IMMUNITY, vol. 35, no. 4, 2011, pages 596 - 610
CAREY; SUNDBERG: "Advanced Organic Chemistry 4th Ed", vol. A, B, 2000, PLENUM PRESS
D.M. WEIR & C.C. BLACKWELL,: "Handbook of experimental immunology", .
EDWARD B. ROCHE: "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
F.M. AUSUBEL ET AL.,: "Current protocols in molecular biology", 1987
FANTI, P.A. ET AL., INT. J. DERMATOL., vol. 45, no. 12, 2006, pages 1464 - 5
FEDORAK ET AL., AM. J. PHYSIOL., vol. 269, 1995, pages G210 - 218
FRIDMAN, J. S. ET AL., J. INVEST. DERMATOL., vol. 131, no. 9, 2011, pages 1838 - 1844
HOCHHAUS ET AL., BIOMED. CHROM., vol. 6, 1992, pages 283 - 286
J. LARSEN ET AL., INT. J. PHARMACEUTICS, vol. 47, 1988, pages 103
J. LARSEN; H. BUNDGAARD, INT. J. PHARMACEUTICS, vol. 37, 1987, pages 87
J.E. COLIGAN ET AL.,: "Current protocols in immunology", 1991
KALLEN ET AL., STRUCTURE, vol. 10, 2002, pages 1697 - 1707
KIDO, M. ET AL., TETRAHEDRON: ASYM., vol. 18, 2007, pages 1934 - 1947
KUMAR ET AL., MOL PHARMACOL., vol. 77, no. 2, 2010, pages 228 - 36
MCLOED ET AL., GASTROENTEROL, vol. 106, 1994, pages 405 - 413
MURAMOTO, K. ET AL., J. PHARMACOL. EXP. THER., vol. 335, no. 1, 2010, pages 23 - 31
NOGRADY: "Medicinal Chemistry A Biochemical Approach", 1985, OXFORD UNIVERSITY PRESS, pages: 388 - 392
RAJAGOPALAN, G., PHYSIOL GENOMICS, vol. 37, 2009, pages 279
ROLLER, A. ET AL., J. IMMUNOL., vol. 189, no. 9, 2012, pages 4612 - 20
SAULNIER ET AL., BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 4, 1994, pages 1985
SILVERMAN: "The Organic Chemistry of Drug Design and Drug Action", 1992, ACADEMIC PRESS, INC., pages: 352 - 401
SINKULA ET AL., J. PHARM. SCI., vol. 64, 1975, pages 181 - 210
STEHLIN ET AL., EMBO J, vol. 20, 2001, pages 5822 - 5831
STEHLIN-GAON ET AL., NATURE STRUCTURAL BIOLOGY, vol. 10, 2003, pages 820 - 825
SWINDELL, W.R. ET AL., PLOS ONE, vol. 6, no. 4, 2011, pages E18266
T. HIGUCHI; V. STELLA: "A.C.S. Symposium Series", vol. 14, article "Pro-drugs as Novel Delivery Systems"
T. W. GREENE: "Protective Groups in Organic Chemistry", 1981, JOHN WILEY & SONS
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Chemistry", 1991, JOHN WILEY & SONS
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Chemistry", 1999, JOHN WILEY & SONS
VAN BELLE, A.B. ET AL., J IMMUNOL., vol. 188, no. 1, 2012, pages 462 - 9
VAN DER FITS, L. ET AL., J. IMMUNOL., vol. 182, no. 9, 2009, pages 5836 - 45
WANG ET AL., J BIOL CHEM., vol. 285, no. 7, 2010, pages 5013 - 5025
YANG ET AL., NATURE, vol. 454, 2008, pages 350 - 352
ZHOU ET AL., MOL ENDOCRINOL, vol. 12, 1998, pages 1594 - 1604

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336748B2 (en) 2015-01-30 2019-07-02 Pfizer Inc. Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
WO2018229079A1 (en) * 2017-06-14 2018-12-20 Ucb Biopharma Sprl Spirocyclic indolines as il-17 modulators
US11052076B2 (en) 2017-06-14 2021-07-06 UCB Biopharma SRL Spirocyclic indolines as IL-17 modulators
KR20190068946A (en) 2017-12-11 2019-06-19 씨제이헬스케어 주식회사 Intermediates of chiral piperidine derivatives and preparation method thereof
KR20190120112A (en) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 Intermediates of chiral piperidine derivatives and preparation method thereof

Also Published As

Publication number Publication date
EP3250561A1 (en) 2017-12-06
US10385036B2 (en) 2019-08-20
JP2018510131A (en) 2018-04-12
US20180273504A1 (en) 2018-09-27
CA2975157A1 (en) 2016-08-04
CA2975157C (en) 2019-09-17
WO2016120850A9 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
US10426135B2 (en) Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
EP3027603B1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
US10385036B2 (en) Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof
US10336748B2 (en) Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
OA18254A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof.
OA18716A (en) Heterobicycloaryl RORC2 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16705819

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2016705819

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2975157

Country of ref document: CA

Ref document number: 2017539457

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15547228

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE